var docs;if (!docs) docs =[]; docs["40"]={"4000":"<p><b>Title</b> Mineral Oil / Docusate</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to orally administered mineral oil.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Docusate may increase the absorption of Mineral Oil. <b>Severity</b> Major <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Do not co-administer docusate salts with (oral) mineral oil.</p> \n<p><b>Discussion</b> There is a paucity of literature data confirming this phenomenon. However, most manufacturers of commercially-available docusate and oral mineral oil products recommend not using these products together.<sup>1,2</sup> This is based on a theoretical concern that docusate salts can emulsify mineral oil, leading to systemic absorption and toxicity, possibly manifested as accumulation in hepatic or mesenteric lymphoid tissue.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Colace (docusate) [prescribing information]. Stamford, CT: Purdue Products LP; February 2017. </p>\n<p>2. Kondremul (mineral oil) [prescribing information]. Langhorne, PA: Insight Pharmaceuticals Corp; June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4002":"<p><b>Title</b> Propranolol / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may decrease the serum concentration of Propranolol. Alcohol (Ethyl) may increase the serum concentration of Propranolol. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for changes in heart rate and/or blood pressure if alcohol is consumed while on propranolol.</p> \n<p><b>Discussion</b> The literature on interactions between alcohol and propranolol is inconsistent. Several sources report increased plasma levels of propranolol in healthy adults when moderate amounts of alcohol (to maintain blood alcohol concentrations of 800 mg/L) are consumed.<sup>1,2,3</sup> The mechanisms are unknown, but it has been speculated that a combination of increased or facilitated propranolol absorption in conjunction with inhibited hepatic metabolism may account for this effect. However, other studies have shown exactly the opposite finding, with reductions in propranolol levels.<sup>4,5</sup> A number of factors probably influence the direction and magnitude of this interaction, including the chronicity of alcohol consumption, timing of administration and hepatic status. Despite the conflicting data regarding blood level changes, the studies tend to conclude that the magnitude of hemodynamic effects is modest. Responses are quite variable, with reports suggesting no change in heart rate and/or (systolic) blood pressure,<sup>2,3</sup> some increase in heart rate (due to alcohol),<sup>4</sup> partial inhibition of propranolol's hypotensive and bradycardic effects,<sup>4</sup> or enhanced reductions in diastolic blood pressure<sup>2</sup>. Given the wide variability in responses, it is probably best to avoid heavy consumption of alcohol; minimal consumption would likely not pose a significant hazard to most patients.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Inderal (propranolol). Philadelphia, PA: Wyeth Pharmaceuticals, Inc, 2007.</p>\n<p>2. Chakrabarti A, Garg SK, Sharma PL, “A Preliminary Study on the Interaction Between Ethanol and Propranolol in Normal Human Subjects,” <i>Indian J Physiol Pharmacol</i>, 1992, 36(3):209-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1473855\">[PubMed 1473855]</a></p>\n<p>3. Dorian P, Sellers EM, Kaplan HL et al, “Ethanol-Induced Inhibition of Hepatic Uptake of Propranolol in Perfused Rat Liver and in Man,” <i>Eur J Clin Pharmacol</i>, 1984, 27(2):209-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6499899\">[PubMed 6499899]</a></p>\n<p>4. Sotaniemi EA, Anttila M, Rautio A, et al, “Propranolol and Sotalol Metablism after a Drinking Party,” <i>Clin Pharmacol Ther</i>, 1981, 29(6):705-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7226702\">[PubMed 7226702]</a></p>\n<p>5. Grabowski BS, Cady WJ, Young WW et al, “Effects of Acute Alcohol Administration on Propranolol Absorption,” <i>Int J Clin Pharmacol Ther Toxicol</i>, 1980, 18(7):317-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7429766\">[PubMed 7429766]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4004":"<p><b>Title</b> ClomiPRAMINE / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may increase the serum concentration of ClomiPRAMINE. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs of increased levels/effects of clomipramine.</p> \n<p><b>Discussion</b> The manufacturers of carbamazepine products indicate that coadministration may lead to increased serum concentrations of clomipramine,<sup>1,2,3</sup> as well as its metabolite.<sup>4</sup> The mechanism of this interaction is unknown. Caution is warranted when using these agents concurrently.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tegretol [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2000.</p>\n<p>2. Carbatrol [package insert]. Wayne, PA: Shire US Inc, 2006.</p>\n<p>3. Equetro [package insert]. Wayne, PA: Shire US Inc, 2004.</p>\n<p>4. Gerson GR, Jones RB, Luscombe DK, “Studies on the Concomitant Use of Carbamazepine and Clomipramine for the Relief of Post-Herpetic Neuralgia,” <i>Postgrad Med J,</i> 1977, 53(Suppl 4):104-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=304576\">[PubMed 304576]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4005":"<p><b>Title</b> Quinolones / Corticosteroids (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients receiving quinolone antibiotics and systemic corticosteroids closely for new onset tendon or joint pain. The risk of tendonitis and tendon rupture may be further increased in older patients (usually those older than 60 years) and in recipients of heart, lung, and kidney transplants.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, Gemifloxacin, LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lomefloxacin, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin</p>\n</div> \n<p><b>Discussion</b> US prescribing information for systemic quinolone antibiotics warns that patients receiving these agents are at an elevated risk of tendinitis and tendon rupture.<sup>1,2,3,4,5,6,7,8,9</sup> This risk is further elevated in patients receiving corticosteroids, in older patients (usually those older than 60 years), and in recipients of heart, lung, and kidney transplants. Several large database analyses support this reported increase in risk,<sup>10,11,12,13,14</sup> as do several published reports of patient cases.<sup>15,16,17,18,19</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Levaquin</i> (levofloxacin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; May 2014.</p>\n<p>2. <i>Cipro</i> (ciprofloxacin) [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; August 2013.</p>\n<p>3. <i>Factive</i> (gemifloxacin) [prescribing information]. Seoul, Korea: LG Life Sciences; August 2013.</p>\n<p>4. <i>Maxaquin</i> (lomefloxacin) [prescribing information]. New York, NY: Pfizer Inc; March 2005.</p>\n<p>5. <i>Avelox</i> (moxifloxacin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; August 2013.</p>\n<p>6. <i>NegGram</i> (nalidixic acid) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2012.</p>\n<p>7. <i>Noroxin</i> (norfloxacin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc; August 2013.</p>\n<p>8. Ofloxacin [prescribing information]. Sellersville, PA: Teva Pharmaceuticals USA; April 2014.</p>\n<p>9. Baxdela (delafloxacin) [prescribing information]. Lincolnshire, IL: Melinta Therapeutics Inc; June 2017. </p>\n<p>10. van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HM, Rowlands S, Stricker BH. Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. <i>Arch Intern Med</i>. 2003;163(15):1801-1807. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12912715\">[PubMed 12912715]</a></p>\n<p>11. de La Red G, Mejia JC, Cervera R, Llado A, Mensa J, Font J. Bilateral Achilles tendinitis with spontaneous rupture induced by levofloxacin in a patient with systemic sclerosis. <i>Clin Rheumatol</i>. 2003;22(4-5):367-368. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14579169\">[PubMed 14579169]</a></p>\n<p>12. Seeger JD, West WA, Fife D, Noel GJ, Johnson LN, Walker AM. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. <i>Pharmacoepidemiol Drug Saf</i>. 2006;15(11):784-792. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16456878\">[PubMed 16456878]</a></p>\n<p>13. Corrao G, Zambon A, Bertu L, et al. Evidence of tendinitis provoked by fluoroquinolone treatment: a case-control study. <i>Drug Saf</i>. 2006;29(10):889-896. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16970512\">[PubMed 16970512]</a></p>\n<p>14. Wise BL, Peloquin C, Choi H, Lane NE, Zhang Y. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. <i>Am J Med</i>. 2012;125(12):1228.e23-1228.e28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23026288\">[PubMed 23026288]</a></p>\n<p>15. van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. <i>BMJ</i>. 2002;324(7349):1306-1307. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12039823\">[PubMed 12039823]</a></p>\n<p>16. Sugimoto T, Kaneko H, Deji N, Koya D. Levofloxacin-induced Achilles tendon rupture in a patient with systemic microscopic polyangiitis. <i>Mod Rheumatol</i>. 2005;15(3):217-219. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17029067\">[PubMed 17029067]</a></p>\n<p>17. Basic-Jukic N, Juric I, Racki S, Kes P. Spontaneous tendon ruptures in patients with end-stage renal disease. <i>Kidney Blood Press Res</i>. 2009;32(1):32-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19212123\">[PubMed 19212123]</a></p>\n<p>18. Lewis TG. A rare case of ciprofloxacin-induced bilateral rupture of the Achilles tendon [published online March 5, 2009]. <i>BMJ Case Rep</i>. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21686678\">[PubMed 21686678]</a></p>\n<p>19. Khanzada Z, Rethnam U, Widdowson D, Mirza A. Bilateral spontaneous non-traumatic rupture of the Achilles tendon: a case report. <i>J Med Case Rep</i>. 2011;5:263. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21718513\">[PubMed 21718513]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4007":"<p><b>Title</b> Acetylcholinesterase Inhibitors / Corticosteroids (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for exacerbation of muscular weakness. Dose reduction or tapering of anticholinesterase agent may be beneficial in the setting of high-dose steroid use. Initiation of high-dose steroids in moderate-to-severe myasthenia patients should be undertaken only in the hospital setting to allow close monitoring and respiratory support, if necessary.</p>\n<div>\n <p><b>Acetylcholinesterase Inhibitors Interacting Members</b> Distigmine, Donepezil, Edrophonium, Galantamine, Neostigmine, Physostigmine, Pyridostigmine, Rivastigmine</p>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE*, Triamcinolone (Systemic)</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Both systemically-available corticosteroids and cholinesterase inhibitors appear individually capable of causing an exacerbation of (potentially severe) muscle weakness in myasthenia gravis patients.<sup>1</sup> Concomitant use of these agents may cause an additive effect. Both drug classes appear to cause this weakness in a dose-dependent manner. In the case of cholinesterase inhibitors, excess accumulation of acetylcholine may function to induce a pseudo-depolarizing blockade effect, which may be evident approximately 1 hour after dosing. Conversely, the mechanism of corticosteroid-induced skeletal weakness is not known, but it has been suggested that high-dose steroid use (eg, prednisone 60-100 mg/day) may be associated with observed muscle weakness in ~50% of MG patients. This effect usually occurs within 1-2 weeks of therapy, and may be sufficiently severe to require ventilatory support. The manufacturers of triamcinolone and dexamethasone products recommend withdrawal of anticholinesterase agent 24 hours prior to initiating steroid therapy.<sup>2,3</sup> <br><br>Use of the more CNS-selective cholinesterase inhibitors (eg, donepezil, rivastigmine, galantamine) would seem to be less of, though not necessarily devoid of concern. Published data have demonstrated peripheral cholinergic toxicity with rivastigmine,<sup>4</sup> cholinergic reversal of neuromuscular blockade with galantamine,<sup>5</sup> and donepezil-mediated augmentation of succinylcholine/neostigmine neuromuscular effects during anesthesia.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Barrons RW. “Drug-Induced Neuromuscular Blockade and Myasthenia Gravis,” <i>Pharmacother</i>, 1997, 17(6):1220-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9399604\">[PubMed 9399604]</a></p>\n<p>2. Decadron [package insert]. Whitehouse Station, NJ: Merck 7 Co, Inc., 2003</p>\n<p>3. Aristospan [package insert]. Princeton, NJ: Sandoz, inc., 2006.</p>\n<p>4. Lai MW, Moen M, Ewald MB, “Pesticide-Like Poisoning from a Prescription Drug,” <i>NEJM</i>, 2005, 353(3):317-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16034024\">[PubMed 16034024]</a></p>\n<p>5. Pearson VE, “Galantamine: A New Alzheimer Drug with a Past Life,” <i>Ann Pharmacother</i>, 2001, 35(11):1406-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11724094\">[PubMed 11724094]</a></p>\n<p>6. Sprung J, Castellani WJ, Srinivasan V, et al, “The Effects of Donepezil and Neostigmine in a Patient with Unusual Pseudocholinesterase Activity,” <i>Anesth Analg</i>, 1998, 87:1203-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9806710\">[PubMed 9806710]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4008":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents (Nonselective) / Corticosteroids (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs of epigastric or abdominal pain, or other symptoms of gastrointestinal upset.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n <p><b>Nonsteroidal Anti-Inflammatory Agents (Nonselective) Interacting Members</b> Aceclofenac, Acemetacin, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Nabumetone, Naproxen, Oxaprozin, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Systemic corticosteroids may increase the risk of gastrointestinal adverse effects associated with systemically-administered nonsteroidal antiinflammatory agents. Corticosteroids have been independently associated with gastrointestinal ulceration,<sup>1,2</sup> as well as identified as a significant risk factor for gastrointestinal complications when used in combination with NSAIDs.<sup>3</sup> Much like the known gastroirritant pharmacology of non-steroidal agents, the mechanism of corticosteroid-induced GI ulcerations likely reflects the magnitude of prostaglandin synthesis inhibition, with subsequent reductions in GI protective mucosal secretions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ellershaw JE, Kelly MJ. Corticosteroids and peptic ulceration. <i>Palliat Med</i>. 1994;8(4):313-319. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7882482\">[PubMed 7882482]</a></p>\n<p>2. Pecora PG, Kaplan B. Corticosteroids and ulcers: is there an association? <i>Ann Pharmacother</i>. 1996;30(7-8):870-872. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8826\">[PubMed 8826]</a></p>\n<p>3. Harris CL, Raisch DW, Abhyankar U, Marfatia S, Campbell HM, Sather MR. GI risk factors and use of GI protective agents among patients receiving nonsteroidal antiinflammatory drugs. <i>Ann Pharmacother</i>. 2006;40(11):1921-1931. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17047140\">[PubMed 17047140]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4009":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) / Corticosteroids (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for gastrointestinal bleeding if systemic corticosteroids are used with COX-2 selective nonsteroidal anti-inflammatory agents.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n <p><b>Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) Interacting Members</b> Celecoxib, Etoricoxib, Morniflumate, Nimesulide, Parecoxib, Talniflumate</p>\n</div> \n<p><b>Discussion</b> Systemic corticosteroids may increase the risk of gastrointestinal adverse effects associated with systemically-administered nonsteroidal antiinflammatory drugs (NSAIDs). Corticosteroids have been independently associated with gastrointestinal ulceration,<sup>1,2</sup> as well as identified as a significant risk factor for gastrointestinal complications when used in combination with NSAIDs.<sup>3</sup> <br><br>Prescribing information for at least one COX-2 selective NSAID states that because concomitant use with corticosteroids may increase the risk of GI ulceration or bleeding, patients should be monitored closely for signs of bleeding when these agents are combined.<sup>4</sup> <br><br>Although the gastroirritant pharmacology of COX-2 selective NSAIDs is less than that of nonselective NSAIDs, when combined with corticosteroids (drugs that also inhibit the synthesis of GI protective prostaglandins) the risk for GI ulcerations and bleeding is increased.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ellershaw JE, Kelly MJ. Corticosteroids and peptic ulceration. <i>Palliat Med</i>. 1994;8(4):313-319. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7882482\">[PubMed 7882482]</a></p>\n<p>2. Pecora PG, Kaplan B. Corticosteroids and ulcers: is there an association? <i>Ann Pharmacother</i>. 1996;30(7-8):870-872. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8826\">[PubMed 8826]</a></p>\n<p>3. Harris CL, Raisch DW, Abhyankar U, Marfatia S, Campbell HM, Sather MR. GI risk factors and use of GI protective agents among patients receiving nonsteroidal antiinflammatory drugs. <i>Ann Pharmacother</i>. 2006;40(11):1921-1931. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17047140\">[PubMed 17047140]</a></p>\n<p>4. Celebrex (celecoxib) [prescribing information]. New York, NY: Pfizer Inc; May 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4011":"<p><b>Title</b> Warfarin / Corticosteroids (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin. <b>Severity</b> Major <b>Onset</b> Delayed <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor INR if corticosteroid treatment is initiated with stable warfarin therapy. Onset of changes in INR is variable and may be anticipated 3-10 days after initiating steroid. Adjustment of warfarin dose should be expected.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n</div> \n<p><b>Discussion</b> Warfarin dose requirements were more than 50% lower (0.057mg/kg/day vs. 0.12mg/kg/day) during concurrent corticosteroid therapy (during first and second induction phases) in 29 children randomized to low-dose warfarin (i.e., target INR of 1.3-1.9) in a study of pediatric cancer patients (n=62).<sup>1</sup><br><br>A retrospective medical record review from a pharmacist-run anticoagulant clinic found that initiation of prednisone (varying dosages) or methylprednisone (dose-pack) in patients (n=32 encounters) previously stabilized on warfarin therapy was associated with an INR increase in 91% of patients, from a baseline mean of 2.33 +/- 0.37 to a mean post-steroid INR of 3.57 +/- 1.07 (p&lt;0.001). Five patients exhibited post-steroid INR values exceeding 5, while a total of 16 (50%) required warfarin dose modification.<sup>2</sup><br><br>Two other reports have described increased INRs associated with corticosteroid use in patients treated with warfarin, though both reports included few patients receiving warfarin, as most were receiving fluindione (a non-coumarin vitamin K antagonist not available in the U.S.).<sup>3,4</sup><br><br>The mechanism by which corticosteroid use is associated with an increase in INR and decrease in warfarin dose requirements is not clear. A direct inhibition of warfarin metabolism by the corticosteroids is possible, since CYP3A is at least partially involved in the metabolism of both warfarin and most steroids; however, this mechanism seems unlikely since corticosteroids appear to primarily induce CYP3A (vs. inhibit) and since CYP2C9 is primarily responsible for warfarin metabolism. It is important to note, though, that steroid-regulation of drug metabolism is complex,<sup>5</sup> so a direct or indirect metabolism-related mechanism remains one possible mechanism. Of note, it is also important to consider that other mechanisms, including an effect of the underlying conditions that necessitate steroid therapy, may be involved as several inflammatory conditions themselves have been associated with altered drug elimination.<sup>6</sup> A similar effect seen with fluindione<sup>3,4</sup> suggests that this interaction may not be (solely) pharmacokinetic in nature but rather related to warfarin's vitamin K-antagonizing effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ruud E, Holmstrom H, Bergan S, et al, “Oral Anticoagulation With Warfarin Is Significantly Influenced by Steroids and CYP2C9 Polymoprhisms in Children With Cancer,” <i>Pediatr Blood Cancer</i>, 2008, 50:710-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17226852\">[PubMed 17226852]</a> </p>\n<p>2. Hazlewood KA, Fugate SE, Harrison DL, “Effect of Oral Corticosteroids on Chronic Warfarin Therapy,” <i>Ann Pharmacother</i>, 2006, 40:2101-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17119104\">[PubMed 17119104]</a></p>\n<p>3. Sellam J, Costedoat-Chalumeau N, Amoura Z, et al, “Potentiation of Fluindione or Warfarin by Dexamethasone in Multiple Myeloma and AL Amyloidosis,” <i>Joint Bone Spine</i>, 2007, 74(5):446-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17692552\">[PubMed 17692552]</a> </p>\n<p>4. Costedoat-Chalumeau N, Amoura Z, Aymard G, et al, “Potentiation of Vitamin K Antagonists by High-Dose Intravenous Methylprednisolone,” <i>Ann Intern Med</i>, 2000, 132(8):631-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10766681\">[PubMed 10766681]</a></p>\n<p>5. Pascussi JM, Gerbal-Chaloin S, Drocourt L, et al, “The Expression of CYP2B6, CYP2C9 and CYP3A4 Genes: a Tangle of Networks of Nuclear and Steroid Receptors,” <i>Biochim Biophys Acta</i>, 2003, 1619(3):243-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12573484\">[PubMed 12573484]</a> </p>\n<p>6. Iber H, Sewer MB, Barclay TB, et al, “Modulation of Drug Metabolism in Infectious and Inflammatory Diseases,” <i>Drug Metab Rev</i>, 1999, 31(1):29-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10065364\">[PubMed 10065364]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4013":"<p><b>Title</b> Loop Diuretics / Corticosteroids (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor serum potassium. Addition of potassium-sparing diuretic and/or potassium supplementation may be necessary with concomitant treatment.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> Based on their respective pharmacology, systemic corticosteroids and diuretics (loop and thiazide) are known to induce renal potassium wasting. Concurrent therapy is likely to be additive in this regard. <br><br>A large hospital drug monitoring study reviewed the records of 2,439 patients on potassium-wasting diuretic therapy in order to identify other factors which influenced serum potassium levels.<sup>1</sup> It was found that oral or parenteral prednisone therapy (5-2,000 mg/day) was a significant risk factor for the development of hypokalemia.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Widmer P, Maibach R, Kunzi UP, “Diuretic-Related Hypokalaemia: The Role of Diuretics, Potassium Supplements, Glucocorticoids and Beta 2-Adrenoceptor Agonists. Results from the Comprehensive Hospital Drug Monitoring Programme, Berne (CHDM),” <i>Eur J Clin Pharmacol</i>, 1995, 49(1-2):31-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8751018\">[PubMed 8751018]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4014":"<p><b>Title</b> Thiazide and Thiazide-Like Diuretics / Corticosteroids (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor serum potassium. Addition of potassium-sparing diuretic and/or potassium supplementation may be necessary with concomitant treatment.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> Based on their respective pharmacology, systemic corticosteroids and diuretics (loop and thiazide) are known to induce renal potassium wasting. Concurrent therapy is likely to be additive in this regard.<br><br>A large hospital drug monitoring study reviewed the records of 2,439 patients on potassium-wasting diuretic therapy in order to identify other factors which influenced serum potassium levels.1 It was found that oral or parenteral prednisone therapy (5-2,000 mg/day) was a significant risk factor for the development of hypokalemia.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Widmer P, Maibach R, Kunzi UP, “Diuretic-Related Hypokalaemia: The Role of Diuretics, Potassium Supplements, Glucocorticoids and Beta 2-Adrenoceptor Agonists. Results from the Comprehensive Hospital Drug Monitoring Programme, Berne (CHDM),” Eur J Clin Pharmacol, 1995, 49(1-2):31-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8751018\">[PubMed 8751018]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4015":"<p><b>Title</b> Amphotericin B / Corticosteroids (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor cardiac function and serum electrolytes (especially potassium) if concomitant therapy desired.</p>\n<div>\n <p><b>Amphotericin B Interacting Members</b> Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex</p>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n</div> \n<p><b>Discussion</b> The manufacturer of Ambisome states that corticosteroids can potentiate the hypokalemic effect of liposomal amphotericin.<sup>1</sup> A case study report noted the occurrence of cardiac enlargement and congestive failure in 3 patients receiving amphotericin B and hydrocortisone (25-40 mg/day). Cardiac symptoms diminished upon discontinuation of the steroid and initiation of potassium supplementation.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ambisome [package insert]. San Dimas, CA: Gilead Sciences, Inc., 2002.</p>\n<p>2. Chung D-K, Koenig MG, “Reversible Cardiac Enlargement During Treatment with Amphotericin B and Hydrocortisone. Report of 3 Cases,” <i>Am Rev Respir Dis</i>, 1971, 103:831-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4253584\">[PubMed 4253584]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4016":"<p><b>Title</b> Aspirin / Selective Serotonin Reuptake Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased risk of bleeding during concomitant use of selective serotonin reuptake inhibitors (SSRIs) and aspirin.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine, FluvoxaMINE, PARoxetine, Sertraline, Vilazodone, Vortioxetine</p>\n</div> \n<p><b>Discussion</b> Selective serotonin reuptake inhibitors (SSRIs) may have antiplatelet effects, and the combination of an SSRI and aspirin may increase the risk of gastrointestinal bleeding. Studies in post-myocardial infarction and heart failure patients already receiving aspirin have found that SSRI use was associated with additional impairment of platelet function.<sup>1,2</sup>. Multiple case-control and retrospective cohort studies have reported statistically significant associations between concurrent SSRI and aspirin use and an increased risk of gastrointestinal bleeding, with the combination increasing the risk by approximatlely 1.4- to 7-fold.<sup>3,4,5,6,7</sup> Attempts to determine differences in risk among individual SSRIs or according to dose have been limited by the nature of available studies, with current data not sufficient to discriminate among individual agents or according to SSRI dose. Some studies have suggested that agents with greater inhibition of serotonin reuptake (i.e., paroxetine, sertraline, fluoxetine) are more likely to be associated with bleeding events,<sup>5,8</sup> but at present, these conclusions are based on relatively limited evidence. It is important to note that available studies all have substantial limitations, most related to their design and retrospective nature that make it difficult to determine how best to manage this potential interaction. However, considering the number of studies suggesting an association together with a plausible mechanism and evidence of an antiplatelet effect of SSRIs independent of aspirin, it seems prudent to recommend increased monitoring for bleeding in patients receiving this combination and even possible consideration of alternative therapy when appropriate.<br><br>Several potential mechanisms for an antiplatelet effect of the SSRIs have been reported, but the primary suspected mechanism involves depletion of platelet serotonin concentrations.<sup>1,2,9</sup> Serotonin enhances platelet aggregration, and since platelets can not synthesize serotonin, transporter-mediated uptake from blood is required for maintenance of normal intra-platelet serotonin concentrations. Inhibition of this uptake by SSRIs is thought to lead to a gradual depletion of platelet serotonin and consequently, to impaired platelet aggregation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Serebruany VL, Glassman AH, Malinin AI, et al, “Platelet/Endothelial Biomarkers in Depressed Patients Treated with the Selective Serotonin Reuptake Inhibitor Sertraline After Acute Coronary Events,” <i>Circulation</i>, 2003, 108:939-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12912814\">[PubMed 12912814]</a></p>\n<p>2. Serebruany VL, Glassman AH, Malinin AI, et al, “Selective Serotonin Reuptake Inhibitors Yield Additional Antiplatelet Protection in Patients with Congestive Heart Failure Treated with Antecedent Aspirin, ” <i> Eur J Heart Fail</i>, 2003, 5:517-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12921813\">[PubMed 12921813]</a></p>\n<p>3. Dalton SO, Johansen C, Mellelkjaer L, et al, “Use of Selective Serotonin Reuptake Inhibitors and Risk of Upper Gastrointestinal Tract Bleeding,” <i>Arch Intern Med</i>, 2003, 163:59-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12523917\">[PubMed 12523917]</a></p>\n<p>4. de Abajo FJ, Rodriguez LAG, Montero D, “Association Between Selective Serotonin Reuptake Inhibitors and Upper Gastrointestinal Bleeding: Population Based Case-Control Study,” <i>BMJ</i>, 1999, 319:1106-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10531103\">[PubMed 10531103]</a></p>\n<p>5. van Walraven C, Mamdani MM, Wells PS, et al, “Inhibition of Serotonin Reuptake by Antidepressants and Upper Gastrointestinal Bleeding in Elderly Patients: Retrospective Cohort Study,” <i> BMJ</i>, 2001, 323:655-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11566827\">[PubMed 11566827]</a></p>\n<p>6. Wessinger S, Kaplan M, Choi L, et al, “Increased Use of Selective Serotonin Reuptake Inhibitors in Patients Admitted with Gastrointestinal Haemorrhage: A Multicentre Retrospective Analysis,” <i>Aliment Pharmacol Ther</i>, 2006, 23:937-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16573796\">[PubMed 16573796]</a></p>\n<p>7. Labos C, Dasgupta K, Nedjar H, et al, “Risk of Bleeding Associated with Combined Use of Selective Serotonin Reuptake Inhibitors and Antiplatelet Therapy Following Acute Myocardial Infarction,” <i>CMAJ</i>, 2011, 183(16):1835-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21948719\">[PubMed 21948719]</a></p>\n<p>8. Meijer WEE, Heerdink ER, Nolen WA, et al, “Association of Risk of Abnormal Bleeding with Degree of Serotonin Reuptake Inhibition by Antidepressants,” <i>Arch Intern Med</i>, 2004, 164:2367-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15557417\">[PubMed 15557417]</a></p>\n<p>9. Turner MS, May DB, Arthur RR, et al, “Clinical Impact of Selective Serotonin Reuptake Inhibitors Therapy with Bleeding Risks,” <i>J Intern Med</i>, 2007, 261:205-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17305643\">[PubMed 17305643]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4017":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents (Nonselective) / Selective Serotonin Reuptake Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> To minimize the risk of bleeding associated with this combination, consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent, such as a proton pump inhibitor for the time that combined selective serotonin reuptake inhibitor (SSRIs) and nonsteroidal anti-inflammatory drugs (NSAIDs) is necessary. While there are no published guidelines regarding the management of this interaction, these recommendations echo those found in a recent review<sup>1</sup> and a large cohort study.<sup>2</sup> It is important to note, however, that another recent review stopped short of recommending an alteration of therapy.<sup>3</sup> Minimally, close monitoring for increased risk of bleeding and/or decreased SSRI clinical effectiveness during concomitant SSRI-NSAID use is recommended.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents (Nonselective) Interacting Members</b> Aceclofenac, Acemetacin, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Nabumetone, Naproxen, Oxaprozin, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine, FluvoxaMINE, PARoxetine, Sertraline, Vilazodone, Vortioxetine</p>\n</div> \n<p><b>Discussion</b> <u>Potential for Increased Bleeding</u><br>Multiple case-control and retrospective cohort studies have reported statistically significant associations between concurrent SSRI and NSAID use and risk of gastrointestinal bleeding, with the combination increasing the risk by anywhere from 2.8-fold to 15.6-fold.<sup>2,4,5,6,7,8,9,10,11</sup> Studies evaluating the risk of intracranial bleeding with combination SSRI-NSAID therapy have found a marginally significant increase in risk anywhere from 1.4-fold to 4.3-fold.<sup>12,13,14</sup> In contrast, two case-control studies have reported that the bleeding risk with the SSRI-NSAID combination is not significantly different from the risk associated with the use of NSAIDs alone.<sup>15,16</sup> Others that have reported a significant increase in risk with the combination have noted only a modest increase in risk (OR=1.6) vs. the risk with NSAIDs alone.<sup>17</sup> It is important to note that available studies all have substantial limitations, most related to their design and retrospective nature that make it difficult to determine how best to manage this potential interaction. In particular, the studies evaluating the risk of the combination on intracranial bleeding are limited by a very small number of cases. However, considering the number of studies suggesting an association together with a plausible mechanism and evidence for an antiplatelet effect of SSRIs independent of NSAIDs, it seems prudent to recommend altering therapy to minimize risk when possible and increased monitoring for bleeding in all patients receiving this combination.<br><br>The suspected mechanism for this reported increase in bleeding risk involves both the reduction of gastroprotective prostaglandins by NSAIDs and the antiplatelet effects of both NSAIDs and SSRIs.<sup>1</sup> This dual mechanism is important as it seems that existing tissue damage (e.g., NSAID-related gastric erosions) is critical for the appearance of bleeding associated with this interaction.<sup>18</sup> Such absence of a source of tissue damage has been cited as a reason for such a lower absolute risk of cerebrovascular vs. gastrointestinal bleeding with the combination.<sup>1,18</sup><br><br>Several potential mechanisms for an antiplatelet effect of the SSRIs have been reported, but the primary suspected mechanism involves depletion of platelet serotonin concentrations.<sup>3</sup> Serotonin enhances platelet aggregration, and since platelets can not synthesize serotonin, transporter-mediated uptake from blood is required for maintenance of normal intra-platelet serotonin concentrations. Inhibition of this uptake by SSRIs is thought to lead to a gradual depletion of platelet serotonin and consequently, to impaired platelet aggregation.<br><br>Attempts to determine differences in risk among individual SSRIs or according to dose have been limited by the nature of available studies, with current data not sufficient to discriminate among individual agents or according to SSRI dose. Some studies have suggested that agents with greater inhibition of serotonin reuptake (i.e., paroxetine, sertraline, fluoxetine) are more likely to be associated with bleeding events,<sup>7,19</sup> but at present, these conclusions are based on relatively limited evidence. Data regarding differential risk among individual NSAIDs are even more limited, with two studies suggesting lower risk of bleeding with selective COX-2 inhibitors vs. nonselective NSAIDs,<sup>7,17</sup> one reporting a decreased risk with “semi-selective” NSAIDs (etodolac, meloxicam, nabumetone, nimelsulide) vs. nonselective NSAIDs,<sup>17</sup> and another study reporting no difference between COX-2 inhibitors and nonselective NSAIDs.<sup>8</sup><br><br><u>Possible Decrease in SSRI Effectiveness</u><br>A post-hoc analysis of a large clinical trial of antidepressant treatments found decreased rates of depression remission among subjects who reported any NSAID use (45%, 182/409) compared to those who reported no NSAID use (55%, 628/1137).<sup>20</sup> A series of studies in mice provided two possible explanations for this finding. In one series of studies, NSAID treatment was shown to block many of the changes in cytokine and other regulatory protein concentrations that are normally observed following SSRI treatment.<sup>20</sup> Studies with other antidepressant found that NSAIDs had only a minimal effect on the cytokine effects observed following tricyclic antidepressant treatment and no effect on the effects of tranycypromine (a monoamine oxidase inhibitor) or bupropion (an atypical antidepressant). A second possible explanation is a pharmacokinetic interaction, where NSAIDs decrease the concentrations of SSRIs. In one study in mice, average serum concentrations of citalopram and its didesmethyl metabolite were decreased by approximately 64% and 73%, respectively, with concurrent ibuprofen.<sup>20</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mort JR, Aparasu RR, Baer RK. Interaction between selective serotonin reuptake inhibitors and nonsteroidal antiinflammatory drugs: review of the literature. <i>Pharmacotherapy</i>. 2006;26(9):1307-1313. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16945053\">[PubMed 16945053]</a></p>\n<p>2. de Jong JCF, van den Berg PB, Tobi H, et al. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. <i> Br J Clin Pharmacol</i>. 2003;55:591-595. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12814454\">[PubMed 12814454]</a></p>\n<p>3. Turner MS, May DB, Arthur RR, et al. Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks. <i>J Intern Med</i>. 2007;261:205-213. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17305643\">[PubMed 17305643]</a></p>\n<p>4. Dalton SO, Johansen C, Mellelkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding. <i> Arch Intern Med</i>. 2003;163:59-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12523917\">[PubMed 12523917]</a></p>\n<p>5. de Abajo FJ, Rodriguez LAG, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. <i>BMJ</i>. 1999;319:1106-1109. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10531103\">[PubMed 10531103]</a></p>\n<p>6. van Walraven C, Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. <i>BMJ</i>. 2001;323:655-658. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11566827\">[PubMed 11566827]</a></p>\n<p>7. Wessinger S, Kaplan M, Choi L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. <i>Aliment Pharmacol Ther</i>. 2006;23:937-944. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16573796\">[PubMed 16573796]</a></p>\n<p>8. Tata LJ, Fortun PJ, Hubbard RB, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? <i>Aliment Pharmacol Ther</i>. 2005;22:175-181. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16091054\">[PubMed 16091054]</a></p>\n<p>9. Dall M, Schaffalitzky de Muckadell OB, Lassen AT, et al. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. <i>Clin Gastroenterol Hepatol</i>. 2009;7(12):1314-1321. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19716436\">[PubMed 19716436]</a></p>\n<p>10. Lewis JD, Strom BL, Localio AR, et al. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. <i>Pharmacoepidemiol Drug Saf</i>. 2008;17(4):328-335. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18188866\">[PubMed 18188866]</a></p>\n<p>11. de Abajo FJ, Garcia-Rodriguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. <i>Arch Gen Psychiatry</i>. 2008;65(7):795-803. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18606952\">[PubMed 18606952]</a></p>\n<p>12. de Abajo FJ, Jick H, Derby L, et al. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. <i> Br J Clin Pharmacol</i>. 2000;50:43-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10886117\">[PubMed 10886117]</a></p>\n<p>13. Bak S, Tsiropoulos I, Kjaersgaard JO, et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. <i>Stroke</i>. 2002;33:1465-1473. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12052976\">[PubMed 12052976]</a></p>\n<p>14. Shin JY, Park MJ, Lee SH, et al. Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study. <i>BMJ</i>. 351:h3517. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26173947\">[PubMed 26173947]</a></p>\n<p>15. Vidal X, Ibanez L, Vendrell L, et al. Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study. <i>Drug Saf</i>. 2008;31(2):159-168. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18217791\">[PubMed 18217791]</a></p>\n<p>16. Targownik LE, Bolton JM, Metge CJ, et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2009;104(6):1475-1482. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19491861\">[PubMed 19491861]</a></p>\n<p>17. Helin-Salmivaara A, Huttunen T, Gronroos JM, et al. Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: a case-control study in the general population. <i>Eur J Clin Pharmacol</i>. 2007;63(4):403-408. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17347805\">[PubMed 17347805]</a></p>\n<p>18. Weinrieb RM, Auriacombe M, Lynch KG, et al. Selective serotonin re-uptake inhibitors and the risk of bleeding. <i>Expert Opin Drug Saf</i>. 2005;4:337-344. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15794724\">[PubMed 15794724]</a></p>\n<p>19. Meijer WEE, Heerdink ER, Nolen WA, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. <i>Arch Intern Med</i>, 2004;164:2367-2370. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15557417\">[PubMed 15557417]</a></p>\n<p>20. Warner-Schmidt JL, Vanover KE, Chen EY, et al. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. <i>Proc Natl Acad Sci U S A</i>. 2011;108(22):9262-9267. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21518864\">[PubMed 21518864]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4018":"<p><b>Title</b> Corticosteroids (Systemic) / Neuromuscular-Blocking Agents (Nondepolarizing)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor closely for new onset or worsening muscle weakness, reduction or loss of deep tendon reflexes and/or peripheral sensory decriments. Although concomitant neuromuscular blockade and corticosteroid therapy may be therapeutically necessary, critical care guidelines<sup>1</sup> recommend using a neuromuscular blocking drug only when absolutely necessary, employing the lowest doses possible and limiting the duration of either agent to limit the risk of developing myopathy or neuropathy.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone*, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n <p><b>Neuromuscular-Blocking Agents (Nondepolarizing) Interacting Members</b> Atracurium*, Cisatracurium*, Mivacurium, Pancuronium*, Rocuronium, Vecuronium*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Corticosteroids (high-dose, systemic use) and neuromuscular blocking agents (non-depolarizing, NDNMB) have each independently been shown to have an adverse effect on neuromuscular transmission.<sup>2,3,4</sup> The combination of these agents may lead to further increased risk of prolonged muscle weakness, including neuropathy, myopathy, and/or paralysis. This has been observed most commonly in the ICU setting, particularly in patients presenting with sepsis or severe asthma requiring high-dose intravenous steroids and mechanical ventilation. Recovery from these effects may take weeks to months.<br><br>The mechanism(s) of muscle impairment are not well understood. The combination of NDNMB and corticosteroids have been shown to cause a loss of thick myosin filaments, accompanied by increases in serum creatinine kinase levels. Additional mechanisms that have been observed with corticosteroids include reduced electrical excitability (decreased motor end-plate potentials and impairment of sodium channels) which may be due to noncompetitive antagonism of nicotinic acetylcholine receptors. An <i>in vitro</i> study documented that this antagonism was additive with the competitive antagonism demonstrated by vecuronium.<sup>5</sup> Although only the steroidal neuromuscular blocking drugs were originally implicated as the cause of neuropathy/myopathy,<sup>6</sup> subsequent reports have identified similar phenomena in depolarizing blockers without the steroidal nucleus as well.<sup>7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Murray MJ, Cowen J, DeBlock H, et al, “Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient,” <i>Crit Care Med</i>, 2002, 30:142-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11902255\">[PubMed 11902255]</a></p>\n<p>2. Murray MJ, Brull SJ, Bolton CF, “Brief Review: Nondepolarizing Neuromuscular Blocking Drugs and Critical Illness Myopathy,” <i>Can J Anesth</i>, 2006, 53(11):1148-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17079642\">[PubMed 17079642]</a></p>\n<p>3. Fischer JR, Baer RK, “Acute Myopathy Associated with Combined Use of Corticosteroids and Neuromuscular Blocking Agents,” <i>Ann Pharmacother</i>, 1996, 30(12):1437-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8968457\">[PubMed 8968457]</a></p>\n<p>4. Reeves ST, Turcasso NM, “Nondepolarizing Neuromuscular Blocking Drugs in the Intensive Care Unit: A Clinical Review,” <i>South Med J</i>, 1997, 90(8):769-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9258301\">[PubMed 9258301]</a></p>\n<p>5. Kindler CH, Verotta D, Gray AT, et al, “Additive Inhibition of Nicotinic Acetylcholine Receptors by Corticosteroids and the Neuromuscular Blocking Drug Vecuronium,” <i> Anesthesiology</i>, 2000, 92:821-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10719961\">[PubMed 10719961]</a></p>\n<p>6. Griffin D, Fairman N, Coursin D, et al, “Acute Myopathy During Treatment of Status Asthmaticus with Corticosteroids and Steroidal Muscle Relaxants,” <i>Chest</i>, 1992, 102, 510-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1386568\">[PubMed 1386568]</a></p>\n<p>7. Davis NA, Rodgers JE, Gonzalez ER, “Prolonged Weakness after Cisatracurium Infusion: A Case Report,” <i>Crit Care Med</i>, 1998, 26:1290-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9671384\">[PubMed 9671384]</a></p>\n<p>8. Corsin DB, Prielipp RC, “Prolonged Paralysis with Atracurium Infusion (Letter),” <i>Crit Care Med</i>, 1995, 23:1155-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7774234\">[PubMed 7774234]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4019":"<p><b>Title</b> Gemifloxacin / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may decrease the excretion of Gemifloxacin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects or toxicities related to gemifloxacin if coadministered with probenecid.</p> \n<p><b>Discussion</b> The manufacturer of gemifloxacin reports a 50% decrease in the renal excretion of gemifloxacin when given to healthy subjects also receiving repeated dosing of probenecid (4.5 g total).<sup>1</sup> The decrease in renal clearance resulted in a 45% increase in AUC and a 1.6-hour prolongation of half-life.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Factive [package insert]. Waltham, MA: Oscient Pharmaceuticals, 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4020":"<p><b>Title</b> LORazepam / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of LORazepam. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects of lorazepam, particularly CNS depressant effects, if lorazepam is coadministered with probenecid. The duration of benzodiazepine effects may be more prolonged with concomitant therapy. Product labeling recommends a 50% dose reduction of lorazepam when concurrent therapy is employed.</p> \n<p><b>Discussion</b> In a cross-over pharmacokinetic study, 9 subjects received lorazepam (2 mg IV) in the presence or absence of probenecid (500 mg every 6 hours).<sup>1</sup> In combination with probenecid, the renal clearance of lorazepam was significantly decreased (44%), resulting in more than a 2-fold prolongation of lorazepam half-life. Lorazepam is rapidly metabolized via conjugation to inactive glucuronide metabolites, presumably through the action of one or more uridine diphosphate glucuronosyltransferase (UGT) enzymes.<sup>2</sup> Probenecid has been shown in vitro to block lorazepam glucuronidation,<sup>3</sup> as well as to inhibit multiple isoforms of human UGT.<sup>4</sup> These data suggest that probenecid may impair the normal hepatic phase II metabolism of lorazepam, and thus the manufacturer recommends a 50% dose reduction of lorazepam if used with probenecid.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Abernethy DR, Greenblatt DJ, Ameer B, et al, “Probenecid Impairment of Acetaminophen and Lorazepam Clearance: Direct Inhibition of Ether Glucuronide Formation,” <i>J Pharmacol Exp Ther</i>, 1985, 234(2):345-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4020675\">[PubMed 4020675]</a></p>\n<p>2. Prescribing information. Ativan (lorazepam). Bridgewater, NJ: BTA Pharmaceuticals, Inc., 10/09.</p>\n<p>3. von Moltke LL, Manis M, Harmatz JS, et al, “Inhibition of Acetaminophen and Lorazepam Glucuronidation In Vitro by Probenecid,” <i>Biopharm Drug Dispos</i>, 1993, 14(2):119-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8453022\">[PubMed 8453022]</a></p>\n<p>4. Uchaipichat V, Mackenzie PI, Guo XH, et al, “Human UDP-Glucuronosyltransferases: Isoform Selectivity and Kinetics of 4-Methylumbelliferone and 1-Naphthol Glucuronidation, Effects of Organic Solvents, and Inhibition by Diclofenac and Probenecid,” <i>Drug Metab Dispos</i>, 2004, 32(4):413-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15039294\">[PubMed 15039294]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4023":"<p><b>Title</b> Loop Diuretics / Corticosteroids (Orally Inhaled)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor serum potassium. Addition of potassium-sparing diuretic and/or potassium supplementation may be necessary with concomitant treatment.</p>\n<div>\n <p><b>Corticosteroids (Orally Inhaled) Interacting Members</b> Beclomethasone (Oral Inhalation), Budesonide (Oral Inhalation), Ciclesonide (Oral Inhalation), Flunisolide (Oral Inhalation), Fluticasone (Oral Inhalation), Mometasone (Oral Inhalation), Triamcinolone (Systemic)</p>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> Based on their respective pharmacology, systemic corticosteroids and diuretics (loop and thiazide) are known to induce renal potassium wasting. Concurrent therapy is likely to be additive in this regard. Two separate case reports have shown budesonide treatment of Crohn's disease to be associated with severe hypokalemia,<sup>1,2</sup> in one of the cases precipitating rhabdomyolysis. <br><br>A large hospital drug monitoring study reviewed the records of 2,439 patients on potassium-wasting diuretic therapy in order to identify other factors which influenced serum potassium levels.<sup>3</sup> It was found that oral or parenteral prednisone therapy (5-2,000 mg/day) was a significant risk factor for the development of hypokalemia.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mangone M, Spagnolo A, Capurso G, et al, “Rhabdomyolysis Due to Severe Hypokalemia in a Crohn's Disease Patient After Budesonide Treatment,” <i>Dig Liver Dis</i>, 2006, epub Oct, 16, 2006. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17049941\">[PubMed 17049941]</a> </p>\n<p>2. Rosenbach Y, Zahavi I, Rachmal A, et al, “Severe Hypokalemia After Budesonide Treatment for Crohn's Disease,” <i>J Pediatr Gastroenterol Nutr</i>, 1997, 24(3):352-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9138184\">[PubMed 9138184]</a></p>\n<p>3. Widmer P, Maibach R, Kunzi UP, “Diuretic-Related Hypokalaemia: The Role of Diuretics, Potassium Supplements, Glucocorticoids and Beta 2-Adrenoceptor Agonists. Results from the Comprehensive Hospital Drug Monitoring Programme, Berne (CHDM),” <i>Eur J Clin Pharmacol</i>, 1995, 49(1-2):31-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8751018\">[PubMed 8751018]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4024":"<p><b>Title</b> Thiazide and Thiazide-Like Diuretics / Corticosteroids (Orally Inhaled)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor serum potassium. Addition of potassium-sparing diuretic and/or potassium supplementation may be necessary with concomitant treatment.</p>\n<div>\n <p><b>Corticosteroids (Orally Inhaled) Interacting Members</b> Beclomethasone (Oral Inhalation), Budesonide (Oral Inhalation), Ciclesonide (Oral Inhalation), Flunisolide (Oral Inhalation), Fluticasone (Oral Inhalation), Mometasone (Oral Inhalation), Triamcinolone (Systemic)</p>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> Based on their respective pharmacology, systemic corticosteroids and diuretics (loop and thiazide) are known to induce renal potassium wasting. Concurrent therapy is likely to be additive in this regard. Two separate case reports have shown budesonide treatment of Crohn's disease to be associated with severe hypokalemia,<sup>1,2</sup> in one of the cases precipitating rhabdomyolysis. <br><br>A large hospital drug monitoring study reviewed the records of 2,439 patients on potassium-wasting diuretic therapy in order to identify other factors which influenced serum potassium levels.<sup>3</sup> It was found that oral or parenteral prednisone therapy (5-2,000 mg/day) was a significant risk factor for the development of hypokalemia.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mangone M, Spagnolo A, Capurso G, et al, “Rhabdomyolysis Due to Severe Hypokaliemia in a Crohn's Disease Patient After Budesonide Treatment,” <i>Dig Liver Dis</i>, 2006, epub Oct, 16, 2006. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17049941\">[PubMed 17049941]</a> </p>\n<p>2. Rosenbach Y, Zahavi I, Rachmal A, et al, “Severe Hypokalemia After Budesonide Treatment for Crohn's Disease,” <i>J Pediatr Gastroenterol Nutr</i>, 1997, 24(3):352-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9138184\">[PubMed 9138184]</a></p>\n<p>3. Widmer P, Maibach R, Kunzi UP, “Diuretic-Related Hypokalaemia: The Role of Diuretics, Potassium Supplements, Glucocorticoids and Beta 2-Adrenoceptor Agonists. Results from the Comprehensive Hospital Drug Monitoring Programme, Berne (CHDM),” <i>Eur J Clin Pharmacol</i>, 1995, 49(1-2):31-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8751018\">[PubMed 8751018]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4025":"<p><b>Title</b> Amphotericin B / Corticosteroids (Orally Inhaled)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor cardiac function and serum electrolytes (especially potassium) if concomitant therapy desired.</p>\n<div>\n <p><b>Amphotericin B Interacting Members</b> Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex</p>\n <p><b>Corticosteroids (Orally Inhaled) Interacting Members</b> Beclomethasone (Oral Inhalation), Budesonide (Oral Inhalation), Ciclesonide (Oral Inhalation), Flunisolide (Oral Inhalation), Fluticasone (Oral Inhalation), Mometasone (Oral Inhalation), Triamcinolone (Systemic)</p>\n</div> \n<p><b>Discussion</b> The manufacturer of Ambisome states that corticosteroids can potentiate the hypokalemic effect of liposomal amphotericin.<sup>1</sup> A case study report noted the occurrence of cardiac enlargement and congestive failure in 3 patients receiving amphotericin B and hydrocortisone (25-40 mg/day). Cardiac symptoms diminished upon discontinuation of the steroid and initiation of potassium supplementation.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ambisome [package insert]. San Dimas, CA: Gilead Sciences, Inc., 2002.</p>\n<p>2. Chung D-K, Koenig MG, “Reversible Cardiac Enlargement During Treatment with Amphotericin B and Hydrocortisone. Report of 3 Cases,” <i>Am Rev Respir Dis</i>, 1971, 103:831-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4253584\">[PubMed 4253584]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4026":"<p><b>Title</b> Aspirin / Tricyclic Antidepressants (Tertiary Amine)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tricyclic Antidepressants (Tertiary Amine) may enhance the antiplatelet effect of Aspirin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased risk of bleeding during concomitant use of tertiary tricyclic antidepressants and aspirin.</p>\n<div>\n <p><b>Tricyclic Antidepressants (Tertiary Amine) Interacting Members</b> Amitriptyline, ClomiPRAMINE, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Trimipramine</p>\n</div> \n<p><b>Discussion</b> Tertiary tricyclic antidepressants may further impair platelet activity in patients already receiving aspirin, and the combination of these agents and aspirin may increase the risk of gastrointestinal bleeding. Studies of antidepressants that are potent inhibitors of serotonin transport (e.g., clomipramine, paroxetine, sertraline, fluoxetine) have suggested that such agents are associated with an increased risk of gastointestinal bleeding, and that even agents with more moderate and non-selective inhibition of serotonin transport, such as most tertiary tricyclic antidepressants, were also associated with increased gastrointestinal bleeding.<sup>1</sup> <br><br>Most studies of this interaction have regarded clomipramine as a potent and selective inhibitor of serotonin reuptake based on its high affinity for the serotonin transporter.<sup>2</sup> Thus, as reported for other selective serotonin reuptake inhibitors, studies suggest that combined use of clomipramine and aspirin may be associated with an increased risk of gastrointestinal bleeding of at least 2-7-fold.<sup>3,4,5</sup> Some studies have suggested that agents with greater inhibition of serotonin reuptake (e.g., clomipramine, paroxetine, sertraline, fluoxetine) are more likely to be associated with bleeding events,<sup>1,4</sup> but at present, these conclusions are based on relatively limited evidence. With the exception of clomipramine, which is generally considered a potent serotonin reuptake inhibitor as noted above, most other tertiary tricyclic antidepressants are considered to be non-selective, intermediate or moderate inhibitors of serotonin transport.<sup>2,3,4</sup> Studies of the interaction between these agents and aspirin have yielded mixed results, with one study reporting approximately twice the risk of gastrointestinal bleeding with the aspirin-tertiary tricyclic antidepressant combination than with a tertiary tricyclic antidepressant alone and nearly twice the risk versus the combination of aspirin and an antidepressant that does not impact serotonin transport.<sup>3</sup> Conversely, another study found no difference in the risk of gastrointestinal bleeding with intermediate inhibitors of serotonin transport, such as the tertiary tricyclic antidepressants, when combined with aspirin as compared to the combination of aspirin and an antidepressant with little/no impact on serotonin transport.<sup>4</sup> Despite the conflicting findings of available studies regarding the interaction between these tertiary tricyclic antidepressants and aspirin, it is recommended that clinicians regularly monitor signs and symptoms of bleeding in all patients receiving this combination.<br><br>It is important to note that available studies all have substantial limitations, most related to their design and retrospective nature that make it difficult to determine how best to manage this potential interaction. However, considering the number of studies suggesting an association, a plausible mechanism, and evidence for an antiplatelet effect of potent serotonin transport inhibitors independent of aspirin, it seems prudent to recommend increased monitoring for bleeding in patients receiving this combination and even possible consideration of alternative therapy when appropriate.<br><br>Several potential mechanisms for an antiplatelet effect of antidepressants with an effect on serotonin transport have been reported, but the primary suspected mechanism involves depletion of platelet serotonin concentrations.<sup>6</sup> Serotonin enhances platelet aggregration, and since platelets can not synthesize serotonin, transporter-mediated uptake from blood is required for maintenance of normal intra-platelet serotonin concentrations. Inhibition of this uptake is thought to lead to a gradual depletion of platelet serotonin, and consequently, to impaired platelet aggregation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Meijer WEE, Heerdink ER, Nolen WA, et al, “Association of Risk of Abnormal Bleeding with Degree of Serotonin Reuptake Inhibition by Antidepressants,” <i>Arch Intern Med</i>, 2004, 164:2367-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15557417\">[PubMed 15557417]</a></p>\n<p>2. Tatsumi M, Groshan K, Blakely RD, et al, “Pharmacological Profile of Antidepressants and Related Compounds at Human Monoamine Transporters,” <i> Eur J Pharmacol</i>, 1997, 340:249-58. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9537821\">[PubMed 9537821]</a></p>\n<p>3. Dalton SO, Johansen C, Mellelkjaer L, et al, “Use of Selective Serotonin Reuptake Inhibitors and Risk of Upper Gastrointestinal Tract Bleeding,” <i> Arch Intern Med</i>, 2003, 163:59-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12523917\">[PubMed 12523917]</a></p>\n<p>4. van Walraven C, Mamdani MM, Wells PS, et al, “Inhibition of Serotonin Reuptake by Antidepressants and Upper Gastrointestinal Bleeding in Elderly Patients: Retrospective Cohort Study, ” <i> BMJ</i>, 2001, 323:655-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11566827\">[PubMed 11566827]</a></p>\n<p>5. de Abajo FJ, Rodriguez LAG, Montero D, “Association Between Selective Serotonin Reuptake Inhibitors and Upper Gastrointestinal Bleeding: Population Based Case-Control Study,” <i>BMJ</i>, 1999, 319:1106-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10531103\">[PubMed 10531103]</a></p>\n<p>6. Turner MS, May DB, Arthur RR, et al, “Clinical Impact of Selective Serotonin Reuptake Inhibitors Therapy with Bleeding Risks,” <i> J Intern Med</i>, 2007, 261:205-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17305643\">[PubMed 17305643]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4027":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) / Tricyclic Antidepressants (Tertiary Amine)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tricyclic Antidepressants (Tertiary Amine) may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased risk of bleeding during concomitant tertiary tricyclic antidepressant-nonsteroidal anti-inflammatory drug (NSAID) use. Of all tertiary tricyclic antidepressants, the risk associated with this interaction appears to be greatest for clomipramine, so for interactions involving clomipramine and an NSAID, consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent, such as a proton pump inhibitor.</p>\n<div>\n <p><b>Tricyclic Antidepressants (Tertiary Amine) Interacting Members</b> Amitriptyline, ClomiPRAMINE, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Trimipramine</p>\n <p><b>Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) Interacting Members</b> Celecoxib, Etoricoxib, Morniflumate, Nimesulide, Parecoxib, Talniflumate</p>\n</div> \n<p><b>Discussion</b> Tertiary tricyclic antidepressants may further impair platelet function in patients already receiving NSAIDs, and the combination of a tertiary tricyclic antidepressant and NSAID may increase the risk of gastrointestinal or intracranial bleeding. Most studies of this interaction have regarded clomipramine as a potent inhibitor of serotonin reuptake and grouped it with the selective serotonin reuptake inhibitors based on its high affinity for the serotonin transporter.<sup>1</sup> Thus, the majority of the findings related to the antiplatelet effects of the SSRIs and the interaction between SSRIs and NSAIDs also apply to clomipramine (but not necessarily to the other tertiary tricyclic antidepressants). These studies report a significant increase in risk of gastrointestinal bleeding, beyond just an additive risk, with the combination increasing the risk 2.8-fold to 15.6-fold.<sup>2,3,4,5</sup> Studies evaluating the risk of intracranial bleeding with combination SSRI (including clomipramine)-NSAID therapy have found a marginally significant increase in risk from 2.4-fold (95% CI: 0.9-6.2)<sup>6</sup> to 4.3-fold (95% CI: 1.0-19.1).<sup>7</sup> It is important to note that available studies all have substantial limitations, most related to their design and retrospective nature that make it difficult to determine how best to manage this potential interaction. In particular, the studies evaluating the risk of the combination on intracranial bleeding are limited by a very small number of cases. However, considering the number of studies suggesting an association together with a plausible mechanism and evidence for an antiplatelet effect of potent serotonin transport inhibitors (i.e., clomipramine and SSRIs) independent of NSAIDs, close monitoring for bleeding in all patients receiving this combination is recommended. Further, given the seriousness of the potential outcomes of this interaction and the routine grouping of clomipramine with the SSRIs in studies, it seems prudent to also consider altering therapy to minimize risk whenever possible.<br><br>With the exception of clomipramine, which is generally considered a potent serotonin reuptake inhibitor as noted above, most other tertiary tricyclic antidepressants are considered to be non-selective, intermediate or moderate inhibitors of serotonin transport.<sup>2,3,8</sup> Studies of the interaction between these agents and NSAIDs have generally reported that the risk of gastrointestinal bleeding associated with this combination is less than that associated with the SSRI-NSAID combination but greater than that associated with combination of an NSAID with an antidepressant that has little/no effect on serotonin transport.<sup>2,3,4</sup> Another study found virtually no difference between tertiary tricyclic antidepressants and SSRIs with regard to bleeding risk when combined with an NSAID, with each drug class associated with a 2.7 to 2.9-fold increase in risk.<sup>5</sup> To minimize the potentially serious outcome associated with this interaction, close monitoring of all patients receiving this combination is recommended, and when clinically appropriate, consider modifying therapy (e.g., change to alternative analgesic therapy or add gastroprotective agent) to minimize risk.<br><br>The suspected mechanism for this reported increase in bleeding risk involves both the reduction of gastroprotective prostaglandins by NSAIDs and the antiplatelet effects of both NSAIDs and tertiary tricyclic antidepressants.<sup>9</sup> This dual mechanism is important as it seems that existing tissue damage (e.g., NSAID-related gastric erosions) is critical for the appearance of bleeding associated with this interaction.<sup>10</sup> Such absence of a source of tissue damage has been cited as a reason for such a lower absolute risk of cerebrovascular vs. gastrointestinal bleeding with the combination.<sup>9,10</sup> Several potential mechanisms for an antiplatelet effect of the tertiary tricyclic antidepressants have been reported, but the primary suspected mechanism involves depletion of platelet serotonin concentrations.<sup>11</sup> Serotonin enhances platelet aggregration, and since platelets can not synthesize serotonin, transporter-mediated uptake from blood is required for maintenance of normal intra-platelet serotonin concentrations. Inhibition of this uptake by tertiary tricyclic antidepressants is thought to lead to a gradual depletion of platelet serotonin and consequently, to impaired platelet aggregation. Although studies have suggested that more potent inhibitors of serotonin transport (e.g., clomipramine, paroxetine, sertraline, fluoxetine) may be associated with a greater bleeding risk, available data do suggest that even agents with more moderate and non-selective inhibition of serotonin transport, such as most of the tertiary tricyclic antidepressants, are also associated with an increased risk of bleeding.<sup>2,8</sup> Data regarding differential risk among individual NSAIDs are even more limited, with one study suggesting lower risk of bleeding with selective COX-2 inhibitors vs. nonselective NSAIDs (in a study of SSRIs only - not tertiary tricyclic antidepressants)<sup>12</sup> and another study reporting no difference between COX-2 inhibitors and nonselective NSAIDs (this study did include tertiary tricyclic antidepressants).<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tatsumi M, Groshan K, Blakely RD, et al, “Pharmacological Profile of Antidepressants and Related Compounds at Human Monoamine Transporters,” <i>Eur J Pharmacol</i>, 1997, 340:249-58. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9537821\">[PubMed 9537821]</a></p>\n<p>2. van Walraven C, Mamdani MM, Wells PS, et al, “Inhibition of Serotonin Reuptake by Antidepressants and Upper Gastrointestinal Bleeding in Elderly Patients: Retrospective Cohort Study,” <i>BMJ</i>, 2001, 323:655-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11566827\">[PubMed 11566827]</a></p>\n<p>3. Dalton SO, Johansen C, Mellelkjaer L, et al, “Use of Selective Serotonin Reuptake Inhibitors and Risk of Upper Gastrointestinal Tract Bleeding,” <i>Arch Intern Med</i>, 2003, 163:59-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12523917\">[PubMed 12523917]</a></p>\n<p>4. de Abajo FJ, Rodriguez LAG, Montero D, “Association Between Selective Serotonin Reuptake Inhibitors and Upper Gastrointestinal Bleeding: Population Based Case-Control Study,” <i>BMJ</i>, 1999, 319:1106-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10531103\">[PubMed 10531103]</a></p>\n<p>5. Tata LJ, Fortun PJ, Hubbard RB, et al, “Does Concurrent Prescription of Selective Serotonin Reuptake Inhibitors and Non-Steroidal Anti-Inflammatory Drugs Substantially Increase the Risk of Upper Gastrointestinal Bleeding?” <i>Aliment Pharmacol Ther</i>, 2005, 22:175-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16091054\">[PubMed 16091054]</a></p>\n<p>6. de Abajo FJ, Jick H, Derby L, et al, “Intracranial Haemorrhage and Use of Selective Serotonin Reuptake Inhibitors, ” <i>Br J Clin Pharmacol</i>, 2000, 50:43-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10886117\">[PubMed 10886117]</a></p>\n<p>7. Bak S, Tsiropoulos I, Kjaersgaard JO, et al, “Selective Serotonin Reuptake Inhibitors and the Risk of Stroke: a Population-Based Case-Control Study,” <i>Stroke</i>, 2002, 33:1465-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12052976\">[PubMed 12052976]</a></p>\n<p>8. Meijer WEE, Heerdink ER, Nolen WA, et al, “Association of Risk of Abnormal Bleeding with Degree of Serotonin Reuptake Inhibition by Antidepressants,” <i>Arch Intern Med</i>, 2004, 164:2367-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15557417\">[PubMed 15557417]</a></p>\n<p>9. Mort JR, Aparasu RR, Baer RK, “ Interaction Between Selective Serotonin Reuptake Inhibitors and Nonsteroidal Antiinflammatory Drugs: Review of the Literature,” <i>Pharmacotherapy</i>, 2006, 26(9):1307-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16945053\">[PubMed 16945053]</a></p>\n<p>10. Weinrieb RM, Auriacombe M, Lynch KG, et al, “Selective Serotonin Re-Uptake Inhibitors and the Risk of Bleeding,” <i>Expert Opin Drug Saf</i>, 2005, 4:337-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15794724\">[PubMed 15794724]</a></p>\n<p>11. Turner MS, May DB, Arthur RR, et al, “Clinical Impact of Selective Serotonin Reuptake Inhibitors Therapy with Bleeding Risks,” <i>J Intern Med</i>, 2007, 261:205-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17305643\">[PubMed 17305643]</a></p>\n<p>12. Wessinger S, Kaplan M, Choi L, et al, “Increased Use of Selective Serotonin Reuptake Inhibitors in Patients Admitted with Gastrointestinal Haemorrhage: a Multicentre Retrospective Analysis,” <i>Aliment Pharmacol Ther</i>, 2006, 23:937-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16573796\">[PubMed 16573796]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4028":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents (Nonselective) / Tricyclic Antidepressants (Tertiary Amine)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tricyclic Antidepressants (Tertiary Amine) may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased risk of bleeding during concomitant tertiary tricyclic antidepressant-nonsteroidal anti-inflammatory drug (NSAID) use. Of all tertiary tricyclic antidepressants, the risk associated with this interaction appears to be greatest for clomipramine, so for interactions involving clomipramine and an NSAID, consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent, such as a proton pump inhibitor.</p>\n<div>\n <p><b>Tricyclic Antidepressants (Tertiary Amine) Interacting Members</b> Amitriptyline, ClomiPRAMINE, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Trimipramine</p>\n <p><b>Nonsteroidal Anti-Inflammatory Agents (Nonselective) Interacting Members</b> Aceclofenac, Acemetacin, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Nabumetone, Naproxen, Oxaprozin, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Tertiary tricyclic antidepressants may further impair platelet function in patients already receiving NSAIDs, and the combination of a tertiary tricyclic antidepressant and NSAID may increase the risk of gastrointestinal or intracranial bleeding. Most studies of this interaction have regarded clomipramine as a potent inhibitor of serotonin reuptake and grouped it with the selective serotonin reuptake inhibitors based on its high affinity for the serotonin transporter.<sup>1</sup> Thus, the majority of the findings related to the antiplatelet effects of the SSRIs and the interaction between SSRIs and NSAIDs also apply to clomipramine (but not necessarily to the other tertiary tricyclic antidepressants). These studies report a significant increase in risk of gastrointestinal bleeding, beyond just an additive risk, with the combination increasing the risk 2.8-fold to 15.6-fold.<sup>2,3,4,5</sup> Studies evaluating the risk of intracranial bleeding with combination SSRI (including clomipramine)-NSAID therapy have found a marginally significant increase in risk from 2.4-fold (95% CI: 0.9-6.2)<sup>6</sup> to 4.3-fold (95% CI: 1.0-19.1).<sup>7</sup> One study evaluated the use of antidepressant therapy (SSRI, tricyclic antidepressants, or selective norepinephrine reuptake inhibitors) and NSAID use and found that the combination increased the risk of intracranial hemmorhage compared with antidepressant therapy alone (HR 1.6 [95% CI: 1.32-1.85]).<sup>8</sup> It is important to note that available studies all have substantial limitations, most related to their design and retrospective nature that make it difficult to determine how best to manage this potential interaction. In particular, the studies evaluating the risk of the combination on intracranial bleeding are limited by a very small number of cases. However, considering the number of studies suggesting an association together with a plausible mechanism and evidence for an antiplatelet effect of potent serotonin transport inhibitors (i.e., clomipramine and SSRIs) independent of NSAIDs, close monitoring for bleeding in all patients receiving this combination is recommended. Further, given the seriousness of the potential outcomes of this interaction and the routine grouping of clomipramine with the SSRIs in studies, it seems prudent to also consider altering therapy to minimize risk whenever possible.<br><br>With the exception of clomipramine, which is generally considered a potent serotonin reuptake inhibitor as noted above, most other tertiary tricyclic antidepressants are considered to be non-selective, intermediate or moderate inhibitors of serotonin transport.<sup>2,3,9</sup> Studies of the interaction between these agents and NSAIDs have generally reported that the risk of gastrointestinal bleeding associated with this combination is less than that associated with the SSRI-NSAID combination but greater than that associated with combination of an NSAID with an antidepressant that has little/no effect on serotonin transport.<sup>2,3,4</sup> Another study found virtually no difference between tertiary tricyclic antidepressants and SSRIs with regard to bleeding risk when combined with an NSAID, with each drug class associated with a 2.7 to 2.9-fold increase in risk.<sup>5</sup> To minimize the potentially serious outcome associated with this interaction, close monitoring of all patients receiving this combination is recommended, and when clinically appropriate, consider modifying therapy (e.g., change to alternative analgesic therapy or add gastroprotective agent) to minimize risk.<br><br>The suspected mechanism for this reported increase in bleeding risk involves both the reduction of gastroprotective prostaglandins by NSAIDs and the antiplatelet effects of both NSAIDs and tertiary tricyclic antidepressants.<sup>10</sup> This dual mechanism is important as it seems that existing tissue damage (e.g., NSAID-related gastric erosions) is critical for the appearance of bleeding associated with this interaction.<sup>11</sup> Such absence of a source of tissue damage has been cited as a reason for such a lower absolute risk of cerebrovascular vs. gastrointestinal bleeding with the combination.<sup>10,11</sup> Several potential mechanisms for an antiplatelet effect of the tertiary tricyclic antidepressants have been reported, but the primary suspected mechanism involves depletion of platelet serotonin concentrations.<sup>12</sup> Serotonin enhances platelet aggregration, and since platelets can not synthesize serotonin, transporter-mediated uptake from blood is required for maintenance of normal intra-platelet serotonin concentrations. Inhibition of this uptake by tertiary tricyclic antidepressants is thought to lead to a gradual depletion of platelet serotonin and consequently, to impaired platelet aggregation. Although studies have suggested that more potent inhibitors of serotonin transport (e.g., clomipramine, paroxetine, sertraline, fluoxetine) may be associated with a greater bleeding risk, available data do suggest that even agents with more moderate and non-selective inhibition of serotonin transport, such as most of the tertiary tricyclic antidepressants, are also associated with an increased risk of bleeding.<sup>2,9</sup> Data regarding differential risk among individual NSAIDs are even more limited, with one study suggesting lower risk of bleeding with selective COX-2 inhibitors vs. nonselective NSAIDs (in a study of SSRIs only - not tertiary tricyclic antidepressants)<sup>13</sup> and another study reporting no difference between COX-2 inhibitors and nonselective NSAIDs (this study did include tertiary tricyclic antidepressants).<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tatsumi M, Groshan K, Blakely RD, et al, “Pharmacological Profile of Antidepressants and Related Compounds at Human Monoamine Transporters,” <i>Eur J Pharmacol</i>, 1997, 340:249-58. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9537821\">[PubMed 9537821]</a></p>\n<p>2. van Walraven C, Mamdani MM, Wells PS, et al, “Inhibition of Serotonin Reuptake by Antidepressants and Upper Gastrointestinal Bleeding in Elderly Patients: Retrospective Cohort Study,” <i>BMJ</i>, 2001, 323:655-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11566827\">[PubMed 11566827]</a></p>\n<p>3. Dalton SO, Johansen C, Mellelkjaer L, et al, “Use of Selective Serotonin Reuptake Inhibitors and Risk of Upper Gastrointestinal Tract Bleeding,” <i>Arch Intern Med</i>, 2003, 163:59-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12523917\">[PubMed 12523917]</a></p>\n<p>4. de Abajo FJ, Rodriguez LAG, Montero D, “Association Between Selective Serotonin Reuptake Inhibitors and Upper Gastrointestinal Bleeding: Population Based Case-Control Study,” <i>BMJ</i>, 1999, 319:1106-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10531103\">[PubMed 10531103]</a></p>\n<p>5. Tata LJ, Fortun PJ, Hubbard RB, et al, “Does Concurrent Prescription of Selective Serotonin Reuptake Inhibitors and Non-Steroidal Anti-Inflammatory Drugs Substantially Increase the Risk of Upper Gastrointestinal Bleeding?” <i>Aliment Pharmacol Ther</i>, 2005, 22:175-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16091054\">[PubMed 16091054]</a></p>\n<p>6. de Abajo FJ, Jick H, Derby L, et al, “Intracranial Haemorrhage and Use of Selective Serotonin Reuptake Inhibitors, ” <i>Br J Clin Pharmacol</i>, 2000, 50:43-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10886117\">[PubMed 10886117]</a></p>\n<p>7. Bak S, Tsiropoulos I, Kjaersgaard JO, et al, “Selective Serotonin Reuptake Inhibitors and the Risk of Stroke: a Population-Based Case-Control Study,” <i>Stroke</i>, 2002, 33:1465-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12052976\">[PubMed 12052976]</a></p>\n<p>8. Shin JY, Park MJ, Lee SH, et al. Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched study. <i>BMJ</i>. 351:h3517. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26173947\">[PubMed 26173947]</a></p>\n<p>9. Meijer WEE, Heerdink ER, Nolen WA, et al, “Association of Risk of Abnormal Bleeding with Degree of Serotonin Reuptake Inhibition by Antidepressants,” <i>Arch Intern Med</i>, 2004, 164:2367-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15555417\">[PubMed 15555417]</a></p>\n<p>10. Mort JR, Aparasu RR, Baer RK, “ Interaction Between Selective Serotonin Reuptake Inhibitors and Nonsteroidal Antiinflammatory Drugs: Review of the Literature,” <i>Pharmacotherapy</i>, 2006, 26(9):1307-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16945053\">[PubMed 16945053]</a></p>\n<p>11. Weinrieb RM, Auriacombe M, Lynch KG, et al, “Selective Serotonin Re-Uptake Inhibitors and the Risk of Bleeding,” <i>Expert Opin Drug Saf</i>, 2005, 4:337-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15794724\">[PubMed 15794724]</a></p>\n<p>12. Turner MS, May DB, Arthur RR, et al, “Clinical Impact of Selective Serotonin Reuptake Inhibitors Therapy with Bleeding Risks,” <i>J Intern Med</i>, 2007, 261:205-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17305643\">[PubMed 17305643]</a></p>\n<p>13. Wessinger S, Kaplan M, Choi L, et al, “Increased Use of Selective Serotonin Reuptake Inhibitors in Patients Admitted with Gastrointestinal Haemorrhage: a Multicentre Retrospective Analysis,” <i>Aliment Pharmacol Ther</i>, 2006, 23:937-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16573796\">[PubMed 16573796]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4029":"<p><b>Title</b> Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) / Selective Serotonin Reuptake Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased risk of bleeding during concomitant use of selective serotonin reuptake inhibitors (SSRIs) and COX-2-selective nonsteroidal anti-inflammatory agents (NSAIDs). The degree of risk with a COX-2 inhibitor is less clear than the level of risk with a non-selective NSAID, but when clinically appropriate, consider using alternative analgesics and/or addition of an gastroprotective agent, such as a proton pump inhibitor, for the time that combined SSRI and NSAID is necessary. Minimally, close monitoring for increased risk of bleeding during concomitant SSRI-NSAID use is recommended.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) Interacting Members</b> Celecoxib, Etoricoxib, Morniflumate, Nimesulide, Parecoxib, Talniflumate</p>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine, FluvoxaMINE, PARoxetine, Sertraline, Vilazodone, Vortioxetine</p>\n</div> \n<p><b>Discussion</b> <u>Potential for Increased Bleeding</u><br>Multiple case-control and retrospective cohort studies have reported statistically significant associations between concurrent SSRI and NSAID use and risk of gastrointestinal bleeding, with the combination increasing the risk by anywhere from 2.8-fold to 15.6-fold.<sup>1,2,3,4,5,6,7,8,9,10</sup> Studies evaluating the risk of intracranial bleeding with combination SSRI-NSAID therapy have found a marginally significant increase in risk from 2.4-fold (95% CI: 0.9-6.2)<sup>10</sup> to 4.3-fold (95% CI: 1.0-19.1).<sup>11</sup> In contrast, two case-control studies have reported that the bleeding risk with the SSRI-NSAID combination is not significantly different from the risk associated with the use of NSAIDs alone.<sup>12,13</sup> Others that have reported a significant increase in risk with the combination have noted only a modest increase in risk (OR=1.6) vs. the risk with NSAIDs alone.<sup>14</sup> It is important to note that available studies all have substantial limitations, most related to their design and retrospective nature that make it difficult to determine how best to manage this potential interaction. In particular, the studies evaluating the risk of the combination on intracranial bleeding are limited by a very small number of cases. However, considering the number of studies suggesting an association together with a plausible mechanism and evidence for an antiplatelet effect of SSRIs independent of NSAIDs, it seems prudent to recommend altering therapy to minimize risk when possible and increased monitoring for bleeding in all patients receiving this combination.<br><br>The suspected mechanism for this reported increase in bleeding risk involves both the reduction of gastroprotective prostaglandins by NSAIDs and the antiplatelet effects of both NSAIDs and SSRIs. This dual mechanism is important as it seems that existing tissue damage (e.g., NSAID-related gastric erosions) is critical for the appearance of bleeding associated with this interaction.<sup>15</sup> Such absence of a source of tissue damage has been cited as a reason for such a lower absolute risk of cerebrovascular vs. gastrointestinal bleeding with the combination.<br><br>Several potential mechanisms for an antiplatelet effect of the SSRIs have been reported, but the primary suspected mechanism involves depletion of platelet serotonin concentrations. Serotonin enhances platelet aggregration, and since platelets can not synthesize serotonin, transporter-mediated uptake from blood is required for maintenance of normal intra-platelet serotonin concentrations. Inhibition of this uptake by SSRIs is thought to lead to a gradual depletion of platelet serotonin and consequently, to impaired platelet aggregation.<br><br>Attempts to determine differences in risk among individual SSRIs or according to dose have been limited by the nature of available studies, with current data not sufficient to discriminate among individual agents or according to SSRI dose. Some studies have suggested that agents with greater inhibition of serotonin reuptake (i.e., paroxetine, sertraline, fluoxetine) are more likely to be associated with bleeding events,<sup>5,16</sup> but at present, these conclusions are based on relatively limited evidence. Data regarding differential risk among individual NSAIDs are even more limited, with two studies suggesting lower risk of bleeding with selective COX-2 inhibitors vs. nonselective NSAIDs,<sup>5,14</sup> one reporting a decreased risk with “semi-selective” NSAIDs (etodolac, meloxicam, nabumetone, nimelsulide) vs. nonselective NSAIDs,<sup>16</sup> and another study reporting no difference between COX-2 inhibitors and nonselective NSAIDs.<sup>6</sup><br><br><u>Possible Decrease in SSRI Effectiveness</u><br>A post-hoc analysis of a large clinical trial of antidepressant treatments found decreased rates of depression remission among subjects who reported any NSAID use (45%, 182/409) compared to those who reported no NSAID use (55%, 628/1137).<sup>17</sup> A series of studies in mice provided two possible explanations for this finding. In one series of studies, NSAID treatment was shown to block many of the changes in cytokine and other regulatory protein concentrations that are normally observed following SSRI treatment.<sup>17</sup> Studies with other antidepressant found that NSAIDs had only a minimal effect on the cytokine effects observed following tricyclic antidepressant treatment and no effect on the effects of tranycypromine (a monoamine oxidase inhibitor) or bupropion (an atypical antidepressant). A second possible explanation is a pharmacokinetic interaction, where NSAIDs decrease the concentrations of SSRIs. In one study in mice, average serum concentrations of citalopram and its didesmethyl metabolite were decreased by approximately 64% and 73%, respectively, with concurrent ibuprofen.<sup>17</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. de Jong JCF, van den Berg PB, Tobi H, et al, “Combined Use of SSRIs and NSAIDs Increases the Risk of Gastrointestinal Adverse effects, ” <i> Br J Clin Pharmacol</i>, 2003, 55:591-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12814454\">[PubMed 12814454]</a></p>\n<p>2. Dalton SO, Johansen C, Mellelkjaer L, et al, “Use of Selective Serotonin Reuptake Inhibitors and Risk of Upper Gastrointestinal Tract Bleeding,” <i> Arch Intern Med</i>, 2003, 163:59-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12523917\">[PubMed 12523917]</a></p>\n<p>3. de Abajo FJ, Rodriguez LAG, Montero D, “Association Between Selective Serotonin Reuptake Inhibitors and Upper Gastrointestinal Bleeding: Population Based Case-Control Study, ” <i>BMJ</i> 1999, 319:1106-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10531103\">[PubMed 10531103]</a> </p>\n<p>4. van Walraven C, Mamdani MM, Wells PS, et al, “Inhibition of Serotonin Reuptake by Antidepressants and Upper Gastrointestinal Bleeding in Elderly Patients: Retrospective Cohort Study, ” <i> BMJ</i>, 2001, 323:655-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11566827\">[PubMed 11566827]</a> </p>\n<p>5. Wessinger S, Kaplan M, Choi L, et al, “Increased Use of Selective Serotonin Reuptake Inhibitors in Patients Admitted with Gastrointestinal Haemorrhage: A Multicentre Retrospective Analysis,” <i> Aliment Pharmacol Ther</i>, 2006, 23:937-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16573796\">[PubMed 16573796]</a></p>\n<p>6. Tata LJ, Fortun PJ, Hubbard RB, et al, “Does Concurrent Prescription of Selective Serotonin Reuptake Inhibitors and Non-Steroidal Anti-Inflammatory Drugs Substantially Increase the Risk of Upper Gastrointestinal Bleeding?” <i>Aliment Pharmacol Ther</i>, 2005, 22:175-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16091054\">[PubMed 16091054]</a></p>\n<p>7. Dall M, Schaffalitzky de Muckadell OB, Lassen AT, et al, “An Association Between Selective Serotonin Reuptake Inhibitor Use and Serious Upper Gastrointestinal Bleeding,” <i>Clin Gastroenterol Hepatol</i>, 2009, 7(12):1314-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19716436\">[PubMed 19716436]</a></p>\n<p>8. Lewis JD, Strom BL, Localio AR, et al, “Moderate and High Affinity Serotonin Reuptake Inhibitors Increase the Risk of Upper Gastrointestinal Toxicity,” <i>Pharmacoepidemiol Drug Saf</i>, 2008, 17(4):328-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18188866\">[PubMed 18188866]</a></p>\n<p>9. de Abajo FJ, Garcia-Rodriguez LA, “Risk of Upper Gastrointestinal Tract Bleeding Associated with Selective Serotonin Reuptake Inhibitors and Venlafaxine Therapy: Interaction with Nonsteroidal Anti-Inflammatory Drugs and Effect of Acid-Suppressing Agents,” <i>Arch Gen Psychiatry</i>, 2008, 65(7):795-803. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18606952\">[PubMed 18606952]</a></p>\n<p>10. de Abajo FJ, Jick H, Derby L, et al, “Intracranial Haemorrhage and Use of Selective Serotonin Reuptake Inhibitors, ” <i> Br J Clin Pharmacol</i>, 2000, 50:43-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10886117\">[PubMed 10886117]</a></p>\n<p>11. Bak S, Tsiropoulos I, Kjaersgaard JO, et al, “Selective Serotonin Reuptake Inhibitors and the Risk of Stroke: A Population-Based Case-Control Study,” <i>Stroke</i>, 2002, 33:1465-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12052976\">[PubMed 12052976]</a></p>\n<p>12. Vidal X, Ibanez L, Vendrell L, et al, “Risk of Upper Gastrointestinal Bleeding and the Degree of Serotonin Reuptake Inhibition by Antidepressants: A Case-Control Study,” <i>Drug Saf</i>, 2008, 31(2):159-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18217791\">[PubMed 18217791]</a></p>\n<p>13. Targownik LE, Bolton JM, Metge CJ, et al, “Selective Serotonin Reuptake Inhibitors are Associated with a Modest Increase in the Risk of Upper Gastrointestinal Bleeding,” <i>Am J Gastroenterol</i>, 2009, 104(6):1475-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19491861\">[PubMed 19491861]</a></p>\n<p>14. Helin-Salmivaara A, Huttunen T, Gronroos JM, et al, “Risk of Serious Upper Gastrointestinal Events with Concurrent Use of NSAIDs and SSRIs: A Case-Control Study in the General Population,” <i>Eur J Clin Pharmacol</i>, 2007, 63(4):403-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17347805\">[PubMed 17347805]</a></p>\n<p>15. Weinrieb RM, Auriacombe M, Lynch KG, et al, “Selective Serotonin Re-Uptake Inhibitors and the Risk of Bleeding, ” <i>Expert Opin Drug Saf</i>, 2005, 4:337-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15794724\">[PubMed 15794724]</a></p>\n<p>16. Meijer WEE, Heerdink ER, Nolen WA, et al, “Association of Risk of Abnormal Bleeding with Degree of Serotonin Reuptake Inhibition by Antidepressants,” <i> Arch Intern Med</i>, 2004, 164:2367-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15557417\">[PubMed 15557417]</a></p>\n<p>17. Warner-Schmidt JL, Vanover KE, Chen EY, et al, “Antidepressant Effects of Selective Serotonin Reuptake Inhibitors (SSRIs) are Attenuated by Antiinflammatory Drugs in Mice and Humans,” <i>Proc Natl Acad Sci U S A</i>, 2011, 108(22):9262-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21518864\">[PubMed 21518864]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4034":"<p><b>Title</b> Nelarabine / Pentostatin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Pentostatin may diminish the antineoplastic effect of Nelarabine. Conversion of nelarabine, a pro-drug, to its active form may be inhibited by pentostatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of these agents.</p> \n<p><b>Discussion</b> Administration of nelarabine with pentostatin is not recommended per nelarabine prescribing information.<sup>1</sup> Adenosine deaminase converts nelarabine, an inactive pro-drug, to arabinofuranosylguanine, the active antineoplastic agent. Pentostatin is a potent inhibitor of adenosine deaminase<sup>2</sup>, and thus, theoretically, may prevent or reduce the conversion of nelarabine to its active consituent.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Arranon (nelarabine). Research Triangle Park, NC: GlaxoSmithKline, December 2009. </p>\n<p>2. Wu JZ, Yeh LT, Lin CC, et al, “Conversion of Viramidine to Ribavirin In Vivo by Adenosine Deaminase and its Inhibition by 2'-Deoxycoformycin,” <i>Antivir Chem Chemother</i>, 2006, 17(1):33-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16542004\">[PubMed 16542004]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4035":"<p><b>Title</b> Sulfonamide Antibiotics / Procaine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Procaine may diminish the therapeutic effect of Sulfonamide Antibiotics. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of procaine and systemic sulfonamide-based antimicrobials is not recommended.</p>\n<div>\n <p><b>Sulfonamide Antibiotics Interacting Members</b> SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE</p>\n</div> \n<p><b>Discussion</b> Very limited information, primarily from observational studies published back in the 1940's, documents <i>in vitro</i>, <i>in vivo</i> and possibly clinical antagonism of sulfonamide antimicrobial activity by procaine/local anesthetics.<sup>1,2,3,4,5,6</sup> However, it is known that plasma, and likely cerebrospinal cholinesterases, readily hydrolyze procaine to para-aminobenzoic acid (PABA). Given the known mechanism of sulfonamide antimicrobial actitivity (ie, competition with PABA for bacterial dihydropteroate synthase), it is plausible that sufficient amounts of procaine exposure could reduce the therapeutic actions of sulfonamide-based antibiotics. The circumstances under which this might occur, particularly given spinal administration of procaine, is unknown and may only be a concern with treatment of CNS infections. The manufacturer of Novocain discourages the concomitant use of procaine with sulfonamide drugs.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Peterson OL, Finland M, “Sulfonamide Inhibiting Action of Procaine,” <i>Am J Med Sci</i>, 1944, 207:166-75.]</p>\n<p>2. Boroff DA, Cooper A, Bullowa JGM, “Inhibition of Sulfapyridine by Procaine in Chest Fluids after Procaine Anesthesia,” <i>Proc Soc Exp Biol Med</i>, 1941, 47:182-3.</p>\n<p>3. Casten D, Fried JJ, Hallman FA, “Inhibitory Effect of Procaine on the Bacteriostatic Activity of Sulfathiazole,” <i>Surg Gynecol Obstet</i>, 1943, 76:726-8.</p>\n<p>4. Powell HM, Krahl ME, Clowes GHA, “Inhibition of Chemotherapeutic Action of Sulfapyridine by Local Anesthetics,” <i>J Indiana State Med Assoc</i>, 1942, 35:62-3.</p>\n<p>5. Walker BS, Derow MA, “The Antagonism of Local Anesthetics Against the Sulfonamides,” <i>Am J Med Sci</i>, 1945, 210:585-8.</p>\n<p>6. Pfeiffer CC, Grant CW, “The Procaine-Sulfonamide Antagonism: An Evaluation of Local Anesthetics for Use with Sulfonamide Therapy,” <i>Anesthesiology</i>, 1944, 5:605-14.</p>\n<p>7. Novocain [package insert]. Lake Forest, IL: Hospira, Inc., 2005.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4036":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / Temsirolimus</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Temsirolimus may enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of temsirolimus and angiotensin-converting enzyme inhibitors may increase the risk of angioedema. This may occur in individuals without prior history of allergic reaction or intolerance to sirolimus or ACE inhibitors. Monitor closely, particularly within 1 month of initiating concurrent therapy, for signs and symptoms of facial edema, or other systemic manifestations of edematous and/or erythematous reactions.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Since temsirolimus is the ester pro-drug of sirolimus, the potential for an interaction with ACE inhibitors is based on published data with sirolimus.<br><br>Case reports describe a handful of patients developing edema in and around the facial region after initiation of angiotensin-converting enzyme therapy with existing stable sirolimus treatment. In one study of 52 renal transplant patients, 5 patients developed tongue edema within 1 month of starting rampiril (5 mg/day).<sup>1</sup> The patients had no history of allergic reaction, and the episodes were unremarkable for changes in eosinophil, IgE or Clq inhibitor levels. Symptoms resolved 2 weeks after discontinuing ramipril, without adjustment of sirolimus therapy. Ramipril was re-introduced 3 months later without incident at a lower dose.<br><br>Another report documents 2 cases of non-pitting edema of the face occurring within 9 days of initiating enalapril (2.5 mg/day) or ramipril with ongoing sirolimus therapy in renal transplant recipients.<sup>2</sup> In the former case, facial, neck and upper thoracic edema was accompanied by urticarial erythematous skin lesions. Corticosteroid treatment and discontinuation of enalapril resulted in prompt resolution of symptoms. In the latter case, edema presented in a left, unilateral fashion involving the cheek, eyelid, and lips, accompanied by respiratory distress. Discontinuation of both sirolimus and ramipril resulted in symptom improvement. Of note, sirolimus was re-initiated in this patient without incident.<br><br>These cases suggest the possibility of an increased risk of angioedema, or like reactions, with concomitant sirolimus and ACE inhibitor therapy. However, it should be noted that sirolimus alone has been commonly noted to cause extremity edema,<sup>3</sup> as well as specifically implicated in previous cases of eyelid edema in the absence of ACE inhibitor therapy.<sup>4</sup> The extent to which these reactions can be attributable to either therapeutic modality alone, or as a result of synergy between the drug classes is unknown. However, given the known association of angioneurotic edema with the use of ACE inhibitors, and the temporal relation of symptoms to initiation of drug therapy in these cases, it seems prudent to carefully monitor patients for this adverse reaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stallone G, Infante B, Di Paolo S, et al, “Sirolimus and Angiotensin-Converting Enzyme Inhibitors Together Induce Tongue Oedema in Renal Transplant Recipients,” <i>Nephrol Dial Transplant</i>, 2004, 19(11):2906-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15496567\">[PubMed 15496567]</a></p>\n<p>2. Burdese M, Rossetti M, Guarena C, et al, “Sirolimus and ACE-Inhibitors: A Note of Caution,” <i>Transplantation</i>, 2005, 79(2):251-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15665781\">[PubMed 15665781]</a></p>\n<p>3. Buhaescu I, Izzedine H and Covic A, “Sirolimus--Challenging Current Perspectives,” <i>Ther Drug Monit</i>, 2006, 28(5):577-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17038868\">[PubMed 17038868]</a></p>\n<p>4. Mohaupt MG, Vogt B and Frey FJ, “Sirolimus-Associated Eyelid Edema in Kidney Transplant Recipients,” <i>Transplantation</i>, 2001, 72(1):162-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11468553\">[PubMed 11468553]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4038":"<p><b>Title</b> Temsirolimus / Protease Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully monitor for increased sirolimus (active metabolite) serum concentrations. The manufacturer recommends against coadministration with strong CYP3A4 inhibitors.<sup>1</sup> However, if concurrent therapy is necessary, dosage reduction of temsirolimus to 12.5 mg/week is recommended. If discontinuing the strong 3A4 inhibitor, a 1 week washout should be observed before increasing the temsirolimus dose.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir</p>\n</div> \n<p><b>Discussion</b> Since temsirolimus is the ester pro-drug of sirolimus, the potential for an interaction with protease inhibitors is based on published data with oral sirolimus.<br><br>Case report. The AUC of sirolimus (2 mg) was increased 60% in a liver transplant patient when coadministered with nelfinavir compared to data from three other patients receiving sirolimus without nelfinavir.<sup>2</sup> Trough sirolimus concentrations were increased ninefold and fivefold at 0 and 24 hours post-dose, respectively. Sirolimus is a CYP3A4 substrate. Protease inhibitors are effective inhibitors of this enzyme, and most likely will reduce sirolimus metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Torisel [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc., 2007.</p>\n<p>2. Jain AK, Venkataramanan R, Fridell JA, et al, “Nelfinavir, A Protease Inhibitor, Increases Sirolimus Levels in a Liver Transplantation Patient: A Case Report,” <i>Liver Transpl</i>, 2002, 8(9):838-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12200787\">[PubMed 12200787]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4039":"<p><b>Title</b> Temsirolimus / Phenytoin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Phenytoin may decrease the serum concentration of Temsirolimus. Concentrations of the active metabolite, sirolimus, are also likely to be decreased (and maybe to an even greater degree). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully monitor for decreased sirolimus (active metabolite) serum concentrations if phenytoin is initiated/dose increased, and for increased concentrations if phenytoin is discontinued/dose decreased. The manufacturer recommends against coadministration with strong CYP3A4 inducers like phenytoin;<sup>1</sup> however, if concurrent therapy is necessary, an increase in the temsirolimus dose to 50 mg/week should be considered. If discontinuing the strong 3A4 inducer, temsirolimus dose should be decreased to the level used prior to initiation of the inducer.</p> \n<p><b>Discussion</b> Concurrent phenytoin (n=6) or carbamazepine (n=5) were associated with decreased temsirolimus and sirolimus (active metabolite of temsirolimus) concentrations in a study of patients with malignant gliomas or brain metastases who were either receiving an enzyme inducing agent (i.e., phenytoin or carbamazepine) or who were not (i.e., controls, n=14).<sup>2</sup> Among those receiving phenytoin or carbamazepine, the temsirolimus AUC and maximum concentration (Cmax) averaged 15% and 36% lower, respectively, and the sirolimus AUC and Cmax averaged 43% and 67% lower, respectively.<br><br>The mechanism of this interaction is likely phenytoin- and carbamazepine-mediated induction of the CYP3A metabolism of both temsirolimus and sirolimus.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Torisel (temsirolimus). Philadelphia, PA: Wyeth Pharmaceuticals Inc., 5/2007.</p>\n<p>2. Boni J, Leister C, Burns J, et al, “Pharmacokinetic Profile of Temsirolimus with Concomitant Administration of Cytochrome P450-Inducing Medications,” <i>J Clin Pharmacol</i>, 2007, 47:1430-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17913896\">[PubMed 17913896]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4040":"<p><b>Title</b> Temsirolimus / Rifamycin Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Rifamycin Derivatives may decrease the serum concentration of Temsirolimus. Rifamycins will likely cause an even greater decrease in the concentration of the active metabolite sirolimus. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Carefully monitor for decreased sirolimus (active metabolite) serum concentrations if a rifamycin derivative is initiated/dose increased, and increased concentrations if the rifamycin agent is discontinued/dose decreased. The manufacturer recommends against coadministration with strong CYP3A4 inducers such as rifampin;<sup>1</sup> however, if concurrent therapy is necessary, an increase in the temsirolimus dose to 50 mg/week should be considered. If discontinuing the strong 3A4 inducer, temsirolimus dose should be decreased to the level used prior to initiation of the inducer.</p>\n<div>\n <p><b>Rifamycin Derivatives Interacting Members</b> Rifabutin, RifAMPin*, Rifapentine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a study examining the effect of rifampin on both oral and intravenous temsirolimus (n=16 healthy volunteers), there was a substantially greater impact on temsirolimus pharmacokinetics following oral temsirolimus, but a similar magnitude of effect on sirolimus pharmacokinetics regardless of the route of temsirolimus administration.<sup>2</sup> Concurrent rifampin (600mg daily) was associated with 41% and 30% reductions in temsirolimus maximum concentration (Cmax) and AUC following oral temsirolimus (30mg), but only negligible (less than 10%) changes in temsirolimus Cmax and AUC following intravenous temsirolimus (25mg). Conversely, decreases in sirolimus Cmax and AUC were similar following either oral (63% and 60%, respectively) or intravenous (65% and 56%, respectively) temsirolimus administration. These results are similar to data from a study of rifampin and sirolimus, where the AUC of sirolimus (20 mg single oral dose) was decreased 82% in 14 normal subjects when administered following a 14-day course of rifampin (600 mg daily).<sup>3</sup><br><br>The mechanism of this interaction is likely induction of temsirolimus and sirolimus metabolism via CYP3A (and possibly increased efflux via drug transporters such as p-glycoprotein) caused by rifampin. The observed discrepancy in impact on temsirolimus pharmacokinetics suggests that rifampin enhances both the first-pass metabolism of temsirolimus and the overall hepatic metabolism of temsirolimus and its active metabolite sirolimus.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Torisel [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc., 2007.</p>\n<p>2. Boni J, Leister C, Burns J, et al, “Pharmacokinetic Profile of Temsirolimus with Concomitant Administration of Cytochrome P450-Inducing Medications,” <i>J Clin Pharmacol</i>, 2007, 47:1430-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17913896\">[PubMed 17913896]</a></p>\n<p>3. Rapamune [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc, 2004.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4043":"<p><b>Title</b> SUNItinib / Temsirolimus</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Temsirolimus may enhance the adverse/toxic effect of SUNItinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid using these agents in combination whenever possible. If this combination must be used, monitor patients closely for signs of toxicity. Dose reduction or discontinuation of therapy may be required.</p> \n<p><b>Discussion</b> Two of three patients in a phase I study with temsirolimus (15 mg IV per week) and sunitinib (25 mg orally/day) experienced dose-limiting toxicities, including grade 3/4 erythematous maculopapular rash requiring discontinuation in one patient, and grade 3 thrombocytopenia, cellulitis, and gout requiring hospitalization and treatment discontinuation in another patient.<sup>1</sup> The third patient also experienced several adverse effects, but all were mild in severity and did not necessitate treatment discontinuation.<br><br>Since these observed toxicities were severe and ocurred at low initial doses, the authors of this study concluded that use of this combination is not recommended.<sup>1</sup> Temsirolimus prescribing information includes a summary of these data in their Warnings and Precautions section but do not offer any specific guidance on whether this combination should be avoided versus used only with dose modifications and/or with increased monitoring.<sup>2</sup><br><br>Whether these toxicities represent additive or synergistic toxicities of the individual agents vs. an interaction with an unique mechanism is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Patel PH, Senico PL, Curiel RE, et al, “Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma,” <i>Clin Genitourin Cancer</i>, 2009, 7(1):24-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19213664\">[PubMed 19213664]</a></p>\n<p>2. Prescribing information. Torisel (temsirolimus). Philadelphia, PA: Wyeth Pharmaceuticals Inc., 7/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4044":"<p><b>Title</b> Saquinavir / Histamine H2 Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may increase the serum concentration of Saquinavir. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased adverse effects or toxicity of saquinavir when using concomitantly with H<sub>2</sub> antagonists.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine*, Famotidine, Lafutidine, Nizatidine, RaNITIdine*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Two open-label, cross-over design studies evaluated the effects of ranitidine or cimetidine on saquinavir pharmacokinetics. In the first study, cimetidine (400 mg twice daily days 14-26) was adminstered to 12 healthy subjects receiving saquinavir (1200 mg three times daily days 1-13, and twice daily days 14-26).<sup>1</sup> Analysis of pharmacokinetic data from days 13 and 26 revealed a significant increase in saquinavir AUC and C<sub>max</sub> from baseline of 120% and 179%, respectively (p=0.019). The mechanism is presumed to be due to CYP-mediated inhibition by cimetidine.<br><br>In the second study, 12 male subjects received two doses of ranitidine (150 mg) with and without food.<sup>2</sup> One dose was administered the evening before, with the second dose given the following morning with a standard breakfast meal. Atfer a 7-day washout, subjects rotated to the alternate treatment and control (food only) groups. Compared to the control treatment, the bioavailability of saquinavir was increased over 10-fold with the administration of ranitidine. Interestingly, no correlation was seen between the extent of pH elevation and serum concentration increase. As ranitidine is not a known inhibitor of CYP450, the mechanism of this interaction is presently unclear. It is also unclear whether similar effects would be observed with other members of the H<sub>2</sub> antagonist class. Caution and monitoring is advised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Boffito M, Carriero P, Trentini L, et al, “Pharmacokinetics of Saquinavir Co-Administered with Cimetidine,” <i>J Antimicrob Chemother</i>, 2002, 50:1081-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12461038\">[PubMed 12461038]</a></p>\n<p>2. Kakuda TN, Falcon RW, “Effect of Food and Ranitidine on Saquinavir Pharmacokinetics and Gastric pH in Healthy Volunteers,” <i>Pharmacother</i>, 2006, 26(8):1060-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16863482\">[PubMed 16863482]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4045":"<p><b>Title</b> Warfarin / Saquinavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Saquinavir may increase the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increases in PT/INR of warfarin-maintained patients if saquinavir is initiated/dose increased, or decreases if saquinavir is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Saquinavir prescribing information states that saquinavir administration may increase warfarin concentrations.<sup>1</sup> In a case report, an elderly HIV patient maintained on stable warfarin therapy for 5 months was started on saquinavir 600 mg three times daily.<sup>2</sup> From a baseline INR of 2, the INR rose to 4.2 over the course of 2 months. There were no other medication changes noted, and the authors attributed this effect to initiation of saquinavir therapy. A 20% dosage reduction of warfarin led to stabilization of the patient's INR.<br><br>The mechanism of this interaction is unknown. Saquinavir may inhibit warfarin metabolism (e.g., via minor pathways such as CYP3A4 or 2C19).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Invirase (saquinavir). South San Francisco, CA: Genentech USA, Inc., 10/2010.</p>\n<p>2. Darlington MR, “Hypoprothrombinemia During Concomitant Therapy with Warfarin and Saquinavir,” <i>Ann Pharmacother</i>, 1997, 31(5):647. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9161669\">[PubMed 9161669]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4046":"<p><b>Title</b> Somatropin / Estrogen Derivatives</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to orally administered estrogens.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for reduced efficacy of growth hormone. A larger dose of somatropin may be required to reach treatment goal. This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Polyestradiol, Tibolone<br><b>Exceptions</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> The effects of sex steroids on growth hormone regulation are complex. However, a number of studies have demonstrated an antagonistic effect of orally administered estrogen replacement therapy on growth hormone-mediated actions. Metabolic fat oxidation and levels of insulin-like growth factor I (IGF-I, a peptide secreted in response to GH), are significantly reduced in GH-deficient postmenopausal women receiving replacement therapy. These observations have been reliably reproduced in a route-specific manner, with oral estrogens demonstrating the antagonism, but not transdermal formulations. The mechanisms of such effects are unknown, but may relate to higher hepatic estrogen levels achieved with oral, rather than transdermal exposure. In vitro studies have demonstrated that estrogen can directly reduce hepatic fatty acid oxidation in favor of triglyceride synthesis. Clinical observations that estrogens adminstered via the oral but not transdermal route increase hepatic TGs, lends support to a concentration-dependent phenomenon.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wolthers T, Hoffman DM, Nugent AG, et al, “Oral Estrogen Antagonizes the Metabolic Actions of Growth Hormone in Growth Hormone-Deficient Women,” <i>Am J Physiol Endocrinol Metab</i>, 2001, 281:E1191-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11701433\">[PubMed 11701433]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4047":"<p><b>Title</b> Digoxin / SITagliptin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> SITagliptin may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients receiving digoxin should be monitored for signs or symptoms of digoxin toxicity when sitagliptin is started.</p> \n<p><b>Discussion</b> Sitagliptin prescribing information describes an 18% increase in peak digoxin concentrations and an 11% increase in digoxin AUC following 10 days of concomitant sitagliptan 100 mg and digoxin.<sup>1</sup> <br><br>The mechanism for this interaction is unclear as sitagliptin is not a recognized inhibitor of the p-glycoprotein transporter known to influence digoxin uptake and elimination; although, sitagliptin is a p-glycoprotein substrate,<sup>1</sup> raising the possibility of competitive inhibition. Further, sitagliptin is principally renally eliminated (&gt;85% excreted unchanged in urine, only minor metabolism via CYP3A4 and CYP2C8),<sup>1,2</sup> but the involvement of p-glycoprotein in sitagliptin renal elimination is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Januvia (sitagliptin). Whitehouse Station, NJ: Merck &amp; Co., Inc., February 2010.</p>\n<p>2. Vincent SH, Reed JR, Bergman AJ, et al, “Metabolism and Excretion of the Dipeptidyl Peptidase 4 Inhibitor [14C]Sitagliptan in Humans,” <i>Drug Metab Dispos</i>, 2007, 35(4):533-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17220239\">[PubMed 17220239]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4049":"<p><b>Title</b> Agalsidase Beta / Chloroquine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Chloroquine may diminish the therapeutic effect of Agalsidase Beta. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant administration of chloroquine with agalsidase beta as it could theoretically antagonize intracellular alpha-galactosidase activity.</p> \n<p><b>Discussion</b> Canadian prescribing information for agalsidase beta states that coadministration of chloroquine should be avoided due to a possible risk of diminished intracellular alpha-galactosidase activity.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Fabrazyme (agalsidase beta). Mississauga, ON: Genzyme Canada Inc., October 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4050":"<p><b>Title</b> Agalsidase Beta / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Amiodarone may diminish the therapeutic effect of Agalsidase Beta. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant administration of amiodarone with agalsidase beta as it could theoretically antagonize intracellular alpha-galactosidase activity.</p> \n<p><b>Discussion</b> Canadian prescribing information for agalsidase beta states that coadministration of amiodarone should be avoided due to a possible risk of diminished intracellular alpha-galactosidase activity.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product Monograph. Fabrazyme (agalsidase beta). Mississauga, ON: Genzyme Canada Inc., October 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4051":"<p><b>Title</b> HMG-CoA Reductase Inhibitors (Statins) / Colchicine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Colchicine may enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully monitor for signs of muscle pain and/or weakness with concomitant therapy. While this is advised with monotherapy involving either agent (since each can independently cause muscle toxicity), it is especially prudent when using in combination.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin*, Fluvastatin*, Lovastatin*, Pitavastatin, Pravastatin*, Red Yeast Rice, Rosuvastatin, Simvastatin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> At least 9 case reports describe patients in whom myotoxicity, ranging from weakness and myopathy to fatal rhabdomyolysis, developed following initiation of combination therapy involving colchicine and an HMG-CoA Reductase Inhibitor (“statin”).<sup>1,2,3,4,5,6,7,8,9</sup> Reported cases have involved simvastatin,<sup>1,2,3,4</sup> atorvastatin,<sup>5,6</sup> fluvastatin,<sup>7</sup> lovastatin,<sup>8</sup> and pravastatin.<sup>9</sup> While no clear underlying patient risk factors (other than the colchicine-statin) were present in all cases, several of the patients had at least mildly impared renal function,<sup>1,3,4,5,9</sup> and 2 were transplant recipients receiving other potentially interacting drugs (i.e., cyclosporine).<sup>2,6</sup> In most of the cases, muscle weakness was the initial symptom, and the initial onset of symptoms was 2-3 weeks (but as long as several months) after initiation of the combination.<br><br>The precise mechanism of this interaction is unclear, but it may have pharmacodynamic and/or pharmacokinetic components. Colchicine and statins have each been independently associated with myotoxicity; in one review of 475 patients hospitalized for rhabdomyolysis, statins and colchicine were among the prescription agents most commonly involved.<sup>10</sup> Additionally, colchicine and many of the statins (lovastatin, simvastatin, atorvastatin) are metabolized to a substantial degree by CYP3A4,<sup>11</sup> with some in vitro evidence suggesting colchicine may inhibit CYP3A4 to some degree.<sup>12</sup> These data suggest that at least for some statins, colchicine could increase statin concentrations, further increasing the risk of myotoxicity. Further, colchicine may impair the excretion of some statins via inhibition of organic anion transport, an effect that has been demonstrated in vitro with pravastatin.<sup>13</sup> This action would also lead to increased statin concentrations and increased risk of toxicity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Justiniano M, Dold S, Espinoza LR, “Rapid Onset of Muscle Weakness (Rhabdomyolysis) Associated with the Combined Use of Simvastatin and Colchicine,” <i>J Clin Rheumatol</i>, 2007, 13:266-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17921794\">[PubMed 17921794]</a></p>\n<p>2. Francis L, Bonilla E, Soforo E, et al, “Fatal Toxic Myopathy Attributed to Propofol, Methylprednisolone, and Cyclosporine after Prior Exposure to Colchicine and Simvastatin,” <i>Clin Rheumatol</i>, 2008, 27:129-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17628739\">[PubMed 17628739]</a></p>\n<p>3. Baker SK, Goodwin S, Sur M, et al, “Cytoskeletal Myotoxicity from Simvastatin and Colchicine,” <i>Muscle Nerve</i>, 2004, 30:799-802. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15389652\">[PubMed 15389652]</a></p>\n<p>4. Hsu WC, Chen WH, Chang MT, et al, “Colchicine-Induced Acute Myopathy in a Patient with Concomitant Use of Simvastatin,” <i>Clin Neuropharmacol</i>, 2002, 25:266-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12410059\">[PubMed 12410059]</a></p>\n<p>5. Tufan A, Dede DS, Cavus S, et al, “Rhabdomyolysis in a Patient Treated with Colchicine and Atorvastatin,” <i>Ann Pharmacother</i>, 2006, 40:1466-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16772404\">[PubMed 16772404]</a></p>\n<p>6. Phanish MK, Krishnamurthy S, Bloodworth LL, “Colchicine-Induced Rhabdomyolysis,” <i>Am J Med</i>, 2003, 114:166-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12586247\">[PubMed 12586247]</a></p>\n<p>7. Atasoyu EM, Evrenkaya TR, Solmazgul E, “Possible Colchicine Rhabdomyolysis in a Fluvastatin-Treated Patient,” <i>Ann Pharmacother</i>, 2005, 39:1368-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15956236\">[PubMed 15956236]</a></p>\n<p>8. Torgovnick J, Sethi N, Arsura E, “Colchicine and HMG Co-A Reductase Inhibitors Induced Myopathy-a Case Report,” <i>Neurotoxicology</i>, 2006, 27:1126-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17049607\">[PubMed 17049607]</a></p>\n<p>9. Alayli G, Cengiz K, Canturk F, et al, “Acute Myopathy in a Patient with Concomitant Use of Pravastatin and Colchicine,” <i>Ann Pharmacother</i>, 2005, 39:1358-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1594514\">[PubMed 1594514]</a></p>\n<p>10. Melli G, Chaudhry V, Cornblath DR, “Rhabdomyolysis: An Evaluation of 475 Hospitalized Patients,” <i>Medicine (Baltimore)</i>, 2005, 84:377-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16267412\">[PubMed 16267412]</a></p>\n<p>11. Tateishi T, Soucek P, Caraco Y, et al, “Colchicine Biotransformation by Human Liver Microsomes. Identification of CYP3A4 as the Major Isoform Responsible for Colchicine Demethylation,” <i>Biochem Pharmacol</i>, 1997, 53:111-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8960070\">[PubMed 8960070]</a></p>\n<p>12. Dvorak Z, Modriansky M, Pichard-Garcia L, et al, “Colchicine Down-Regulates Cytochrome P450 2B6, 2C8, 2C9, and 3A4 in Human Hepatocytes by Affecting Their Glucocorticoid Receptor-Mediated Regulation,” <i>Mol Pharmacol</i>, 2003, 64:160-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12815172\">[PubMed 12815172]</a></p>\n<p>13. Takikawa H, Sano N, Akimoto K, et al, “Effects of Colchicine and Phenothiazine on Biliary Excretion of Organic Anions in Rats,” <i>J Gastroenterol Hepatol</i>, 1998, 13:427-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9641309\">[PubMed 9641309]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4052":"<p><b>Title</b> Zidovudine / Interferons</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Patients receiving both an Interferon and Zidovudine should be monitored closely for signs and symptoms of hematologic and other toxicities.</p>\n<div>\n <p><b>Interferons Interacting Members</b> Interferon Alfa-2a, Interferon Alfa-2b*, Interferon Alfa-n3, Interferon Alfacon-1, Interferon Beta-1a, Interferon Beta-1b, Interferon Gamma-1b, Peginterferon Alfa-2a, Peginterferon Alfa-2b, Peginterferon Beta-1a</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Several randomized or retrospective studies have compared the toxicities/tolerability of treatment with zidovudine (AZT) plus interferon (IFN)-alpha to treatment without IFN-alpha. Most of these have found substantially more adverse effects, principally hematologic, with combination therapy. In one study of adults with asymptomatic or mildly symptomatic HIV infections randomized to AZT alone (n=117) or AZT plus IFN-alpha 2b (n=139), there were significantly more adverse effects in the combination group, including neutropenia, leukopenia, weight loss, fatigue, and myalgias.<sup>1</sup> Among patients with asymptomatic or mildly symptomatic HIV infections randomized to either AZT monotherapy (n=193) or AZT plus IFN-alpha (n=209), a significantly greater proportion of patients receiving the combination therapy experienced adverse effects, and patients receiving combination therapy required dose adjustment due to haematological and other adverse effects more often than those receiving AZT alone.<sup>2</sup> In HIV-infected subjects (n=256) randomized to either AZT plus zalcitabine or a combination of AZT, zalcitabine, and IFN-alpha for 48 weeks, neutropenia, anemia, and other adverse effects were more common in the group receiving IFN-alpha.<sup>3</sup> A dose-escalation study evaluated 39 patients with HIV infection who received AZT (250mg, 100mg, or 50mg every 4 hours) and were started on IFN-alpha at a dose of 5 million units/day, which was to be increased every 2 weeks until a maximum tolerated dose was reached. The authors concluded that the ability of patients to tolerate IFN-alpha was dependent on AZT dose, with only 1 of 13 patients on AZT 250mg able to tolerate 10 million units/day of IFN-alpha versus 8 of 12 patients in both the AZT 100mg and 50mg dose groups able to tolerate at least 10 million units/day of IFN-alpha. The most common dose-limiting toxicity was neutropenia.<sup>4</sup> In another study comparing AZT with IFN-alpha (n=25) vs. AZT alone (n=20) for 48 weeks in patients with symptomatic HIV-1 infection, severe toxicity was uncommon, with drug-related malaise and anorexia more common in patients receiving combination therapy.<sup>5</sup> A retrospective analysis of patients with HIV and HCV treated with PEG-IFN and ribavirin with (n=62) or without AZT (n=155) found that compared to those receiving other antiretroviral therapy or no antiretroviral therapy, those on AZT had significantly greater decreases in hemoglobin and received more erythropoietin. Approximately one-third of the patients received pegylated IFN-alpha 2a, and the remaining received pegylated IFN-alpha 2b.<sup>6</sup><br><br>Numerous reports from nonrandomized descriptive studies/case series of generally smaller populations of patients with adult T-cell leukemia/lymphoma<sup>7,8,9,10,11,12</sup> or HIV/AIDS<sup>13,14,15</sup> describe the combination of AZT with IFN-alpha as generally well-tolerated, with limiting hematologic toxicity described in only a couple of reports.<sup>7,8</sup><br><br>The precise mechanism for this suspected interaction is unclear, but two primary mechanisms have been proposed. One possible mechanism is that adverse effects result from an additive or synergistic combination of drugs which are each capable of causing these same adverse effects independent of one another. Another possible mechanism is that interferon may interfere with the metabolism of zidovudine, resulting in greater zidovudine concentrations and toxicity (either independently or in conjunction with an additive/synergistic pharmacodynamic mechanism). While there is no published evidence of a pharmacokinetic interaction involving interferon-alpha, one study in 8 patients with AIDS did show that addition of recombinant interferon-beta to patients who had been receiving AZT for 8 weeks resulted in a substantial decrease in AZT metabolism, a doubling of the AZT elimination half-life, and more than a 50% increase in the AZT volume of distribution.<sup>16</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Krown SE, Aeppli D, Balfour HH, “Phase II, Randomized, Open-Label, Community-Based Trial to Compare the Safety and Activity of Combination Therapy with Recombinant Interferon-Alpha2b and Zidovudine Versus Zidovudine Alone in Patients with Asymptomatic to Mildly Symptomatic HIV Infection. HIV Protocol C91-253 Study Team,” <i>J Acquir Immune Defic Syndr Hum Retrovirol</i>, 1999, 20(3):245-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10077172\">[PubMed 10077172]</a></p>\n<p>2. Fernandez-Cruz E, Lang JM, Frissen PH, et al, “Zidovudine Plus Inferferon-? Versus Zidovudine Alone in HIV-Infected Symptomatic or Asymptomatic Persons with CD4+ Cell Counts &gt; 150x10<sup>6</sup>/L: Results of the Zidon Trial,” <i>AIDS</i>, 1995, 9:1025-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8527074\">[PubMed 8527074]</a></p>\n<p>3. Haas DW, Lavelle J, Nadler JP, et al, “A Randomized Trial of Interferon Alpha Therapy for HIV Type 1 Infection,” <i>AIDS Res Hum Retroviruses</i>, 2000, 16(3):183-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10710206\">[PubMed 10710206]</a></p>\n<p>4. Kovacs JA, Deyton L, Davey R, et al, “Combined Zidovudine and Inferferon-Alpha Therapy in Patients with Kaposi Sarcoma and the Acquired Immunodeficiency Syndrome (AIDS),” <i>Ann Intern Med</i>, 1989, 111(4):280-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2757312\">[PubMed 2757312]</a></p>\n<p>5. Frissen PH, van der Ende ME, ten Napel CH, et al, “Zidovudine and Interferon-Alpha Combination Therapy Versus Zidovudine Monotherapy in Subjects with Symptomatic Human Immunodeficiency Virus Type 1 Infection,” <i>J Infect Dis</i>, 1994, 169(6):1351-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7910838\">[PubMed 7910838]</a></p>\n<p>6. Alvarez D, Dieterich DT, Brau N, et al, “Zidovudine Use but Not Weight-Based Ribavirin Dosing Impacts Anaemia During HCV Treatment in HIV-Infected Persons,” <i>J Viral Hepat</i>, 2006, 13(10):683-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16970600\">[PubMed 16970600]</a></p>\n<p>7. White JD, Wharfe G, Stewart DM, et al, “The Combination of Zidovudine and Interferon Alpha-2B in the Treatment of Adult T-Cell Leukemia/Lymphoma,” <i>Leuk Lymphoma</i>, 2001, 40(3-4):287-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11426550\">[PubMed 11426550]</a></p>\n<p>8. Gill PS, Harrington W, Kaplan MH, et al, “Treatment of Adult T-Cell Leukemia-Lymphoma with a Combination of Interferon Alfa and Zidovudine,” <i>N Engl J Med</i>, 1995, 332(26):1744-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7760890\">[PubMed 7760890]</a></p>\n<p>9. Matutes E, Taylor GP, Cavenagh J, et al, “Interferon Alpha and Zidovudine Therapy in Adult T-Cell Leukemia Lymphoma: Response and Outcome in 15 Patients,” <i>Br J Haematol</i>, 2001, 113(3):779-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11380470\">[PubMed 11380470]</a></p>\n<p>10. Hermine O, Allard I, Levy V, et al, “A Prospective Phase II Clinical Trial with the Use of Zidovudine and Interferon-Alpha in the Acute and Lymphoma Forms of Adult T-Cell Leukemia/Lymphoma,” <i>Hematol J</i>, 2002, 3(6):276-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12522449\">[PubMed 12522449]</a></p>\n<p>11. Bazarbachi A, Hermine O, “Treatment with a Combination of Zidovudine and Alpha-Interferon in Naive and Pretreated Adult T-Cell Leukemia/Lymphoma Patients,” <i>J Acquir Immune Defic Syndr Hum Retrovirol</i>, 1996, 13 Suppl 1:S186-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8797722\">[PubMed 8797722]</a></p>\n<p>12. Hermine O, Bouscary D, Gessain A, et al, “Brief Report: Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa,” <i>N Engl J Med</i>, 1995, 332(26):1749-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7760891\">[PubMed 7760891]</a></p>\n<p>13. Del Pozo MA, Arias JR, Pinilla J, et al, “Interferon Alpha Treatment of Chronic Hepatitis C in HIV-Infected Patients Receiving Zidovudine: Efficacy, Tolerance and Response Related Factors,” <i>Hepatogastroenterology</i>, 1998, 45(23):1695-701. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9840131\">[PubMed 9840131]</a></p>\n<p>14. Mildvan D, Bassiakos Y, Zucker ML, et al, “Synergy, Activity and Tolerability of Zidovudine and Interferon-Alpha in Patients with Symptomatic HIV-1 Infection: AIDS Clinical Trial Group 068,” <i>Antivir Ther</i>, 1996, 1(2):77-88. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11321183\">[PubMed 11321183]</a></p>\n<p>15. Mauss S, Jablonowski H, “Efficacy, Safety, and Tolerance of Low-Dose, Long-Term Interferon-Alpha 2b and Zidovudine in Early-Stage AIDS-Associated Kaposi's Sarcoma,” <i>J Acquir Immune Defic Syndr Hum Retrovirol</i>, 1995, 10(2):157-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7552479\">[PubMed 7552479]</a></p>\n<p>16. Nokta M, Loh JP, Douidar SM, et al, “Metabolic Interaction of Recombinant Interferon-Beta and Zidovudine in AIDS Patients,” <i>J Interferon Res</i>, 1991, 11(3):159-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1919075\">[PubMed 1919075]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4053":"<p><b>Title</b> Iron Salts / Dimercaprol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Dimercaprol may enhance the nephrotoxic effect of Iron Salts. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to toxicity concerns, iron salts should not be administered to patients being treated with dimercaprol, and dimercaprol should not be used to treat iron poisoning.</p>\n<div>\n <p><b>Iron Salts Interacting Members</b> Ferric Carboxymaltose, Ferric Citrate, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate, Ferumoxytol, Iron Acetyltransferrin, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose, Polysaccharide-Iron Complex, Sodium Feredetate</p>\n</div> \n<p><b>Discussion</b> According to dimercaprol's product labeling, because of data suggesting that dimercaprol-iron complexes may be more toxic than iron alone, particularly to the kidneys, iron should not be administered to patients being treated with dimercaprol, and dimercaprol should not be used in the treatment of iron poisoning.<sup>1</sup> Published studies evaluating this interaction were not found.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Package insert. BAL in Oil Ampules (Dimercaprol Injection, USP). Decatur, IL: Taylor Pharmaceuticals, 10/06.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4054":"<p><b>Title</b> Anti-Parkinson Agents (Dopamine Agonist) / Metoclopramide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Metoclopramide may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients with Parkinson disease that is being treated with a dopamine agonist should be monitored closely for worsening signs/symptoms (e.g., rigidity, bradykinesia) following initiation of metoclopramide.</p>\n<div>\n <p><b>Anti-Parkinson Agents (Dopamine Agonist) Interacting Members</b> Amantadine, Apomorphine*, Bromocriptine*, Levodopa*, Pergolide, Piribedil, Pramipexole, ROPINIRole, Rotigotine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A case report described 2 patients with diabetes and end-stage renal disease who developed extrapyramidal symptoms while receiving metoclopramide. One patient also had a history of Parkinson disease that had been well-controlled with levodopa prior to metoclopramide. After initiation of metoclopramide for gastroparesis, this patient experienced increased rigidity and bradykinesia that was refractory to levodopa and bromocriptine. In both patients, discontinuation of metoclopramide resulted in rapid resolution of all extrapyramidal symptoms.<sup>1</sup> A case-control study of patients 65 years of age or older showed that patients taking metoclopramide had three times greater odds of beginning levodopa than patients not taking metoclopramide [OR: 3.09 (95% CI: 2.25 to 4.26)], and this increase in odds was dose-dependent, with an OR=1.19 for metoclopramide doses = 10mg/day, OR=3.33 for doses of &gt;10-20mg/day, and OR=5.25 for doses of &gt;20mg/day.<sup>2</sup> The same study also investigated initiation of anticholinergic agents commonly used to treat Parkinson disease and, similarly, found evidence of increased initiation of such agents in metoclopramide users.<br><br>Conversely, other studies have reported that metoclopramide can be used so that it has little/no effect on response to dopamine agonists. A study in 10 subjects with parkinsonism found that pretreatment with a single 60mg dose of metoclopramide had no consistent effect on clinical response to bromocriptine (with separate single doses of 12.5mg, 25mg, 50mg, and 100mg).<sup>3</sup> Similarly, metoclopramide had no consistent effect on bromocriptine plasma concentrations or bromocriptine-induced increases in growth hormone concentrations. Metoclopramide has been shown in healthy volunteers to antagonize the reduced gastric emptying resulting from apomorphine administration,<sup>4</sup> and in healthy and hypertensive volunteers metoclopramide was shown to antagonize the blood pressure-lowering effects of bromocriptine, as well as the effects of bromocriptine on plasma aldosterone concentrations and plasma renin activity.<sup>5,6</sup> Others, however, have reported that metoclopramide does not antagonize the blood pressure effects of levodopa.<sup>7</sup><br><br>Some have attempted to take clinical advantage of the anti-dopaminergic effects of metoclopramide, investigating it as an antiemetic in patients receiving apomorphine. Parkinsonian patients receiving apomorphine 10mg and pretreated with metoclopramide (10mg) experienced diminished tremor and rigidity, and had reduced nausea, vomiting, and sleepiness.<sup>8</sup> In contrast, haloperidol (2mg) prevented both nausea/vomiting as well as the beneficial effects on tremor and rigidity associated with apomorphine administration. A letter describing experience with 40 patients with parkinsonism treated with levodopa and metoclopramide (30-80mg/d) reported that this combination resulted in reduced nausea and vomiting with no worsening of parkinsonism symptoms.<sup>9</sup> A double-blind study in 8 patients with parkinsonism by the same group also showed that 4 weeks of metoclopramide (30-60mg/d) had no effect on parkinsonism symptoms or levodopa-associated involuntary movements, unlike pimozide, another dopamine antagonist.<sup>10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sirota RA, Kimmel PL, Trichtinger MD, et al, “Metoclopramide-Induced Parkinsonism in Hemodialysis Patients. Report of Two Cases,” <i>Arch Intern Med</i>, 1986, 146(10):2070-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3767555\">[PubMed 3767555]</a></p>\n<p>2. Avorn J, Gurwitz JH, Bohn RL, et al, “Increased Incidence of Levodopa Therapy Following Metoclopramide Use,” <i>JAMA</i>, 1995, 274(22):1780-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7500509\">[PubMed 7500509]</a></p>\n<p>3. Price P, Debono A, Parkes JD, et al, “Plasma Bromocriptine Levels, Clinical and Growth Hormone Responses in Parkinsonism,” <i>Br J Clin Pharmacol</i>, 1978, 6(4):303-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=359016\">[PubMed 359016]</a></p>\n<p>4. Ramsbottom N, Hunt JN, “Studies on the Effect of Metoclopramide and Apomorphine on Gastric Emptying and Secretion in Man,” <i>Gut</i>, 1970, 11, 989-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5511820\">[PubMed 5511820]</a></p>\n<p>5. Luchsinger A, Grilli M, Velasco M, “Metoclopramide and Domperidone Block the Antihypertensive Effect of Bromocriptine in Hypertensive Patients,” <i>Am J Ther</i>, 1998, 5(2):81-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10099042\">[PubMed 10099042]</a></p>\n<p>6. Luchsinger A, Grilli M, Forte P, et al, “Metoclopramide Blocks Bromocriptine Induced Antihypertensive Effect in Hypertensive Patients,” <i>Int J Clin Pharmacol Ther</i>, 1995, 33(9):509-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8520809\">[PubMed 8520809]</a></p>\n<p>7. Parkes JD, Debono AG, Marsden CD, “Bromocriptine in Parkinsonism: Long-Term Treatment, Dose-Response, and Comparison with Levodopa,” <i>J Neurol Neurosurg Psychiatry</i>, 1976, 39(11):1101-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1036999\">[PubMed 1036999]</a></p>\n<p>8. Corsini GU, Zompo MD, Cianchetti C, et al, “Therapeutical Efficacy of a Combination of Apomorphine with Sulpiride or Metoclopramide in Parkinsonism,” <i>Psychopharmacologia</i>, 1976, 47(2):169-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1273213\">[PubMed 1273213]</a></p>\n<p>9. Tarsy D, Parkes JD, Marsden CD, “Metoclopramide in Parkinsonism,” <i>Lancet</i>, 1975, 1(7918):1244-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=48872\">[PubMed 48872]</a></p>\n<p>10. Tarsy D, Parkes JD, Marsden CD, “Metoclopramide and Pimozide in Parkinson's Disease and Levodopa-Induced Dyskinesias,” <i>J Neurol Neurosurg Psychiatry</i>, 1975, 38(4):331-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1095689\">[PubMed 1095689]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4055":"<p><b>Title</b> PHENobarbital / Amphetamines</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amphetamines may decrease the serum concentration of PHENobarbital. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Serum concentrations of phenobarbital should be monitored if an amphetamine is to be added to a patient being treated with phenobarbital. This possible interaction may also be minimized by separating the administration of the agents by at least one hour.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n</div> \n<p><b>Discussion</b> No data regarding this potential interaction from human studies or case reports have been found. Data from animal studies suggests amphetamines can increase the ED50 (dose required for a 50% reduction in seizures) of phenobarbital, phenytoin, and ethosuximide by 1.5- to 3-fold when administered with amphetamines.<sup>1</sup> In addition, serum concentrations of the antiepileptic agents were substantially lower following coadministration. When phenobarbital was administered one hour prior to the amphetamine, there were no significant changes in either ED50 or phenobarbital serum concentrations. These data appear to suggest that amphetamines can delay or impair the absorption of the antiepileptic drugs, an effect that is dependent on amphetamine dose (in animal studies, consistently greater with 5-8mg/kg than with 3mg/kg).<br><br>Data from another animal study supports these findings, reporting that when phenobarbital or phenytoin were administered one hour prior to amphetamine, there was no change in the antiepileptic ED50.<sup>2</sup><br><br>Numerous possible mechanisms have been proposed to explain the observed effect of amphetamines on phenobarbital, phenytoin, and ethosuximide ED50 and serum concentrations.<sup>1</sup> Two possible explanations, supported by data from rat, dog, and humans, include amphetamine-induced decreased gastric emptying and decreased gastrointestinal motility. Another proposed mechanism is a decrease in gastrointestinal circulation, leading to impaired drug absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Frey HH, Kampmann E, “Interaction of Amphetamine with Anticonvulsant Drugs. II. Effect of Amphetamine on the Absorption of Anticonvulsant Drugs,” <i>Acta Pharmacol Toxicol (Copenh)</i>, 1966, 24(4):310-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6013114\">[PubMed 6013114]</a></p>\n<p>2. Frey HH, “Note on the Interactions of Amphetamine with Anticonvulsant Drugs,” <i>Acta Pharmacol (Kbh.)</i>, 1964, 21:290-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14209620\">[PubMed 14209620]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4056":"<p><b>Title</b> Phenytoin / Amphetamines</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amphetamines may decrease the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Serum concentrations of phenytoin should be monitored if an amphetamine is to be added to a patient being treated with phenytoin. This possible interaction may also be minimized by separating the administration of the agents by at least two hours.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n</div> \n<p><b>Discussion</b> No data regarding this potential interaction from human studies or case reports have been found. Data from animal studies suggests amphetamines can increase the ED50 (dose required for a 50% reduction in seizures) of phenobarbital, phenytoin, and ethosuximide by 1.5- to 3-fold when administered with amphetamines.<sup>1</sup> In addition, serum concentrations of the antiepileptic agents were substantially lower following coadministration. When phenytoin was administered one hour prior to the amphetamine, there was a smaller, but still statistically significant increased in ED50 and decrease in serum concentrations. When administered two hours prior to amphetamine, however, there were no significant changes in either ED50 or phenytoin serum concentrations. These data appear to suggest that amphetamines can delay or impair the absorption of the antiepileptic drugs, an effect that is dependent on amphetamine dose (in animal studies, consistently greater with 5-8mg/kg than with 3mg/kg).<br><br>Data from another animal study supports these findings, reporting that when phenobarbital or phenytoin were administered one hour prior to amphetamine, there was no change in the antiepileptic ED50.<sup>2</sup><br><br>Numerous possible mechanisms have been proposed to explain the observed effect of amphetamines on phenobarbital, phenytoin, and ethosuximide ED50 and serum concentrations.<sup>1</sup> Two possible explanations, supported by data from rat, dog, and humans, include amphetamine-induced decreased gastric emptying and decreased gastrointestinal motility. Another proposed mechanism is a decrease in gastrointestinal circulation, leading to impaired drug absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Frey HH, Kampmann E, “Interaction of Amphetamine with Anticonvulsant Drugs. II. Effect of Amphetamine on the Absorption of Anticonvulsant Drugs,” <i>Acta Pharmacol Toxicol (Copenh)</i>, 1966, 24(4):310-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6013114\">[PubMed 6013114]</a></p>\n<p>2. Frey HH, “Note on the Interactions of Amphetamine with Anticonvulsant Drugs,” <i>Acta Pharmacol (Kbh.)</i>, 1964, 21:290-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14209620\">[PubMed 14209620]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4057":"<p><b>Title</b> Ethosuximide / Amphetamines</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Serum concentrations of ethosuximide should be monitored if an amphetamine is to be added. This possible interaction may also be minimized by separating the administration of the agents by at least one hour.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n</div> \n<p><b>Discussion</b> No data regarding this potential interaction from human studies or case reports have been found. Data from animal studies suggests amphetamines can increase the ED50 (dose required for a 50% reduction in seizures) of phenobarbital, phenytoin, and ethosuximide by 1.5- to 3-fold when administered with amphetamines.<sup>1</sup> In addition, serum concentrations of the antiepileptic agents were substantially lower following coadministration. For phenobarbital and phenytoin, when either agent was administered 1-2 hours prior to the amphetamine, the interation was absent or minimized; however, no specific data regarding the effect of separating administration was presented for ethosuximide. These data appear to suggest that amphetamines can delay or impair the absorption of the antiepileptic drugs, an effect that is dependent on amphetamine dose (in animal studies, consistently greater with 5-8mg/kg than with 3mg/kg).<br><br>One study with ethosuximide did report that amphetamine antagonized the antiepileptic effect of ethosuximide, as measured by the pentetrazole seizure threshold test, demonstrating a “central antagonist” effect.<sup>2</sup><br><br>Numerous possible mechanisms have been proposed to explain the observed effect of amphetamines on phenobarbital, phenytoin, and ethosuximide ED50 and serum concentrations.<sup>1</sup> Two possible explanations, supported by data from rat, dog, and humans, include amphetamine-induced decreased gastric emptying and decreased gastrointestinal motility. Another proposed mechanism is a decrease in gastrointestinal circulation, leading to impaired drug absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Frey HH, Kampmann E, “Interaction of Amphetamine with Anticonvulsant Drugs. II. Effect of Amphetamine on the Absorption of Anticonvulsant Drugs,” <i>Acta Pharmacol Toxicol (Copenh)</i>, 1966, 24(4):310-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6013114\">[PubMed 6013114]</a></p>\n<p>2. Frey HH, “Note on the Interactions of Amphetamine with Anticonvulsant Drugs,” <i>Acta Pharmacol (Kbh.)</i>, 1964, 21:290-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14209620\">[PubMed 14209620]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4062":"<p><b>Title</b> Amphetamines / Ammonium Chloride</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ammonium Chloride may decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor response to amphetamines when used together with ammonium chloride or other urine acidifying agents as enhanced excretion of amphetamines may result, possibly leading to decreased concentrations and diminished clinical response.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n</div> \n<p><b>Discussion</b> The pH-dependent renal excretion of amphetamines has been repeatedly demonstrated. Acidification of the urine (with ammonium chloride, dosed to pH = 5.3) was shown in one study to increase renal excretion of (+)-amphetamine to 59.0-83.5% of a dose within 24 hours from an average of 32.9% (12-44%) with unregulated urinary pH.<sup>1</sup> In another study, acidification of the urine resulted in more than a 3-fold increase in mean 16-hour excretion of amphetamine compared to that excreted in 16 hours with uncontrolled urinary pH (mean 54.5% vs. 14.5%, respectively; n=6).<sup>2</sup> Acidification of the urine has also been shown to reduce amphetamine plasma concentrations,<sup>3</sup> shorten the elimination half-life,<sup>4</sup> and increase urinary excretion rate.<sup>3</sup><br><br>Studies with amphetamine derivatives (e.g., ephedrine, methylamphetamine, etc.) have generally shown this same pH-dependent renal excretion of unchanged drug,<sup>5</sup> with observations that increasing methylation of the amino group increases this pH-dependence.<sup>5</sup><br><br>The ability to hasten amphetamine removal via acidification has also generated interest in using this to treat cases of amphetamine overdose or toxicity, with studies demonstrating the utility of strategy for both amphetamine<sup>6</sup> and methamphetamine<sup>7</sup> overdoses.<br><br>The most simple mechanism of this interaction that has been proposed is that the basic amphetamine molecule becomes ionized in the acidic filtrate, preventing any renal tubular reabsorption and enhancing urinary elimination. An alternative mechanism has also been proposed after a pharmacokinetic study demonstrated that preventing tubular reabsorption alone would not be able to account for the substantial impact of acidification on plasma amphetamine concentrations and urinary excretion rates.<sup>3</sup> Under this proposed alternative mechanism, diffusion of parent drug directly into the filtrate occurs as a result of the tremendous concentration gradient for unchanged drug between plasma and filtrate (where virtually all amphetamine present is in its ionized form), resulting in enhanced elimination (beyond simply filtered drug becoming ionized and trapped in filtrate/urine) and reduced plasma concentrations.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Beckett AH, Rowland M, “Urinary Excretion Kinetics of Amphetamine in Man,” <i>J Pharm Pharmacol</i>, 1965, 17(10):628-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4379686\">[PubMed 4379686]</a></p>\n<p>2. Beckett AH, Rowland M, Turner P, “Influence of Urinary pH on Excretion of Amphetamine,” <i>Lancet</i>, 1965, 1:303. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14247879\">[PubMed 14247879]</a></p>\n<p>3. Beckett AH, Salmon JA, Mitchard M, “The Relation Between Blood Levels and Urinary Excretion of Amphetamine Under Controlled Acidic and Under Fluctuating Urinary pH Values Using [14C] Amphetamine,” <i>J Pharm Pharmacol</i>, 1969, 21(4):251-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4390145\">[PubMed 4390145]</a></p>\n<p>4. Davis JM, Kopin IJ, Lemberger L, et al, “Effects of Urinary pH on Amphetamine Metabolism,” <i>Ann NY Acad Sci</i>, 1971, 179:493-501. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5285389\">[PubMed 5285389]</a></p>\n<p>5. Wilkinson GR, Beckett AH, “Absorption Metabolism and Excretion of the Ephedrines in Man. I. The Influence of Urinary pH and Urine Volume Output,” <i>J Pharmacol Exp Ther</i>, 1968, 162(1):139-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5656593\">[PubMed 5656593]</a></p>\n<p>6. Anggard E, Jonsson LE, Hogmark AL, et al, “Amphetamine Metabolism in Amphetamine Psychosis,” <i>Clin Pharmacol Ther</i>, 1973, 14(5):870-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4729903\">[PubMed 4729903]</a></p>\n<p>7. Gary NE, Saidi P, “Methamphetamine Intoxication. A Speedy New Treatment,” <i>Am J Med</i>, 1978, 64(3):537-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=637062\">[PubMed 637062]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4063":"<p><b>Title</b> Amphetamines / Alkalinizing Agents</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Alkalinizing Agents may decrease the excretion of Amphetamines. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Since alkalinization of the urine significantly impairs the renal excretion of amphetamines, clinicians should consider alternatives to using amphetamines and alkalinizing agents in combination. If these agents must be used together, patients should be monitored closely for excessive amphetamine effects.</p>\n<div>\n <p><b>Alkalinizing Agents Interacting Members</b> Potassium Citrate, Sodium Bicarbonate, Sodium Citrate, Sodium Lactate, Tromethamine</p>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n</div> \n<p><b>Discussion</b> The pH-dependent renal excretion of amphetamines has been repeatedly demonstrated. Alkalinization of the urine (with sodium bicarbonate) was shown in one study to decrease renal excretion of (+)-amphetamine to 2.2 to 4.2% of a dose within 24 hours from an average of 32.9% (12-44%) with unregulated urinary pH.<sup>1</sup> In another study, alkalinization of the urine (to pH ~8.0) resulted in a decrease in mean 16-hour excretion of amphetamine to only approximately 20% of that excreted in 16 hours with uncontrolled urinary pH (mean 2.9% vs. 14.5%, respectively; n=6).<sup>2</sup> Alkalinization of the urine has also been shown to prolong elimination half-life, possibly by several-fold compared to that of acidic urine.<sup>3</sup><br><br>Studies with amphetamine derivatives (e.g., ephedrine, methylamphetamine, etc.) have generally shown this same pH-dependent renal excretion of unchanged drug,<sup>4</sup> with observations that increasing methylation of the amino group increases this pH-dependence.<sup>4</sup><br><br>While little is known about the clinical consequences of the delayed excretion of amphetamines in the setting of alkaline urine, the prolonged resonance of amphetamines in the body could be expected to result in enhanced clinical effects and possible toxicity, particularly with repeated dosing. In support of this, enhanced amphetamine effects were reported during the alkalinization arm of a pharmacokinetic study evaluating the impact of urinary acidification and alkalinization on amphetamine excretion.<sup>1</sup><br><br>The likely mechanism of this interaction is that the basic amphetamine molecule remains unionized in the alkaline filtrate, facilitating renal tubular reabsorption and minimizing urinary elimination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Beckett AH, Rowland M, “Urinary Excretion Kinetics of Amphetamine in Man,” <i>J Pharm Pharmacol</i>, 1965, 17(10):628-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4379686\">[PubMed 4379686]</a></p>\n<p>2. Beckett AH, Rowland M, Turner P, “Influence of Urinary pH on Excretion of Amphetamine,” <i>Lancet</i>, 1965, 1:303. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14247879\">[PubMed 14247879]</a></p>\n<p>3. Davis JM, Kopin IJ, Lemberger L, et al, “Effects of Urinary pH on Amphetamine Metabolism,” <i>Ann NY Acad Sci</i>, 1971, 179:493-501. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5285389\">[PubMed 5285389]</a></p>\n<p>4. Wilkinson GR, Beckett AH, “Absorption Metabolism and Excretion of the Ephedrines in Man. I. The Influence of Urinary pH and Urine Volume Output,” <i>J Pharmacol Exp Ther</i>, 1968, 162(1):139-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5656593\">[PubMed 5656593]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4065":"<p><b>Title</b> Anthracyclines / Cardiac Glycosides</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cardiac Glycosides may diminish the cardiotoxic effect of Anthracyclines. Anthracyclines may decrease the serum concentration of Cardiac Glycosides. The effects of liposomal formulations may be unique from those of the free drug, as liposomal formulation have unique drug disposition and toxicity profiles, and liposomes themselves may alter digoxin absorption/distribution. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for changes (increased or decreased) in therapeutic effects of digoxin tablets if anthracycline chemotherapy is initiated/dose increased or if anthracycline chemotherapy is discontinued/dose decreased. Also monitor cardiovascular function closely in patients receiving digoxin and an anthracycline agent in combination.</p>\n<div>\n <p><b>Anthracyclines Interacting Members</b> DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), DOXOrubicin (Conventional)*, DOXOrubicin (Liposomal), EpiRUBicin, IDArubicin</p>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> <i>Regarding the Possible Effect of Anthracyclines on Cardiac Glycoside (e.g., digoxin) Concentrations:</i><br>The absorption of digoxin from tablet formulations has been shown to be decreased by approximately 50% when coadministered with a variety of cytotoxic/chemotherapy regimens.<sup>1,2</sup> With respect to anthracyclines in particular, 3 of 21 patients in one case series received a combination including doxorubicin (75mg/m<sup>2</sup> together with bleomycin on first day, with prednisone for 5 days) in conjunction with beta-acetyldigoxin 0.3mg. Average glycoside steady-state concentrations decreased in all patients after chemotherapy (at 24-168 hours after chemotherapy started) and returned to baseline by day 8.<sup>2</sup><br><br>The most likely mechanism for the observed decrease in steady-state glycoside concentrations observed with doxorubicin (and various other chemotherapeutic agents) involves interference with the dissolution of digoxin tablets, as serveral reports document a significantly less substantial interaction with digoxin solution.<sup>1,3</sup> It is also possible that intestinal epithelial toxicity (i.e., decreased cell division and epithelial mass) plays a role in any such interaction.<sup>3</sup> Increased intestinal p-glycoprotein could also be involved, as doxorubicin has been shown to increase p-glycoprotein in rat liver cells and rat astrocytes within 2-4 hours of exposure to doxorubicin.<sup>4,5</sup> If p-glycoprotein is involved in this interaction, liposomal formulations may not interact with digoxin in the same manner, as liposomal doxorubicin is thought to decrease p-glycoprotein<sup>6</sup> and liposomes themselves are thought to be inhibitors of p-glycoprotein.<sup>7</sup> Of note, one conflicting study has reported increased p-glycoprotein in peripheral lymphocytes from patients infected with HIV following exposure to liposomal doxorubicin.<sup>8</sup><br><br><i>Regarding the Possible Effects of Digoxin on Anthracycline Cardiotoxicity:</i><br>In a study of 63 patients with newly diagnosed acute myelogenous leukemia, patients were randomized to digoxin (average 0.25mg daily), vitamin E, or no study drug to be received in conjunction with their chemotherapy (induction with cytarabine, thioguanine, and doxorubicin; maintenance with monthly doxorubicin).<sup>9</sup> Patients were then screened for cariotoxicity before and 2 weeks after each doxorubicin treatment using the ratio of pre-ejection period to ventricular ejection time. No patients receiving less than 400mg/m<sup>2</sup> of doxorubicin exhbited any evidence of cardiotoxicity. An anlysis of those patients surviving to receive more than 400mg/m<sup>2</sup> of doxorubicin found significantly less of a change in the systolic time interval (measure of cardiotoxicity) in those patients receiving digoxin as compared to control patients. There was no significant difference in this measure between vitamin E-treated patients and controls. Whether digoxin pre-treatment was protective or simply masked any cardiotoxicity that did occur was unclear. Conversely, an study in a rabbit model found evidence of greater cardiotoxicity among rabbits receiving doxorubicin and digoxin vs. either doxorubicin alone or controls.<sup>10</sup><br><br>The mechanism by which digoxin could protect against doxorubicin is unclear, but an vitro study has shown that digoxin is capable of blocking the binding of doxorubicin to rat myocardial tissue, a finding that could help to explain at least mechanism by which digoxin is protective.<sup>11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Huang AT, Roth P, et al, “Effects of High-Dose Cancer Chemotherapy on the Absorption of Digoxin in Two Different Formulations,” <i>Clin Pharmacol Ther</i>, 1986, 39:25-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3943266\">[PubMed 3943266]</a></p>\n<p>2. Kuhlmann J, Zilly W, and Wilke J, “Effects of Cytostatic Drugs on Plasma Levels and Renal Excretion of Beta-Acetyldigoxin,” <i>Clin Pharmacol Ther</i>, 1981, 30:518-27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7285486\">[PubMed 7285486]</a></p>\n<p>3. Jusko WB, Conti DR, Molson A, et al, “Digoxin Absorption from Tablets and Elixir: The Effect of Radiation-Induced Malabsorption,” <i>JAMA</i>, 1974, 230:1554-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4479663\">[PubMed 4479663]</a></p>\n<p>4. Fardel O, Lecureur V, Daval S, et al, “Up-Regulation of P-glycoprotein Expression in Rat Liver Cells by Acute Doxorubicin Treatment,” <i>Eur J Biochem</i>, 1997, 246(1):186-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9210482\">[PubMed 9210482]</a></p>\n<p>5. Mercier C, Decleves X, Masseguin C, et al, “P-glycoprotein (ABCB1) but not Multidrug Resistance-Associated Protein 1 (ABCC1) is Induced by Doxorubicin in Primary Cultures of Rat Astrocytes,” <i>J Neurochem</i>, 2003, 87(4):820-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14622113\">[PubMed 14622113]</a></p>\n<p>6. Cattel L, Passera R, Katsaros D, et al, “Pegylated Liposomal Doxorubicin and Vinorelbine in Recurrent Ovarian Carcinoma: A Pharmacokinetic Study on Alternate Administration Sequences,” <i>Anticancer Res</i>, 2006, 26(1B):745-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16739347\">[PubMed 16739347]</a></p>\n<p>7. Thierry AR, Dritschilo A, Rahman A, “Effect of Liposomes on P-glycoprotein Function in Multidrug Resistant Cells,” <i>Biochem Biophys Res Commun</i>, 1992, 187(2):1098-105. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1356335\">[PubMed 1356335]</a></p>\n<p>8. Lucia MB, Rutella S, Leone G, et al, “In Vitro and In Vivo Modulation of MDR1/P-glycoprotein in HIV-Infected Patients Administered Highly Active Antiretroviral Therapy and Liposomal Doxorubicin,” <i>J Acquir Immune Defic Syndr</i>, 2002, 30(4):369-78. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12138343\">[PubMed 12138343]</a></p>\n<p>9. Whittaker JA, Al-Ismail SAD, “Effect of Digoxin and Vitamin E in Preventing Cardiac Damage Caused by Doxorubicin in Acute Myeloid Leukemia,” <i>Br Med J</i>, 1984, 288:283-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6419896\">[PubMed 6419896]</a></p>\n<p>10. Reeves WC, Griffith JW, Wood MA, et al, “Exacerbation of Doxorubicin Cardiotoxicity by Digoxin Administration in an Experimental Rabbit Model,” <i>Int J Cancer</i>, 1990, 45(4):731-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2157677\">[PubMed 2157677]</a></p>\n<p>11. Alvarez-Cedron L, Lopez FG, Lanao JM, “Influence of Verapamil and Digoxin on the In Vitro Binding of Doxorubicin to the Rat Heart,” <i>Biol Pharm Bull</i>, 1998, 21(8):839-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9743253\">[PubMed 9743253]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4066":"<p><b>Title</b> Anthracyclines / Taxane Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Taxane Derivatives may enhance the adverse/toxic effect of Anthracyclines. Taxane Derivatives may increase the serum concentration of Anthracyclines. Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Several methods of minimizing toxicity with this combination have been proposed, including administering doxorubicin prior to paclitaxel (or at least separating by as much time as possible),<sup>1,2</sup> using liposomal doxorubicin or epirubicin instead of doxorubicin,<sup>3,4,5,6</sup> and using docetaxel instead of paclitaxel.<sup>5,7,8</sup> Regardless of which specific combination or regimen is used, patients should be monitored closely for the development of cardiovascular and other toxicities.</p>\n<div>\n <p><b>Anthracyclines Interacting Members</b> DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), DOXOrubicin (Conventional)*, DOXOrubicin (Liposomal)*, EpiRUBicin*, IDArubicin</p>\n <p><b>Taxane Derivatives Interacting Members</b> Cabazitaxel, DOCEtaxel*, PACLitaxel (Conventional)*, PACLitaxel (Protein Bound)</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Several studies have demonstrated that paclitaxel can interfere with the elimination of doxorubicin, particularly when paclitaxel is administered prior to or shortly after doxorubicin.<sup>1,2,9</sup> In addition to resulting in increased plasma concentration and AUC (of both doxorubicin and the metabolite doxorubicinol), this interaction reportedly led to greater nonlinearity of doxorubicin, meaning that subsequent changes in doxorubicin dose would have less predictable pharmacodynamic effects.<sup>9</sup> In addition to doxorubicin, this interaction has also been detected with liposomal doxorubicin<sup>10,11</sup> and epirubicin,<sup>12,13</sup> though others have reported either the absence of or a less substantial interaction with these products.<sup>4,5,6</sup><br><br>The paclitaxel-doxorubicin interaction has also been associated with greater cardiovascular toxicity in clinical<sup>2,7</sup> and in vitro studies,<sup>5,14,15</sup> and/or with other toxicities (e.g., hematologic, mucosal).<sup>1</sup> Idarubicin prescribing information warns that concomitant use of idarubicin and paclitaxel may increase the risk for cardiotoxicity.<sup>16</sup> Initiation of idarubin at least 5 half-lives after discontinuation of paclitaxel is suggested in order to minimize the cardiotoxic risk of this combination.<sup>16</sup><br><br>The mechanism for the pharmacokinetic interaction (i.e., increased plasma concentration and increased AUC) between the taxanes and doxorubicin is unclear. One proposed mechanism involves inhibition of p-glycoprotein-mediated transport of doxorubicin by the taxane (paclitaxel or docetaxel), a component of the taxane formulation (i.e., Cremophor EL, polysorbate 80), or both.<sup>9</sup> Since liposomal doxorubicin appears less sensitive to p-glycoprotein-mediated transport,<sup>17</sup> but still exhibits evidence of an interaction with the taxanes, the role of p-glycoprotein in this interaction is questionable.<br><br>Beyond increased plasma concentrations of doxorubicin and its doxorubicinol metabolite, several studies have suggested that a taxane-mediated increase in the production of toxic metabolites in heart tissue may represent the primary mechanism by which taxanes can increase the cardiotoxicity of doxorubicin (and possibly other anthracyclines). In these in vitro studies, paclitaxel and docetaxel (at clinically relevant concentrations) both increased the formation of the toxic doxorubicinol metabolite via increased activity of cellular aldehyde reductases.<sup>5,14,15</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Holmes FA, Madden T, Newman RA, et al, “Sequence-Dependent Alteration of Doxorubicin Pharmacokinetics by Paclitaxel in a Phase I Study of Paclitaxel and Doxorubicin in Patients with Metastatic Breast Cancer,” <i>J Clin Oncol</i>, 1996, 14(10):2713-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8874332\">[PubMed 8874332]</a></p>\n<p>2. Moreira A, Lobato R, Morais J, et al, “Influence of the Interval between the Administration of Doxorubicin and Paclitaxel on the Pharmacokinetics of these Drugs in Patients with Locally Advanced Breast Cancer,” <i>Cancer Chemother Pharmacol</i>, 2001, 48(4):333-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11710635\">[PubMed 11710635]</a></p>\n<p>3. Safra T, “Cardiac Safety of Liposomal Anthracyclines,” <i>Oncologist</i>, 2003, 8(Suppl 2):17-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13679592\">[PubMed 13679592]</a></p>\n<p>4. Janinis J, Stathopoulos GP, Nikolaidis P, et al, “Pegylated Liposomal Doxorubicin Hydrochloride (PLD) and Paclitaxel in Recurrent or Metastatic Head and Neck Carcinoma: a Phase I/II Study Conducted by the Hellenic Cooperative Oncology Group (HeCOG),” <i>Anticancer Drugs</i>, 2004, 15(5):119-25. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1507667\">[PubMed 1507667]</a></p>\n<p>5. Platel D, Pouna P, Bonoron-Adele S, et al, “Preclinical Evaluation of the Cardiotoxicity of Taxane-Anthracycline Combinations Using the Model of Isolated Perfused Rat Heart,” <i>Toxicol Appl Pharmacol</i>, 2000, 163(2):135-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10698671\">[PubMed 10698671]</a></p>\n<p>6. Salvatorelli E, Menna P, Gianni L, et al, “Defective Taxane Stimulation of Epirubicinol Formation in the Human Heart: Insight into the Cardiac Tolerability of Epirubicin-Taxane Chemotherapies,” <i>J Pharmacol Exp Ther</i>, 2007, 320(2):790-800. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17135345\">[PubMed 17135345]</a></p>\n<p>7. Holmes FA and Rowinsky EK, “Pharmacokinetic Profiles of Doxorubicin in Combination With Taxanes,” <i>Semin Oncol</i>, 2001, 28(4 Suppl 12):8-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11552225\">[PubMed 11552225]</a></p>\n<p>8. Briasoulis E, Karavasilis V, Tzamakou E, et al, “Interaction Pharmacokinetics of Pegylated Liposomal Doxorubicin (Caelyx) on Coadministration with Paclitaxel or Docetaxel,” <i>Cancer Chemother Pharmacol</i>, 2004, 53(5):452-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14749894\">[PubMed 14749894]</a></p>\n<p>9. Gianni L, Vigano L, Locatelli A, et al, “Human Pharmacokinetic Characterization and In Vitro Study of the Interaction between Doxorubicin and Paclitaxel in Patients with Breast Cancer,” <i>J Clin Oncol</i>, 1997, 15(5):1906-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9164201\">[PubMed 9164201]</a></p>\n<p>10. Bourgeois H, Ferru A, Lortholary A, et al, “Phase I-II Study of Pegylated Liposomal Doxorubicin Combined with Weekly Paclitaxel as First-Line Treatment in Patients with Metastatic Breast Cancer,” <i>Am J Clin Oncol</i>, 2006, 29(3):267-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16755180\">[PubMed 16755180]</a></p>\n<p>11. Briasoulis E, Pentheroudakis G, Karavasilis V, et al, “Weekly Paclitaxel Combined with Pegylated Liposomal Doxorubicin (Caelyx<sup>TM</sup>) Given Every 4 Weeks: Dose-Finding and Pharmacokinetic Study in Patients with Advanced Solid Tumors,” <i>Ann Oncol</i>, 2004, 15(10):1566-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15367419\">[PubMed 15367419]</a></p>\n<p>12. Esposito M, Venturini M, Vannozzi MO, et al, “Comparative Effects of Paclitaxel and Docetaxel on the Metabolism and Pharmacokinetics of Epirubicin in Breast Cancer Patients,” <i>J Clin Oncol</i>, 1999, 17(4):1132. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10561171\">[PubMed 10561171]</a></p>\n<p>13. Danesi R, Innocenti F, Fogli S, et al, “Pharmacokinetics and Pharmacodynamics of Combination Chemotherapy with Paclitavel and Epirubicin in Breast Cancer Patients,” <i>Br J Clin Pharmacol</i>, 2002, 53(5):508-18. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11994057\">[PubMed 11994057]</a></p>\n<p>14. Salvatorelli E, Menna P, Cascegna S, et al, “Paclitaxel and Docetaxel Stimulation of Doxorubicinol Formation in the Human Heart: Implications for Cardiotoxicity of Doxorubicin-Taxane Chemotherapies,” <i>J Pharmacol Exp Ther</i>, 2006, 318(1):424-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16614166\">[PubMed 16614166]</a></p>\n<p>15. Minotti G, Saponiero A, Licata S, et al, “Paclitaxel and Docetaxel Enhance the Metabolism of Doxorubicin to Toxic Species in Human Myocardium,” <i>Clin Cancer Res</i>, 2001, 7(6):1511-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11410484\">[PubMed 11410484]</a></p>\n<p>16. <i>Idamycin</i> (idarubicin) [prescribing information]. New York, NY: Pfizer Inc; December 2014.</p>\n<p>17. Advani R, Lum BL, Fisher GA, et al, “A Phase I Trial of Liposomal Doxorubicin, Paclitaxel and Valspodar (PSC-833), an Inhibitor of Multidrug Resistance,” <i>Ann Oncol</i>, 2005, 16(12):1968-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16126736\">[PubMed 16126736]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4067":"<p><b>Title</b> Stavudine / DOXOrubicin (Liposomal)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> DOXOrubicin (Liposomal) may diminish the therapeutic effect of Stavudine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced stavudine efficacy (eg, decreased CD4 count, increased HIV viral load) if combined with doxorubicin.</p> \n<p><b>Discussion</b> In vitro data demonstrate the ability of doxorubicin to inhibit the phosphorylation process that is responsible for converting stavudine to an active antiviral product within cells.<sup>1,2</sup> The effectiveness of stavudine during concomitant use may be reduced. However, 2 clinical trials found that treatment-naive patients with HIV who received a doxorubicin-containing chemotherapy regimen plus stavudine-containing highly active antiretroviral therapy (HAART) had stable or improved HIV viral loads and CD4 counts compared with patients who received stavudine-containing HAART alone.<sup>3,4</sup><br><br>Stavudine prescribing information states that because the activation of stavudine may be impaired by doxorubicin, concomitant use should be undertaken with caution.<sup>1</sup> Whether this interaction occurs with liposomal formulations of doxorubicin is unclear given the altered distribution and elimination profile of such products.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zerit (stavudine) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; November 2011.</p>\n<p>2. Hoggard PG, Kewn S, Barry MG, Khoo SH, Back DJ. Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro. <i>Antimicrob Agents Chemother</i>. 1997;41(6):1231-1236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9174176\">[PubMed 9174176]</a></p>\n<p>3. Mosam A, Shaik F, Uldrick TS, et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active retroviral therapy and chemotherapy in treatment-naive patients with HIV-associated Kaposi sarcoma in South Africa. <i>J Acquir Immune Defic Syndr</i>. 2012;60(2):150-157. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22395672\">[PubMed 22395672]</a></p>\n<p>4. Ratner L, Lee J, Tang S, et al; AIDS Malignancy Consortium. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma in combination with highly active antiretroviral therapy. <i>J Clinical Oncol</i>. 2001;19(8):2171-2178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11304769\">[PubMed 11304769]</a></p>\n<p>5. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin. <i>Clin Pharmacokinet</i>. 2003;42(5):419-436. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12739982\">[PubMed 12739982]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4068":"<p><b>Title</b> Zidovudine / DOXOrubicin (Liposomal)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> DOXOrubicin (Liposomal) may enhance the adverse/toxic effect of Zidovudine. DOXOrubicin (Liposomal) may diminish the therapeutic effect of Zidovudine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of liposomal doxorubicin and zidovudine should probably be avoided.<sup>1,2</sup> Reduced efficacy of zidovudine is possible (<i>in vitro</i> data). Also, increased myelosuppressive effects are possible with combined administration.</p> \n<p><b>Discussion</b> <i>In vitro</i> data demonstrate the ability of doxorubicin to inhibit the phosphorylation process that is responsible for converting zidovudine to an active antiviral product within cells.<sup>1,2</sup> The effectiveness of zidovudine during concomitant use may be reduced. Further, the myelosuppressive effects of each agent may be additive, or possibly synergistic, leading to greater hematologic toxicity. The concurrent use of zidovudine and doxorubicin is not recommended.<sup>1</sup> Whether this interaction occurs with liposomal formulations of doxorubicin is unclear given the altered distribution, elimination, and toxicity profile of such products.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Retrovir [package insert]. Research Trianlge Park, NC: GlaxoSmithKline, 2006.</p>\n<p>2. Hoggard PG, Veal GJ, Wild MJ, et al, “Drug Interactions with Zidovudine Phosphorylation In Vitro,” <i>Antimicrob Agents Chemother</i>, 1995, 39(6):1376-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7574535\">[PubMed 7574535]</a></p>\n<p>3. Gabizon A, Shmeeda H, Barenholz Y, “Pharmacokinetics of Pegylated Liposomal Doxorubicin,” <i>Clin Pharmacokinet</i>, 2003, 42(5):419-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12739982\">[PubMed 12739982]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4070":"<p><b>Title</b> Topiramate / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Topiramate. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased seizure control if carbamazepine is initiated/dose increased with stable topiramate therapy. Dosage increase of topiramate may be required with concomitant therapy.</p> \n<p><b>Discussion</b> A study of 12 patients receiving stable carbamazepine (CBZ; 300-800 mg every 8 hours) for partial epilepsy evaluated the pharmacokinetics of topiramate (TPM; up to 400 mg every 12 hours) given concomitantly compared to TPM alone.<sup>1</sup> Compared to 2 weeks of TPM monotherapy, steady-state administration of both anticonvulsants resulted in TPM serum levels (eg, Cmax, AUC) that were ~40% lower than when TPM was administered in the absence of CBZ. Another study in 12 healthy volunteers evaluated the pharmacokinetic parameters of single dose TPM (200 mg) given on day 18 of a 24-day CBZ regimen (600 mg/day).<sup>2</sup> In this study, oral clearance of TPM was increased by 2-fold, with a corresponding 35% reduction in TPM half-life and 2- to 3-fold increase in metabolites. The mechanism of this interaction is most likely induction of hepatic metabolic enzymes by CBZ. <br><br>However, another paper reviewed 25 cases of unsolicited reports to an epilepsy nurse specialist of drug intoxication which occurred when TPM was added to stable therapy of a modified release formulation of CBZ.<sup>3</sup> A spectrum of complaints ranging from CNS depression-related events to evidence of ataxia was reported by patients receiving 900-3600 mg/day of CBZ with the addition of 25-800 mg/day of TPM. Symptoms generally resolved with dose reductions of one or both agents. The mechanism of this apparent augmentation of CNS effects is not known. <br><br>Close monitoring of TPM levels are recommended when given concurrently with CBZ, in conjunction with physical assessments for any CNS-related adverse effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sachdeo RC, Sachdeo SK, Walker SA, et al, “Steady-State Pharmacokinetics of Topiramate and Carbamazepine in Patients with Epilepsy During Monotherapy and Concomitant Therapy,” <i>Epilepsia</i>, 1996, 37(8):774-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8764818\">[PubMed 8764818]</a></p>\n<p>2. Britzi M, Perucca E, Soback S, et al, “Pharmacokinetic and Metabollic Investigation of Topiramate Disposition in Healthy Subjects in the Absence and in the Presence of Enzyme Induction by Carbamazepine,” <i>Epilepsia</i>, 2005, 46(3):378-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15730535\">[PubMed 15730535]</a></p>\n<p>3. Mack CJ, Kuc S, Mulcrone SA, et al, “Interaction of topiramate with Carbamazepine: Two Case Reports and a Review of Clinical Experience,” <i>Seizure</i>, 2002, 11:464-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12237076\">[PubMed 12237076]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4071":"<p><b>Title</b> Digoxin / Topiramate</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Topiramate may decrease the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No routine monitoring is recommended. However, if any signs of reduced digoxin efficacy become evident (eg, increased heart rate, worsening atrial fibrillation, shortness of breath, etc), digoxin levels should be obtained.</p> \n<p><b>Discussion</b> A small study reports a minor reduction in digoxin serum levels in 12 healthy subjects with concomitant topiramate therapy (100 mg twice daily for 9 days).<sup>1</sup> The AUC of digoxin was reported to be diminished by only 12%, and thus the clinical significance of this interaction appears minimal.<sup>2</sup> The mechanism of this supposed pharmacokinetic interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Liao S, Palmer M, “Digoxin and Topiramate Drug Interaction Study in Male Volunteers,” <i>Pharm Res</i>, 1993, 10 (Suppl):S405.]2. Package Insert. Topamax (topiramate). Titusville, NJ: Ortho-McNeil Neurologics, 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4073":"<p><b>Title</b> Cortisone / Somatropin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Somatropin may diminish the therapeutic effect of Cortisone. Growth hormone may reduce the conversion of cortisone to the active cortisol metabolite. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for reduced efficacy of cortisone treatment. Patients receiving glucocorticoid therapy for hypoadrenalism may require increased maintenance or stress doses of the steroid.</p> \n<p><b>Discussion</b> At clinically relevant doses, human growth hormone (GH) has been shown to inhibit the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11BHSD1).<sup>1,2,3,4</sup> This enzyme is required for the bioactivation of prednisone and cortisone. Reduction of the keto moiety at the 11 position of these steroids by 11BHSD results in the formation of the active 11-hydroxy compounds prednisolone and cortisol, respectively. Since all of the other systemic corticosteroids have a parent structure already possessing the 11-hydroxy group, bioactivation is unecessary and these compounds are active at glucocorticoid receptors without enzymatic conversion. <br><br>Whereas the inhibition of 11BHSD by growth hormone has been well established, only a limited number of studies have demonstrated specific GH-mediated inhibition of the pharmacological effects of exogenously administered cortisone<sup>5,6</sup> and prednisone.<sup>7</sup> One comparative study evaluated serum cortisol levels as a function of exogenously administered hydrocortisone or cortisone in 10 hypopituitary patients receiving GH supplementation.<sup>8</sup> While further confirming GH-mediated inhibition of 11BHSD (via hydroxyl/oxo cortisol metabolite ratios), this study also demonstrated significant reductions (after initiation of GH therapy) in mean serum cortisol in cortisone-treated patients (-18.7%) and hydrocortisone-treated patients (-10.9%). While it is unclear from this observation why circulating corticosteroid levels were lower after administering an exogenously bioactive steroid (hydrocortisone), it does provide further support for the potential benefit of employing corticosteroid therapy which does not require enzymatic activation in the setting of GH treatment.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Paulsen SK, Pedersen SB, Jorgensen JO, et al, “Growth Hormone (GH) Substitution in GH-Deficient Patients Inhibits 11Beta-Hydroxysteroid Dehydrogenase Type 1 Messenger Ribonucleic Acid Expression in Adipose Tissue,” <i>J Clin Endocrinol Metab</i>, 2006, 91(3):1093-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16368752\">[PubMed 16368752]</a></p>\n<p>2. Tomlinson JW, Crabtree N, Clark PM, et al, “Low-Dose Growth Hormone Inhibits 11 Beta-Hydroxysteroid Dehydrogenase Type 1 But Has No Effect Upon Fat Mass in Patients with Simple Obesity,” <i>J Clin Endocrinol Metab</i>, 2003, 88(5):2113-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12727963\">[PubMed 12727963]</a></p>\n<p>3. Walker EA, Stewart PM, “11Beta-Hydroxysteroid Dehydrogenase: Unexpected Connections,” <i>Trends Endocrinol Metab</i>, 2003, 14(7):334-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12946876\">[PubMed 12946876]</a></p>\n<p>4. Stewart PM, Toogood AA, Tomlinson JW, “Growth Hormone, Insulin-Like Growth Factor-I and the Cortisol-Cortisone Shuttle,” <i>Horm Res</i>, 2001, 56 Suppl 1:1-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11786677\">[PubMed 11786677]</a> </p>\n<p>5. Blomgren J, Ekman B, Andersson PO, et al, “Non-Physiological Levels of Circulating Cortisol in Growth Hormone-Treated Hypopituitary Adults After Conventional Cortisone Substitution,” <i>Scand J Clin Lab Invest</i>, 2004, 64(2):132-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15115251\">[PubMed 15115251]</a></p>\n<p>6. Beentjes JA, Kerstens MN, Dullaart RP, “Effects of Growth Hormone Replacement on Cortisol Metabolism in Hypopituitary Patients Treated with Cortisone Acetate,” <i>Scand J Clin Lab Invest</i>, 2001, 61(4):277-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11465341\">[PubMed 11465341]</a></p>\n<p>7. Horber FF, Haymond MW, “Human Growth Hormone Prevents the Protein Catabolic Side Effects of Prednisone in Humans,” <i>J Clin Invest</i>, 1990, 86(1):265-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2195062\">[PubMed 2195062]</a></p>\n<p>8. Swords FM, Carroll PV, Kisalu J et al, “The Effects of Growth Hormone Deficiency and Replacement on Glucocorticoid Exposure in Hypopituitary Patients on Cortisone Acetate and Hydrocortisone Replacement,” <i>Clin Endocrinol</i>, 2003, 59:613-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14616886\">[PubMed 14616886]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4074":"<p><b>Title</b> PredniSONE / Somatropin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Somatropin may diminish the therapeutic effect of PredniSONE. Growth hormone may reduce the conversion of prednisone to the active prednisolone metabolite. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced efficacy of prednisone treatment. Patients receiving glucocorticoid therapy for hypoadrenalism may require increased maintenance or stress doses of the steroid.</p> \n<p><b>Discussion</b> At clinically relevant doses, human growth hormone (GH) has been shown to inhibit the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11BHSD1).<sup>1,2,3,4</sup> This enzyme is required for the bioactivation of prednisone and cortisone. Reduction of the keto moiety at the 11 position of these steroids by 11BHSD results in the formation of the active 11-hydroxy compounds prednisolone and cortisol, respectively. Since all of the other systemic corticosteroids have a parent structure already possessing the 11-hydroxy group, bioactivation is unecessary and these compounds are active at glucocorticoid receptors without enzymatic conversion. <br><br>Whereas the inhibition of 11BHSD by growth hormone has been well established, only a limited number of studies have demonstrated specific GH-mediated inhibition of the pharmacological effects of exogenously administered cortisone<sup>5,6</sup> and prednisone.<sup>7</sup> Nevertheless, it is prudent to carefully monitor the patient for reduced corticosteroid efficacy in this setting.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Paulsen SK, Pedersen SB, Jorgensen JO, et al, “Growth Hormone (GH) Substitution in GH-Deficient Patients Inhibits 11Beta-Hydroxysteroid Dehydrogenase Type 1 Messenger Ribonucleic Acid Expression in Adipose Tissue,” <i>J Clin Endocrinol Metab</i>, 2006, 91(3):1093-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16368752\">[PubMed 16368752]</a></p>\n<p>2. Tomlinson JW, Crabtree N, Clark PM, et al, “Low-Dose Growth Hormone Inhibits 11 Beta-Hydroxysteroid Dehydrogenase Type 1 But Has No Effect Upon Fat Mass in Patients with Simple Obesity,” <i>J Clin Endocrinol Metab</i>, 2003, 88(5):2113-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12727963\">[PubMed 12727963]</a></p>\n<p>3. Walker EA, Stewart PM, “11Beta-Hydroxysteroid Dehydrogenase: Unexpected Connections,” <i>Trends Endocrinol Metab</i>, 2003, 14(7):334-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12946876\">[PubMed 12946876]</a></p>\n<p>4. Stewart PM, Toogood AA, Tomlinson JW, “Growth Hormone, Insulin-Like Growth Factor-I and the Cortisol-Cortisone Shuttle,” <i>Horm Res</i>, 2001, 56 Suppl 1:1-6. </p>\n<p>5. Blomgren J, Ekman B, Andersson PO, et al, “Non-Physiological Levels of Circulating Cortisol in Growth Hormone-Treated Hypopituitary Adults After Conventional Cortisone Substitution,” <i>Scand J Clin Lab Invest</i>, 2004, 64(2):132-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15115251\">[PubMed 15115251]</a></p>\n<p>6. Beentjes JA, Kerstens MN, Dullaart RP, “Effects of Growth Hormone Replacement on Cortisol Metabolism in Hypopituitary Patients Treated with Cortisone Acetate,” <i>Scand J Clin Lab Invest</i>, 2001, 61(4):277-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11465341\">[PubMed 11465341]</a></p>\n<p>7. Horber FF, Haymond MW, “Human Growth Hormone Prevents the Protein Catabolic Side Effects of Prednisone in Humans,” <i>J Clin Invest</i>, 1990, 86(1):265-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2195062\">[PubMed 2195062]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4078":"<p><b>Title</b> Codeine / CYP2D6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Consider using an alternative analgesic (one that does not require activation via CYP2D6) in patients receiving strong CYP2D6 inhibitors. Monitor for decreased therapeutic response (e.g., analgesia) to codeine when coadministered with strong CYP2D6 inhibitors.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> Several studies of healthy volunteers have reported that quinidine, a strong inhibitor of the CYP2D6 enzyme, substantially diminishes codeine's analgesic effects.<sup>1,2,3,4</sup> In another study, fluoxetine (another potent CYP2D6 inhibitor) significantly decreased codeine consumption in a group of 14 patients addicted to codeine.<sup>5</sup> Of note, CYP2D6 inhibitors that do not readily cross the blood-brain barrier may not completely inhibit codeine-to-morphine conversion (and thus codeine-related analgesia) as functional CYP2D6 is present in the brain<sup>6</sup> and may metabolize codeine to morphine locally, leading to preservation of at least some analgesic effects.<sup>1</sup><br><br>Related studies comparing patients or healthy volunteers with a genetic mutation resulting in an absence of functional CYP2D6 (i.e., poor metabolizers, PMs) to those with genetically “normal” CYP2D6 (i.e., extensive metabolizers, EMs) have found similar results, with PMs consistently reporting substantially less analgesic response to codeine as compared to EMs.<sup>7,8,9,10,11,12,13,14</sup><br><br>Codeine itself is nearly 200-fold less potent than morphine,<sup>15</sup> but approximately 15% of a codeine dose is converted to morphine via CYP2D6-mediated O-demethylation.<sup>16,17</sup> Consequently, inhibition of CYP2D6 activity (or presence of genetically dysfunctional CYP2D6) prohibits the conversion of codeine to morphine (decreased by 80-90% with quinidine<sup>1,2</sup>), abolishing much or all of the associated analgesia.<br><br>CYP inhibitors have been labeled “strong” because a) the serum concentration of the inhibitor drug required to effectively inhibit the cytochrome enzyme (ie, inhibition constant (Ki) as established via <i>in vitro</i> studies) is likely to be achieved during the course of standard dosing of the drug; or b) <i>in vivo</i> pharmacokinetic studies have demonstrated a fivefold increase in the serum concentration of a probe substrate (one known to be primarily metabolized by the enzyme of interest) in the presence of the inhibitor drug administered in standard doses.<sup>18</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sindrup SH, Arendt-Nielsen L, Brosen K, et al, “The Effect of Quinidine on the Analgesic Effect of Codeine,” <i>Eur J Clin Pharmacol</i>, 1992, 42(6):587-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1623898\">[PubMed 1623898]</a></p>\n<p>2. Caraco Y, Sheller J, Wood AJ, “Impact of Ethnic Origin and Quinidine Coadministration on Codeine’s Disposition and Pharmacodynamic Effects,” <i>J Pharmacol Exp Ther</i>, 1999, 290(1):413-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10381807\">[PubMed 10381807]</a></p>\n<p>3. Desmeules J, Gascon MP, Dayer P, et al, “Impact of Environmental and Genetic Factors on Codeine Analgesia,” <i>Eur J Clin Pharmacol</i>, 1991, 41:23-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1782973\">[PubMed 1782973]</a></p>\n<p>4. Kathiramalainathan K, Kaplan HL, Romach MK, et al, “Inhibition of Cytochrome P450 2D6 Modifies Codeine Abuse Liability,” <i>J Clin Psychopharmacol</i>, 2000, 20(4):435-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10917405\">[PubMed 10917405]</a></p>\n<p>5. Romach MK, Otton SV, Somer G, et al, “Cytochrome P450 2D6 and Treatment of Codeine Dependence,” <i>J Clin Psychopharmacol</i>, 2000, 20(1):43-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10653207\">[PubMed 10653207]</a></p>\n<p>6. Funae Y, Kishimoto W, Cho T, et al, “CYP2D in the Brain,” <i>Drug Metab Pharmacokinet</i>, 2003, 18(6):337-49. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15618754\">[PubMed 15618754]</a></p>\n<p>7. Sindrup SH, Brosen K, Bjerring P, et al, “Codeine Increases Pain Thresholds to Copper Vapor Laser Stimuli in Extensive but not Poor Metabolizers of Sparteine,” <i>Clin Pharmacol Ther</i>, 1990, 48(6):686-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2249379\">[PubMed 2249379]</a></p>\n<p>8. Caraco Y, Sheller J, Wood AJ, “Pharmacogenetic Determination of the Effects of Codeine and Prediction of Drug Interactions,” <i>J Pharmacol Exp Ther</i>, 1996, 278(3):1165-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8819499\">[PubMed 8819499]</a></p>\n<p>9. Hasselstrom J, Yue QY, Sawe J, “The Effect of Codeine on Gastrointestinal Transit in Extensive and Poor Metabolisers of Debrisoquine,” <i>Eur J Clin Pharmacol</i>, 1997, 53(2):145-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9403287\">[PubMed 9403287]</a></p>\n<p>10. Poulsen L, Brosen K, Arendt-Nielsen L, et al, “Codeine and Morphine in Extensive and Poor Metabolizers of Sparteine: Pharmacokinetics, Analgesic Effect and Side Effects,” <i>Eur J Clin Pharmacol</i>, 1996, 51(3-4):289-95. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9010701\">[PubMed 9010701]</a></p>\n<p>11. Mikus G, Trausch B, Rodewald C, et al, “Effect of Codeine on Gastrointestinal Motility in Relation to CYP2D6 Phenotype,” <i>Clin Pharmacol Ther</i>, 1997, 61(4):459-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9129563\">[PubMed 9129563]</a></p>\n<p>12. Poulsen L, Riishede L, Brosen K, et al, “Codeine in Postoperative Pain: Study of the Influence of Sparteine Phenotype and Serum Concentrations of Morphine and Morphine-6-Glucuronide,” <i>Eur J Clin Pharmacol</i>, 1998, 54(6):451-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9776433\">[PubMed 9776433]</a></p>\n<p>13. Persson K, Sjostrom S, Sigurdardottir I, et al, “Patient-Controlled Analgesia (PCA) with Codeine for Postoperative Pain Relief in Ten Extensive Metabolisers and One Poor Metaboliser of Dextromethorphan,” <i>Br J Clin Pharmacol</i>, 1995, 39(2):182-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7742159\">[PubMed 7742159]</a></p>\n<p>14. Eckhardt K, Li S, Ammon S, et al, “Same Incidence of Adverse Drug Events after Codeine Administration Irrespective of the Genetically Determined Differences in Morphine Formation,” <i>Pain</i>, 1998, 76(1-2):27-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9696456\">[PubMed 9696456]</a></p>\n<p>15. Mignat C, Wille U, Ziegler A, “Affinity Profiles of Morphine, Codeine, Dihydrocodeine and Their Glucuronides at Opioid Receptor Subtypes,” <i>Life Sci</i>, 1995, 56(10):793-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7885194\">[PubMed 7885194]</a></p>\n<p>16. Yue QY, Svensson JO, Alm C, et al, “Codeine O-Demethylation Co-Segregates with Polymorphic Debrisoquine Hydroxylation,” <i>Br J Clin Pharmacol</i>, 1989, 28(6):639-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2611086\">[PubMed 2611086]</a></p>\n<p>17. Yue QY, Hasselstrom J, Svensson JO, et al, “Pharmacokinetics of Codeine and its Metabolites in Caucasian Healthy Volunteers: Comparisons between Extensive and Poor Hydroxylators of Debrisoquine,” <i>Br J Clin Pharmacol</i>, 1991, 31(6):635-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1867957\">[PubMed 1867957]</a></p>\n<p>18. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4079":"<p><b>Title</b> Codeine / CYP2D6 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic response (e.g., analgesia) to codeine when coadministered with moderate CYP2D6 inhibitors. Consider an analgesic that does not require metabolic activation via CYP2D6 if changing from codeine in patients who do not experience an adequate response with codeine.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Moderate) Interacting Members</b> Abiraterone Acetate, Asunaprevir, BuPROPion, Cinacalcet, Darifenacin, Darunavir, DULoxetine, Lorcaserin, Mirabegron, Perhexiline, Rolapitant, Terbinafine (Systemic), Thioridazine</p>\n</div> \n<p><b>Discussion</b> Several studies of healthy volunteers have reported that quinidine, a strong inhibitor of the CYP2D6 enzyme, substantially diminishes codeine's analgesic effects.<sup>1,2,3,4</sup> In another study, fluoxetine (another potent CYP2D6 inhibitor) significantly decreased codeine consumption in a group of 14 patients addicted to codeine.<sup>5</sup> Of note, CYP2D6 inhibitors that do not readily cross the blood-brain barrier may not completely inhibit codeine-to-morphine conversion (and thus codeine-related analgesia) as functional CYP2D6 is present in the brain<sup>6</sup> and may metabolize codeine to morphine locally, leading to preservation of at least some analgesic effects.<sup>1</sup><br><br>Related studies comparing patients or healthy volunteers with a genetic mutation resulting in an absence of functional CYP2D6 (i.e., poor metabolizers, PMs) to those with genetically “normal” CYP2D6 (i.e., extensive metabolizers, EMs) have found similar results, with PMs consistently reporting substantially less analgesic response to codeine as compared to EMs.<sup>7,8,9,10,11,12,13,14</sup><br><br>Codeine itself is nearly 200-fold less potent than morphine,<sup>15</sup> but approximately 15% of a codeine dose is converted to morphine via CYP2D6-mediated O-demethylation.<sup>16,17</sup> Consequently, inhibition of CYP2D6 activity (or presence of genetically dysfunctional CYP2D6) prohibits the conversion of codeine to morphine (decreased by 80-90% with quinidine<sup>1,2</sup>), abolishing much or all of the associated analgesia.<br><br>CYP inhibitors have been labeled “moderate” because a) the serum concentration of the inhibitor drug required to effectively inhibit the cytochrome enzyme (ie, inhibition constant (Ki) as established via <i>in vitro</i> studies) may be achieved in some patients during the course of therapy (especially in higher doses); or b) <i>in vivo</i> pharmacokinetic studies have demonstrated a two- to fivefold increase in the serum concentration of a probe substrate (one known to be primarily metabolized by the enzyme of interest) in the presence of the inhibitor drug administered in standard doses.<sup>18</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sindrup SH, Arendt-Nielsen L, Brosen K, et al, “The Effect of Quinidine on the Analgesic Effect of Codeine,” <i>Eur J Clin Pharmacol</i>, 1992, 42(6):587-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1623898\">[PubMed 1623898]</a></p>\n<p>2. Caraco Y, Sheller J, Wood AJ, “Impact of Ethnic Origin and Quinidine Coadministration on Codeine’s Disposition and Pharmacodynamic Effects,” <i>J Pharmacol Exp Ther</i>, 1999, 290(1):413-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10381807\">[PubMed 10381807]</a></p>\n<p>3. Desmeules J, Gascon MP, Dayer P, et al, “Impact of Environmental and Genetic Factors on Codeine Analgesia,” <i>Eur J Clin Pharmacol</i>, 1991, 41:23-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1782973\">[PubMed 1782973]</a></p>\n<p>4. Kathiramalainathan K, Kaplan HL, Romach MK, et al, “Inhibition of Cytochrome P450 2D6 Modifies Codeine Abuse Liability,” <i>J Clin Psychopharmacol</i>, 2000, 20(4):435-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10917405\">[PubMed 10917405]</a></p>\n<p>5. Romach MK, Otton SV, Somer G, et al, “Cytochrome P450 2D6 and Treatment of Codeine Dependence,” <i>J Clin Psychopharmacol</i>, 2000, 20(1):43-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10653207\">[PubMed 10653207]</a></p>\n<p>6. Funae Y, Kishimoto W, Cho T, et al, “CYP2D in the Brain,” <i>Drug Metab Pharmacokinet</i>, 2003, 18(6):337-49. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15618754\">[PubMed 15618754]</a></p>\n<p>7. Sindrup SH, Brosen K, Bjerring P, et al, “Codeine Increases Pain Thresholds to Copper Vapor Laser Stimuli in Extensive but not Poor Metabolizers of Sparteine,” <i>Clin Pharmacol Ther</i>, 1990, 48(6):686-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2249379\">[PubMed 2249379]</a></p>\n<p>8. Caraco Y, Sheller J, Wood AJ, “Pharmacogenetic Determination of the Effects of Codeine and Prediction of Drug Interactions,” <i>J Pharmacol Exp Ther</i>, 1996, 278(3):1165-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8819499\">[PubMed 8819499]</a></p>\n<p>9. Hasselstrom J, Yue QY, Sawe J, “The Effect of Codeine on Gastrointestinal Transit in Extensive and Poor Metabolisers of Debrisoquine,” <i>Eur J Clin Pharmacol</i>, 1997, 53(2):145-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9403287\">[PubMed 9403287]</a></p>\n<p>10. Poulsen L, Brosen K, Arendt-Nielsen L, et al, “Codeine and Morphine in Extensive and Poor Metabolizers of Sparteine: Pharmacokinetics, Analgesic Effect and Side Effects,” <i>Eur J Clin Pharmacol</i>, 1996, 51(3-4):289-95. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9010701\">[PubMed 9010701]</a></p>\n<p>11. Mikus G, Trausch B, Rodewald C, et al, “Effect of Codeine on Gastrointestinal Motility in Relation to CYP2D6 Phenotype,” <i>Clin Pharmacol Ther</i>, 1997, 61(4):459-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9129563\">[PubMed 9129563]</a></p>\n<p>12. Poulsen L, Riishede L, Brosen K, et al, “Codeine in Postoperative Pain: Study of the Influence of Sparteine Phenotype and Serum Concentrations of Morphine and Morphine-6-Glucuronide,” <i>Eur J Clin Pharmacol</i>, 1998, 54(6):451-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9776433\">[PubMed 9776433]</a></p>\n<p>13. Persson K, Sjostrom S, Sigurdardottir I, et al, “Patient-Controlled Analgesia (PCA) with Codeine for Postoperative Pain Relief in Ten Extensive Metabolisers and One Poor Metaboliser of Dextromethorphan,” <i>Br J Clin Pharmacol</i>, 1995, 39(2):182-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7742159\">[PubMed 7742159]</a></p>\n<p>14. Eckhardt K, Li S, Ammon S, et al, “Same Incidence of Adverse Drug Events after Codeine Administration Irrespective of the Genetically Determined Differences in Morphine Formation,” <i>Pain</i>, 1998, 76(1-2):27-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9696456\">[PubMed 9696456]</a></p>\n<p>15. Mignat C, Wille U, Ziegler A, “Affinity Profiles of Morphine, Codeine, Dihydrocodeine and Their Glucuronides at Opioid Receptor Subtypes,” <i>Life Sci</i>, 1995, 56(10):793-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7885194\">[PubMed 7885194]</a></p>\n<p>16. Yue QY, Svensson JO, Alm C, et al, “Codeine O-Demethylation Co-Segregates with Polymorphic Debrisoquine Hydroxylation,” <i>Br J Clin Pharmacol</i>, 1989, 28(6):639-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2611086\">[PubMed 2611086]</a></p>\n<p>17. Yue QY, Hasselstrom J, Svensson JO, et al, “Pharmacokinetics of Codeine and its Metabolites in Caucasian Healthy Volunteers: Comparisons between Extensive and Poor Hydroxylators of Debrisoquine,” <i>Br J Clin Pharmacol</i>, 1991, 31(6):635-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1867957\">[PubMed 1867957]</a></p>\n<p>18. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4080":"<p><b>Title</b> TraMADol / CYP2D6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of TraMADol. CYP2D6 Inhibitors (Strong) may increase the serum concentration of TraMADol. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic response (e.g., analgesia) to tramadol when coadministered with strong CYP2D6 inhibitors.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> The AUC of tramadol was significantly increased and the AUC of the active, mu receptor opioid agonist tramadol M1 metabolite was significantly decreased (67% decrease for the (+)-M1 enantiomer and 40% decrease for the (-)-M1 enantiomer) with concurrent use of the strong CYP2D6 inhibitor paroxetine (20mg for 3 days prior to tramadol) in a clinical study of 16 healthy volunteers.<sup>1</sup> According to various experimental pain models, the analgesic potency of tramadol was also partially inhibited with concurrent paroxetine. Similarly, the tramadol AUC was an average of 115% higher and the M1 AUC was an average of 64% lower with concurrent administration of the moderate CYP2D6 inhibitor terbinafine (250 mg/day) according to a study of 12 healthy volunteers.<sup>2</sup> Terbinafine administration was also associated with a decreased subjective response to tramadol. The risk for fall-related injuries in patients receiving tramadol was higher without concurrent use of CYP2D6 inhibitors (OR=3.04) than it was with a CYP2D6 inhibitor (OR=2.19) (as compared to no opioid use in both comparisons) in a broader case-crossover study examining opioid use and falls (n=167,257 patients with fall-related injuries).<sup>3</sup> These results are consistent with data suggesting CYP2D6 inhibition results in less opioid-like effect from tramadol via reduced formation of its active M1 metabolite. It is important to note that most of the drugs characterized as CYP2D6 inhibitors in this study are only weak CYP2D6 inhibitors or not inhibitors of CYP2D6 based on a review of available clinical data.<br><br>These clinical findings are consistent with the results of studies using human liver microsomes, which have shown that the strong CYP2D6 inhibitor quinidine significantly interferes with the formation of the active O-desmethyl-tramadol (M1) metabolite.<sup>4,5</sup> Related studies comparing patients or healthy volunteers with a genetic mutation resulting in an absence of or significant reduction in functional CYP2D6 (ie, poor metabolizers, PMs) to those with genetically “normal” CYP2D6 (ie, extensive metabolizers, EMs) have generally found similar results, with PMs displaying significantly altered tramadol/M1 concentrations,<sup>6,7,8</sup> greater tramadol consumption,<sup>8</sup> and at least a partial interference with clinical response as compared to EMs.<sup>6,7,8,9</sup><br><br>Tramadol causes analgesia via a dual mechanism involving both opioid receptor agonism and inhibition of serotonin and norepinephrine reuptake.<sup>10</sup> The active (+)-M1 metabolite of tramadol is the primary opioid agonist following tramadol administration, and this metabolite is formed via O-demethylation by CYP2D6.<sup>10</sup> Thus, inhibition of CYP2D6 activity (or presence of genetically dysfunctional CYP2D6) leads to a lower concentration of the active metabolite and less opioid-receptor-mediated analgesia. Residual (non-opioid) analgesic effects may, however, remain or be enhanced because of the resulting higher concentrations of unmetabolized tramadol.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH, Brosen K. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. <i>Clin Pharmacol Ther</i>. 2005;77(4):312-323. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15903129\">[PubMed 15903129]</a></p>\n<p>2. Saarikoski T, Saari TI, Hagelberg NM, et al. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. <i>Eur J Clin Pharmacol</i>. 2015;71(3):321-327. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25560051\">[PubMed 25560051]</a></p>\n<p>3. Moller J, Laflamme L, Soderberg Lofdal K. CYP2D6-inhibiting drugs and the increased risk of fall-related injuries due to newly initiated opioid treatment--a Swedish, register-based case-crossover study. <i>Basic Clin Pharmacol Toxicol</i>. 2015;116(2):134-139. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24975450\">[PubMed 24975450]</a></p>\n<p>4. Paar WD, Frankus P, Dengler HJ. The metabolism of tramadol by human liver microsomes. <i>Clin Investig</i>. 1992;70(8):708-710. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1392452\">[PubMed 1392452]</a></p>\n<p>5. Subrahmanyam V, Renwick AB, Walters DG, et al. Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. <i>Drug Metab Dispos</i>. 2001;29(8):1146-1155. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11454734\">[PubMed 11454734]</a></p>\n<p>6. Slanar O, Nobilis M, Kvetina J, et al. Miotic action of tramadol is determined by CYP2D6 genotype. <i>Physiol Res</i>. 2007;56(1):129-136. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16497087\">[PubMed 16497087]</a></p>\n<p>7. Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. <i>Clin Pharmacol Ther</i>. 2007;82(1):41-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17361124\">[PubMed 17361124]</a></p>\n<p>8. Enggaard TP, Poulsen L, Arendt-Nielsen L, Brosen K, Ossig J, Sindrup SH. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. <i>Anesth Analg</i>. 2006;102(1):146-150. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16368820\">[PubMed 16368820]</a></p>\n<p>9. Wang G, Zhang H, He F, Fang X. Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. <i>Eur J Clin Pharmacol</i>. 2006;62(11):927-931. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16960721\">[PubMed 16960721]</a></p>\n<p>10. Grond S, Sablotzki A. Clinical pharmacology of tramadol. <i>Clin Pharmacokinet</i>. 2004;43(13):879-923. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15509185\">[PubMed 15509185]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4081":"<p><b>Title</b> TraMADol / CYP2D6 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic response (eg, analgesia) to tramadol when coadministered with moderate CYP2D6 inhibitors.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Moderate) Interacting Members</b> Abiraterone Acetate, Asunaprevir, BuPROPion, Cinacalcet, Darifenacin, Darunavir, DULoxetine, Lorcaserin, Mirabegron, Perhexiline, Rolapitant, Terbinafine (Systemic), Thioridazine</p>\n</div> \n<p><b>Discussion</b> Studies using human liver microsomes have shown that the strong CYP2D6 inhibitor quinidine significantly interferes with the formation of the active O-desmethyl-tramadol (M1) metabolite.<sup>1,2</sup> The tramadol AUC was an average of 2.15-fold higher and the M1 AUC was an average of 64% lower with concurrent administration of the moderate CYP2D6 inhibitor terbinafine (250 mg/day) according to a study of 12 healthy volunteers.<sup>3</sup> Since 4 of the 12 subjects in this study were genetic ultra-rapid metabolizers, the higher baseline activity of the group may mean the magnitude of this interaction as observed here is different from what would be expected in those with lower baseline levels of CYP2D6 activity. Terbinafine administration was also associated with a decreased subjective response to tramadol. A clinical study in 16 healthy volunteers found that paroxetine (20mg for 3 days prior to tramadol), a strong CYP2D6 inhibitor, significantly increased tramadol AUC and decreased the AUC of the M1 metabolite (-67% for the (+)-M1 enantiomer and -40% for the (-)-M1 enantiomer). Using various experimental pain models, the analgesic potency of tramadol (with or without paroxetine pretreatment) was also tested, and paroxetine-mediated inhibition only partially inhibited the analgesic response to tramadol.<sup>4</sup> The risk for fall-related injuries in patients receiving tramadol was higher without concurrent use of CYP2D6 inhibitors (OR=3.04) than it was with a CYP2D6 inhibitor (OR=2.19) (as compared to no opioid use in both comparisons) in a broader case-crossover study examining opioid use and falls (n=167,257 patients with fall-related injuries).<sup>5</sup> These results are consistent with data suggesting CYP2D6 inhibition results in less opioid-like effect from tramadol via reduced formation of its active M1 metabolite. It is important to note that most of the drugs characterized as CYP2D6 inhibitors in this study are only weak CYP2D6 inhibitors or not inhibitors of CYP2D6 based on a review of available clinical data.<br><br>Related studies comparing patients or healthy volunteers with a genetic mutation resulting in an absence of or significant reduction in functional CYP2D6 (ie, poor metabolizers, PMs) to those with genetically “normal” CYP2D6 (ie, extensive metabolizers, EMs) have generally found similar results, with PMs displaying significantly altered tramadol/M1 concentrations,<sup>6,7,8</sup> greater tramadol consumption,<sup>9</sup> and at least a partial interference with clinical response as compared to EMs.<sup>6,7,8,9</sup><br><br>Tramadol causes analgesia via a dual mechanism involving both opioid receptor agonism and inhibition of serotonin and norepinephrine reuptake.<sup>10</sup> The active (+)-M1 metabolite of tramadol is the primary opioid agonist following tramadol administration, and this metabolite is formed via O-demethylation by CYP2D6.<sup>10</sup> Thus, inhibition of CYP2D6 activity (or presence of genetically dysfunctional CYP2D6) leads to a lower concentration of the active metabolite and less opioid-receptor-mediated analgesia. Residual (non-opioid) analgesic effects may, however, remain or be enhanced because of the resulting higher concentrations of unmetabolized tramadol.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Paar WD, Frankus P, Dengler HJ. The metabolism of tramadol by human liver microsomes. <i>Clin Investig</i>. 1992;70(8):708-710. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1392452\">[PubMed 1392452]</a></p>\n<p>2. Subrahmanyam V, Renwick AB, Walters DG, et al. Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. <i>Drug Metab Dispos</i>. 2001;29(8):1146-1155. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11454734\">[PubMed 11454734]</a></p>\n<p>3. Saarikoski T, Saari TI, Hagelberg NM, et al. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. <i>Eur J Clin Pharmacol</i>. 2015;71(3):321-327. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25560051\">[PubMed 25560051]</a></p>\n<p>4. Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH, Brosen K. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. <i>Clin Pharmacol Ther</i>. 2005;77(4):312-323. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15903129\">[PubMed 15903129]</a></p>\n<p>5. Moller J, Laflamme L, Soderberg Lofdal K. CYP2D6-inhibiting drugs and the increased risk of fall-related injuries due to newly initiated opioid treatment--a Swedish, register-based case-crossover study. <i>Basic Clin Pharmacol Toxicol</i>. 2015;116(2):134-139. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24975450\">[PubMed 24975450]</a></p>\n<p>6. Slanar O, Nobilis M, Kvetina J, et al. Miotic action of tramadol is determined by CYP2D6 genotype. <i>Physiol Res</i>. 2007;56(1):129-136. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16497087\">[PubMed 16497087]</a></p>\n<p>7. Stamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. <i>Clin Pharmacol Ther</i>. 2007;82(1):41-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17361124\">[PubMed 17361124]</a></p>\n<p>8. Enggaard TP, Poulsen L, Arendt-Nielsen L, Brosen K, Ossig J, Sindrup SH. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. <i>Anesth Analg</i>. 2006;102(1):146-150. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16368820\">[PubMed 16368820]</a></p>\n<p>9. Wang G, Zhang H, He F, Fang X. Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. <i>Eur J Clin Pharmacol</i>. 2006;62(11):927-931. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16960721\">[PubMed 16960721]</a></p>\n<p>10. Grond S, Sablotzki A. Clinical pharmacology of tramadol. <i>Clin Pharmacokinet</i>. 2004;43(13):879-923. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15509185\">[PubMed 15509185]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4084":"<p><b>Title</b> Neuromuscular-Blocking Agents / Colistimethate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B).</p>\n<div>\n <p><b>Neuromuscular-Blocking Agents Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Succinylcholine, Vecuronium</p>\n</div> \n<p><b>Discussion</b> Several case reports describe the occurrence of neuromuscular blockade (respiratory muscle paralysis) during the use of polymyxin antibiotics [e.g., colistimethate (polymyxin E), polymyxin B] with or without concomitant use of neuromuscular-blocking agents.<sup>1,2,3,4,5</sup> Calcium gluconate was effectively employed in reversing the blockade in one patient.<sup>2</sup> The polymyxins appear to possess independent neuromuscular-blocking characteristics. Concomitant therapy with a neuromuscular-blocking agent may result in deeper, prolonged effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pittinger CB, Eryasa Y, and Adamson R, “Antibiotic-Induced Paralysis,” <i>Anesth Analg</i>, 1970, 49:487. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4102601\">[PubMed 4102601]</a></p>\n<p>2. Giala MM and Paradelis AG, “Two Cases of Prolonged Respiratory Depression Due to Interaction of Pancuronium With Colistin and Streptomycin,” <i>J Antimicrob Chemother</i>, 1979, 5:234. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=429254\">[PubMed 429254]</a></p>\n<p>3. Fogdall RP and Miller RD, “Prolongation of Pancuronium-Induced Neuromuscular Blockade by Polymyxin B,” <i>Anesthesiology</i>, 1974, 41:407. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4415332\">[PubMed 4415332]</a></p>\n<p>4. Small GA, “Respiratory Paralysis After a Large Dose of Intraperitoneal Polymyxin B and Bacitracin,” <i>Anesth Analg</i>, 1964, 43:137-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14164930\">[PubMed 14164930]</a></p>\n<p>5. Pohlmann G, “Respiratory Arrest Associated With Intravenous Administration of Polymyxin B Sulfate,” <i>JAMA</i>, 1966, 196:181. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4286165\">[PubMed 4286165]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4085":"<p><b>Title</b> Colistimethate / Aminoglycosides</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n</div> \n<p><b>Discussion</b> Nephrotoxicity represents a significant concern with colistimethate therapy. Early studies of nephrotoxicity generally reported higher rates of toxicity, but many such studies suffered from methodologic limitations such as a lack of standard definitions/criteria and/or different dosing than used more recently.<sup>1</sup> Though risk factors colistimethate-induced nephrotoxicity are unclear, it has been suggested that concurrent administration of other nephrotoxic drugs, such as aminoglycoside antibiotics, increases this risk.<sup>2,3,4</sup> Of note, one recent report describes experience with long-term colistimethate therapy where other potentially nephrotoxic drugs were used in 12 of 19 courses of therapy with little evidence of nephrotoxicity described both overall and with concurrent therapy.<sup>5</sup><br><br>The mechanism for this predicted interaction is additive nephrotoxic effects. The mechanism by which colistimethate causes renal toxicity appears to be via alteration in membrane permeability that leads to cellular swelling and eventual lysis.<sup>1</sup><br><br>Additive or synergistic neuromuscular blockade is also a possible complication of combined colistimethate and aminoglycoside therapy, as both colistimethate and aminoglycosides possess an ability to interfere with nerve transmission and normal neuromuscular function. Consequently, colistimethate prescribing information cautions against using colistimethate with aminoglycosides without extreme caution due to the risk of enhanced neuromuscular blocking effects.<sup>6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Falagas ME,Kasiakou SK, “Toxicity of Polymyxins: A Systematic Review of the Evidence from Old and Recent Studies,” <i>Crit Care</i>, 2006, 10:R27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16507149\">[PubMed 16507149]</a></p>\n<p>2. Elwood CM, Lucas GD,Muehrcke RC, “Acute Renal Failure Associated with Sodium Colistimethate Treatment,” <i>Arch Intern Med</i>, 1966, 118:326-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5925230\">[PubMed 5925230]</a></p>\n<p>3. Koch-Weser J, Sidel VW, Federman EB, et al., “Adverse Effects of Sodium Colistimethate. Manifestations and Specific Reaction Rates During 317 Courses of Therapy,” <i>Ann Intern Med</i>, 1970, 72:857-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5448745\">[PubMed 5448745]</a></p>\n<p>4. Koomanachai P, Tiengrim S, Kiratisin P, et al., “Efficacy and Safety of Colistin (Colistimethate Sodium) for Therapy of Infections Caused by Multidrug-Resistant Pseudomonas Aeruginosa and Acinetobacter Baumannii in Siriraj Hospital, Bangkok, Thailand,” <i>Int J Infect Dis</i>, 2007. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17291803\">[PubMed 17291803]</a> </p>\n<p>5. Falagas ME, Rizos M, Bliziotis IA, et al., “Toxicity after Prolonged (More Than Four Weeks) Administration of Intravenous Colistin,” <i>BMC Infect Dis</i>, 2005, 5:1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15642116\">[PubMed 15642116]</a> </p>\n<p>6. Prescribing information. Coly-Mycin M (colistimethate). Bristol, TN: Monarch Pharmaceuticals, Inc., February 2005.</p>\n<p>7. Prescribing information. Colistimethate. Minneapolis, MN: Paddock Laboratories, Inc., April 2004.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4086":"<p><b>Title</b> Colistimethate / Vancomycin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Vancomycin may enhance the nephrotoxic effect of Colistimethate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the potential for additive or synergistic nephrotoxicity between colistimethate and other nephrotoxic drugs, such as vancomycin, this combination should be avoided whenever possible. If these agents must be used together, patients' renal function should be monitored closely.</p> \n<p><b>Discussion</b> Nephrotoxicity represents a significant concern with colistimethate therapy. Early studies of nephrotoxicity generally reported higher rates of toxicity, but many such studies suffered from methodologic limitations such as a lack of standard definitions/criteria and/or different dosing than used more recently.<sup>1</sup> Though risk factors colistimethate-induced nephrotoxicity are unclear, it has been suggested that concurrent administration of other nephrotoxic drugs, such as vancomycin, increases this risk.<sup>2,3,4</sup> Of note, one recent report describes experience with long-term colistimethate therapy where other potentially nephrotoxic drugs were used in 12 of 19 courses of therapy with little evidence of nephrotoxicity described both overall and with concurrent therapy.<sup>5</sup><br><br>The mechanism for this predicted interaction is additive nephrotoxic effects. The mechanism by which colistimethate causes renal toxicity appears to be via alteration in membrane permeability that leads to cellular swelling and eventual lysis.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Falagas ME, Kasiakou SK, “Toxicity of Polymyxins: A Systematic Review of the Evidence from Old and Recent Studies,” <i>Crit Care</i>, 2006, 10:R27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16507149\">[PubMed 16507149]</a></p>\n<p>2. Elwood CM, Lucas GD,Muehrcke RC, “Acute Renal Failure Associated with Sodium Colistimethate Treatment,” <i>Arch Intern Med</i>, 1966, 118:326-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5925230\">[PubMed 5925230]</a> </p>\n<p>3. Koch-Weser J, Sidel VW, Federman EB, et al., “Adverse Effects of Sodium Colistimethate. Manifestations and Specific Reaction Rates During 317 Courses of Therapy,” <i>Ann Intern Med</i>, 1970, 72:857-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5448745\">[PubMed 5448745]</a></p>\n<p>4. Koomanachai P, Tiengrim S, Kiratisin P, et al., “Efficacy and Safety of Colistin (Colistimethate Sodium) for Therapy of Infections Caused by Multidrug-Resistant Pseudomonas Aeruginosa and Acinetobacter Baumannii in Siriraj Hospital, Bangkok, Thailand,” <i>Int J Infect Dis</i>, 2007.</p>\n<p>5. Falagas ME, Rizos M, Bliziotis IA, et al., “Toxicity after Prolonged (More Than Four Weeks) Administration of Intravenous Colistin,” <i>BMC Infect Dis</i>, 2005, 5:1.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4087":"<p><b>Title</b> Colistimethate / Amphotericin B</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Amphotericin B may enhance the nephrotoxic effect of Colistimethate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the potential for additive or synergistic nephrotoxicity between colistimethate and other nephrotoxic drugs, such as amphotericin B, this combination should be avoided whenever possible. If these agents must be used together, patients' renal function should be monitored closely.</p>\n<div>\n <p><b>Amphotericin B Interacting Members</b> Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex</p>\n</div> \n<p><b>Discussion</b> Nephrotoxicity represents a significant concern with colistimethate therapy. Early studies of nephrotoxicity generally reported higher rates of toxicity, but many such studies suffered from methodologic limitations such as a lack of standard definitions/criteria and/or different dosing than used more recently.<sup>1</sup> Though risk factors colistimethate-induced nephrotoxicity are unclear, it has been suggested that concurrent administration of other nephrotoxic drugs, such as amphotericin B, increases this risk.<sup>2,3,4</sup> Of note, one recent report describes experience with long-term colistimethate therapy where other potentially nephrotoxic drugs were used in 12 of 19 courses of therapy with little evidence of nephrotoxicity described both overall and with concurrent therapy.<sup>5</sup><br><br>The mechanism for this predicted interaction is additive nephrotoxic effects. The mechanism by which colistimethate causes renal toxicity appears to be via alteration in membrane permeability that leads to cellular swelling and eventual lysis.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Falagas ME,Kasiakou SK, “Toxicity of Polymyxins: A Systematic Review of the Evidence from Old and Recent Studies,” <i>Crit Care</i>, 2006, 10:R27.</p>\n<p>2. Elwood CM, Lucas GD,Muehrcke RC, “Acute Renal Failure Associated with Sodium Colistimethate Treatment,” <i>Arch Intern Med</i>, 1966, 118:326-34.</p>\n<p>3. Koch-Weser J, Sidel VW, Federman EB, et al., “Adverse Effects of Sodium Colistimethate. Manifestations and Specific Reaction Rates During 317 Courses of Therapy,” <i>Ann Intern Med</i>, 1970, 72:857-68.</p>\n<p>4. Koomanachai P, Tiengrim S, Kiratisin P, et al., “Efficacy and Safety of Colistin (Colistimethate Sodium) for Therapy of Infections Caused by Multidrug-Resistant Pseudomonas Aeruginosa and Acinetobacter Baumannii in Siriraj Hospital, Bangkok, Thailand,” <i>Int J Infect Dis</i>, 2007.</p>\n<p>5. Falagas ME, Rizos M, Bliziotis IA, et al., “Toxicity after Prolonged (More Than Four Weeks) Administration of Intravenous Colistin,” <i>BMC Infect Dis</i>, 2005, 5:1.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4088":"<p><b>Title</b> Amphetamines / Lithium</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lithium may diminish the stimulatory effect of Amphetamines. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor the effectiveness of amphetamines in patients who are concurrently receiving lithium.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n</div> \n<p><b>Discussion</b> The ability of lithium pre-treatment or co-treatment to diminish at least some amphetamine effects has been shown in numerous studies. This effect of lithium includes attenuation of both the central nervous system (CNS) stimulant (e.g., activation, euphoria)<sup>1,2,3,4</sup> and the cardiovascular effects of amphetamines.<sup>1</sup> In contrast, others have reported that lithium had little or no effect on either the CNS or cardiovascular effects of amphetamines.<sup>5,6</sup> The reason for these discrepant study results is unclear.<br><br>The mechanism for this apparent interaction is unclear, but the ability of levodopa to eliminate the lithium-attenuation effect (in mice) together with other evidence suggests that the mechanism may be at least partially mediated by dopamine.<sup>2,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Angrist B,Gershon S, “Variable Attenuation of Amphetamine Effects by Lithium,” <i>Am J Psychiatry</i>, 1979, 136:806-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=443465\">[PubMed 443465]</a> </p>\n<p>2. van Kammen DP, Docherty JP, Marder SR, et al., “Lithium Attenuates the Activation-Euphoria but Not the Psychosis Induced by D-Amphetamine in Schizophrenia,” <i>Psychopharmacology (Berl)</i>, 1985, 87:111-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3933028\">[PubMed 3933028]</a></p>\n<p>3. Bell EC, Willson MC, Wilman AH, et al., “Lithium and Valproate Attenuate Dextroamphetamine-Induced Changes in Brain Activation,” <i>Hum Psychopharmacol</i>, 2005, 20:87-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15651051\">[PubMed 15651051]</a> </p>\n<p>4. van Kammen DP, Murphy DL, “Attentuation of the Euphoriant and Activating Effects of d- and l-Amphetamine by Lithium Carbonate Treatment,” <i>Psychopharmacologia</i>, 1975, 44(3):215-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1824\">[PubMed 1824]</a> </p>\n<p>5. Silverstone PH, Pukhovsky A,Rotzinger S, “Lithium Does Not Attenuate the Effects of D-Amphetamine in Healthy Volunteers,” <i>Psychiatry Res</i>, 1998, 79:219-26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9704869\">[PubMed 9704869]</a> </p>\n<p>6. Willson MC, Bell EC, Dave S, et al., “Valproate Attenuates Dextroamphetamine-Induced Subjective Changes More Than Lithium,” <i>Eur Neuropsychopharmacol</i>, 2005, 15:633-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15949922\">[PubMed 15949922]</a> </p>\n<p>7. Berggren U, Tallstedt L, Ahlenius S, et al., “The Effect of Lithium on Amphetamine-Induced Locomotor Stimulation,” <i>Psychopharmacology (Berl)</i>, 1978, 59:41-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=100811\">[PubMed 100811]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4089":"<p><b>Title</b> Insulins / Edetate CALCIUM Disodium</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Edetate CALCIUM Disodium may enhance the hypoglycemic effect of Insulins. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor blood glucose concentrations and watch for signs and symptoms of hypoglycemia in patients receiving both insulin and edetate calcium disodium.</p>\n<div>\n <p><b>Insulins Interacting Members</b> Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular</p>\n</div> \n<p><b>Discussion</b> Reports and studies in humans and rats have demonstrated the ability of ethylenediamine tetra-acetic acid (EDTA) salts (i.e., edetate disodium, edetate calcium disodium) to reduce insulin requirements and cause hypoglycemia. Data from diabetics show that disodium EDTA reduces blood sugar in diabetic patients receiving exogenous insulin,<sup>1,2</sup> with the effect apparent within one hour of disodium EDTA administration and persisting for at least 3 hours.<sup>2</sup> This effect was greater with protamine zinc insulin preparations than with isophane insulin (NPH) products but was apparent with both.<sup>2</sup> With long-term disodium EDTA administration to stable diabetics (n=6), insulin requirements gradually declined over a 6-week period.<sup>2</sup> Administration to nondiabetic subjects (n=10) or to diabetic subjects whose insulin was withheld resulted in no significant change in blood glucose concentrations, suggesting this principally involves enhancement of the effects of exogenous insulin.<sup>2</sup> A study in rats showed that both sodium and calcium EDTA products displayed this hypoglycemic/insulin enhancing effect, but interestingly, a magnesium EDTA product did not.<sup>3</sup> Similar to the human data, this study also found that EDTA salts had no significant effect on blood glucose when administered without insulin.<br><br>The mechanism for this apparent interaction is unclear, but theories include an alteration in ion/trace metal concentrations (via chelation)<sup>2,3</sup> and/or decreased homeostatic responses to decreases in blood glucose.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Meltzer LE, Kitchell JR,Palmon F, Jr., “The Long Term Use, Side Effects, and Toxicity of Disodium Ethylenediamine Tetraacetic Acid (Edta),” <i>Am J Med Sci</i>, 1961, 242:11-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13769308\">[PubMed 13769308]</a></p>\n<p>2. Meltzer LE, Palmon FP, Jr.,Kitchell JR, “Hypoglycaemia Induced by Disodium Ethylenediamine Tetraacetic Acid,” <i>Lancet</i>, 1961, 2:637-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13769309\">[PubMed 13769309]</a></p>\n<p>3. Rihan Z, Jarrett RJ,Keen H, “Edta and Insulin. A Study of the Effect of Salts of Edta Upon Insulin Action in Vivo and in Vitro,” <i>Diabetologia</i>, 1967, 3:449-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4982854\">[PubMed 4982854]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4090":"<p><b>Title</b> Insulins / Edetate Disodium</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Edetate Disodium may enhance the hypoglycemic effect of Insulins. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor blood glucose concentrations and watch for signs and symptoms of hypoglycemia in patients receiving both insulin and edetate calcium disodium.</p>\n<div>\n <p><b>Insulins Interacting Members</b> Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular</p>\n</div> \n<p><b>Discussion</b> Reports and studies in humans and rats have demonstrated the ability of ethylenediamine tetra-acetic acid (EDTA) salts (i.e., edetate disodium, edetate calcium disodium) to reduce insulin requirements and cause hypoglycemia. Data from diabetics show that disodium EDTA reduces blood sugar in diabetic patients receiving exogenous insulin,<sup>1,2</sup> with the effect apparent within one hour of disodium EDTA administration and persisting for at least 3 hours.<sup>2</sup> This effect was greater with protamine zinc insulin preparations than with isophane insulin (NPH) products but was apparent with both.<sup>2</sup> With long-term disodium EDTA administration to stable diabetics (n=6), insulin requirements gradually declined over a 6-week period.<sup>2</sup> Administration to nondiabetic subjects (n=10) or to diabetic subjects whose insulin was withheld resulted in no significant change in blood glucose concentrations, suggesting this principally involves enhancement of the effects of exogenous insulin.<sup>2</sup> A study in rats showed that both sodium and calcium EDTA products displayed this hypoglycemic/insulin enhancing effect, but interestingly, a magnesium EDTA product did not.<sup>3</sup> Similar to the human data, this study also found that EDTA salts had no significant effect on blood glucose when administered without insulin.<br><br>The mechanism for this apparent interaction is unclear, but theories include an alteration in ion/trace metal concentrations (via chelation)<sup>2,3</sup> and/or decreased homeostatic responses to decreases in blood glucose.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Meltzer LE, Kitchell JR,Palmon F, Jr., “The Long Term Use, Side Effects, and Toxicity of Disodium Ethylenediamine Tetraacetic Acid (Edta),” <i>Am J Med Sci</i>, 1961, 242:11-7.</p>\n<p>2. Meltzer LE, Palmon FP, Jr.,Kitchell JR, “Hypoglycaemia Induced by Disodium Ethylenediamine Tetraacetic Acid,” <i>Lancet</i>, 1961, 2:637-8.</p>\n<p>3. Rihan Z, Jarrett RJ,Keen H, “Edta and Insulin. A Study of the Effect of Salts of Edta Upon Insulin Action in Vivo and in Vitro,” <i>Diabetologia</i>, 1967, 3:449-52.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4091":"<p><b>Title</b> Opioid Analgesics / Succinylcholine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Succinylcholine may enhance the bradycardic effect of Opioid Analgesics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Watch for signs of excessive bradycardia or heart block/asystole in patients receiving both succinycholine and an opioid anagesic.</p>\n<div>\n <p><b>Opioid Analgesics Interacting Members</b> Alfentanil*, Benzhydrocodone, Buprenorphine, Butorphanol, Codeine, Dihydrocodeine, FentaNYL*, Heroin, HYDROcodone, HYDROmorphone, Levorphanol, Meperidine, Meptazinol, Methadone, Morphine (Liposomal), Morphine (Systemic), Nalbuphine, Opium, Opium Tincture, OxyCODONE, OxyMORphone, Paregoric, Pentazocine, Remifentanil, SUFentanil*, Tapentadol, TraMADol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case reports have described bradycardia and/or related cardiovascular effects (e.g., heart block, asystole, sinus arrest) associated with fentanyl-succinylcholine,<sup>1</sup> alfentanil-succinylcholine,<sup>2</sup> and sufentanil-succinylcholine<sup>3</sup> combinations. Whether these reports represent synergistic or simply additive bradycardia is unclear. Both the opioid analgesics and succinylcholine have been associated with bradycardia.<sup>4,5,6</sup> Though various mechanisms have been proposed, the most likely mechanism by which opioids cause bradycardia is via enhanced vagal tone.<sup>6</sup> Succinycholine is thought to cause bradycardia (possibly more of an effect at lower doses) via ganglionic stimulation.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Egan TD,Brock-Utne JG, “Asystole after Anesthesia Induction with a Fentanyl, Propofol, and Succinylcholine Sequence,” <i>Anesth Analg</i>, 1991, 73:818-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1952185\">[PubMed 1952185]</a> </p>\n<p>2. Rivard JC,Lebowitz PW, “Bradycardia after Alfentanil--Succinylcholine,” <i>Anesth Analg</i>, 1988, 67:907. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3137840\">[PubMed 3137840]</a> </p>\n<p>3. Sherman EP, Lebowitz PW,Street WC, “Bradycardia Following Sufentanil-Succinylcholine,” <i>Anesthesiology</i>, 1987, 66:106. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2948427\">[PubMed 2948427]</a> </p>\n<p>4. Ertama PM, Paakkari I, Paakkari P, et al., “Effect of Neuromuscular Blocking Drugs on Arterial Pressure and Heart Rate in Rats,” <i>Med Biol</i>, 1984, 62:231-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6151034\">[PubMed 6151034]</a> </p>\n<p>5. Fisher DM, “Clinical Pharmacology of Neuromuscular Blocking Agents,” <i>Am J Health Syst Pharm</i>, 1999, 56:S4-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10437710\">[PubMed 10437710]</a></p>\n<p>6. Napier LD, Stanfill A, Yoshishige DA, et al, “Autonomic Control of Heart Rate in Dogs Treated Chronically with Morphine,” <i>Am J Physiol</i>, 1998, 275(6 Pt 2):H2199-210. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9843820\">[PubMed 9843820]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4092":"<p><b>Title</b> Beta-Blockers / Opioids (Anilidopiperidine)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Opioids (Anilidopiperidine) may enhance the bradycardic effect of Beta-Blockers. Opioids (Anilidopiperidine) may enhance the hypotensive effect of Beta-Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor blood pressure, heart rate, and overall cardiovascular status closely when administering an anilidopiperidine opioid (e.g., sufentanil, alfentanil, etc.) to a patient who is also receiving a beta-blocker.</p>\n<div>\n <p><b>Opioids (Anilidopiperidine) Interacting Members</b> Alfentanil, FentaNYL, Remifentanil, SUFentanil</p>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Levobunolol, Metipranolol, Metoprolol, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)</p>\n</div> \n<p><b>Discussion</b> One report describes three cases of severe bradycardia and hypotension following administration of sufentanil and vecuronium to patients who had all been taking a beta-blocker (propranolol 40mg TID in 1 case, atenolol 50mg QD in 1 case, metoprolol 50mg QD in 1 case) with diltiazem (in 2 of 3 cases) for high blood pressure prior to receiving sufentanil.<sup>1</sup> Baseline heart rates were low in all patients (55-62 bpm), a factor that likely contributed to the observed hemodynamic changes following sufentanil. A study of the hemodynamic effects of remifentanil in patients undergoing elective coronary artery revascularization was terminated early after significant decreased in heart rate, blood pressure, systemic vascular resistance, and cardiac index were observed after the first 8 patients (planned enrollment was 60).<sup>2</sup> These changes were judged to be substantial and to represent potentially dangerous changes in 4 of these 8 patients. At baseline, all patients had been receiving nitrates, calcium channel blockers (diltiazem not allowed), angiotensin converting enzyme inhibitors, and beta-blockers. As in the other published case series, the average baseline heart rate was relatively low in this study (55 bpm). No difference according to administration rate was observed (of 4 subjects with greatest change, 2 received 0.2 mcg/kg/min, and 2 received 1 mcg/kg/min).<br><br>The results of animal studies have been mixed regarding this potential interaction. Administration of alfentanil (high-dose) or fentanyl to dogs pretreated with verapamil resulted in only minimal changes in heart rate and blood pressure.<sup>3,4</sup> When combined with both propranolol and diltiazem, sufentanil administration to chronically instrumented dogs resulted in significantly greater reductions in heart rate and vascular resistance than after administration of sufentanil alone or together with propranolol.<sup>5</sup> Even during episodes of bradycardia, adequate systemic hemodynamics were maintained in all animals.<br><br>Anilidopiperidine opioids decrease blood pressure and/or heart rate via a mechanism unique from the histamine-mediated effects of other opioids. While remifentanil reduced blood pressure and heart rate in a study of 6 patients, there were no changes in histamine concentrations.<sup>6</sup> In vitro and animal studies have shown that the anilidopiperidine opioids have a direct relaxant effect on vascular smooth muscle, including possibly both an endothelium-dependent and -independent component.<sup>7,8,9</sup> It is unclear if there are any significant differences among the anilidopiperidine opioids. One study using an isolated canine hindlimb model found no difference in vascular relaxing effects among fentanyl, alfentanil, and sufentanil.<sup>7</sup> Conversely, some have suggested that remifentanil has more potent cardiovascular effects than the other anilidopiperidine opioids,<sup>2,6</sup> and other data suggest that sufentanil may have an additional alpha-receptor-blocking ability that is unique from other anilidopiperidine opioids,<sup>8,10,11</sup> though conflicting data exist.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Starr NJ, Sethna DH,Estafanous FG, “Bradycardia and Asystole Following the Rapid Administration of Sufentanil with Vecuronium,” <i>Anesthesiology</i>, 1986, 64:521-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2870669\">[PubMed 2870669]</a> </p>\n<p>2. Elliott P, O'Hare R, Bill KM, et al., “Severe Cardiovascular Depression with Remifentanil,” <i>Anesth Analg</i>, 2000, 91:58-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10866887\">[PubMed 10866887]</a> </p>\n<p>3. Lehd Pedersen J, Strom J, Berthelsen P, et al., “Hemodynamic Effects of Alfentanil in Verapamil-Treated Dogs,” <i>Acta Anaesthesiol Scand</i>, 1985, 29:354-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2859727\">[PubMed 2859727]</a> </p>\n<p>4. Hill DC, Chelly JE, Dlewati A, et al., “Cardiovascular Effects of and Interaction between Calcium Blocking Drugs and Anesthetics in Chronically Instrumented Dogs. Vi. Verapamil and Fentanyl-Pancuronium,” <i>Anesthesiology</i>, 1988, 68:874-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3377234\">[PubMed 3377234]</a> </p>\n<p>5. Schmeling WT, Kampine JP,Warltier DC, “Negative Chronotropic Actions of Sufentanil and Vecuronium in Chronically Instrumented Dogs Pretreated with Propranolol and/or Diltiazem,” <i>Anesth Analg</i>, 1989, 69:4-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2568103\">[PubMed 2568103]</a> </p>\n<p>6. Sebel PS, Hoke JF, Westmoreland C, et al., “Histamine Concentrations and Hemodynamic Responses after Remifentanil,” <i>Anesth Analg</i>, 1995, 80:990-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7726445\">[PubMed 7726445]</a> </p>\n<p>7. White DA, Reitan JA, Kien ND, et al., “Decrease in Vascular Resistance in the Isolated Canine Hindlimb after Graded Doses of Alfentanil, Fentanyl, and Sufentanil,” <i>Anesth Analg</i>, 1990, 71:29-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2141970\">[PubMed 2141970]</a> </p>\n<p>8. Karasawa F, Iwanov V,Moulds RF, “Sufentanil and Alfentanil Cause Vasorelaxation by Mechanisms Independent of the Endothelium,” <i>Clin Exp Pharmacol Physiol</i>, 1993, 20:705-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7905796\">[PubMed 7905796]</a> </p>\n<p>9. Unlugenc H, Itegin M, Ocal I, et al., “Remifentanil Produces Vasorelaxation in Isolated Rat Thoracic Aorta Strips,” <i>Acta Anaesthesiol Scand</i>, 2003, 47:65-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15243971\">[PubMed 15243971]</a> </p>\n<p>10. O'Keefe RJ, Domalik-Wawrzynski L, Guerrero JL, et al., “Local and Neurally Mediated Effects of Sufentanil on Canine Skeletal Muscle Vascular Resistance,” <i>J Pharmacol Exp Ther</i>, 1987, 242:699-706. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2886649\">[PubMed 2886649]</a> </p>\n<p>11. Karasawa F, Iwanov V,Moulds RF, “Effects of Fentanyl on the Rat Aorta Are Mediated by Alpha-Adrenoceptors Rather Than by the Endothelium,” <i>Br J Anaesth</i>, 1993, 71:877-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8280558\">[PubMed 8280558]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4093":"<p><b>Title</b> Calcium Channel Blockers (Nondihydropyridine) / Opioids (Anilidopiperidine)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Opioids (Anilidopiperidine) may enhance the bradycardic effect of Calcium Channel Blockers (Nondihydropyridine). Opioids (Anilidopiperidine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor blood pressure, heart rate, and overall cardiovascular status closely when administering an anilidopiperidine opioid (e.g., sufentanil, alfentanil, etc.) to a patient who is also receiving a nondihydropyridine calcium channel blocker (i.e., verapamil, diltiazem).</p>\n<div>\n <p><b>Opioids (Anilidopiperidine) Interacting Members</b> Alfentanil, FentaNYL, Remifentanil, SUFentanil</p>\n <p><b>Calcium Channel Blockers (Nondihydropyridine) Interacting Members</b> Bepridil, DilTIAZem, Verapamil</p>\n</div> \n<p><b>Discussion</b> One report describes three cases of severe bradycardia and hypotension following administration of sufentanil and vecuronium to patients who had all been taking a beta-blocker (propranolol 40mg TID in 1 case, atenolol 50mg QD in 1 case, metoprolol 50mg QD in 1 case) with diltiazem (in 2 of 3 cases) for high blood pressure prior to receiving sufentanil.<sup>1</sup> Baseline heart rates were low in all patients (55-62 bpm), a factor that likely contributed to the observed hemodynamic changes following sufentanil. A study of the hemodynamic effects of remifentanil in patients undergoing elective coronary artery revascularization was terminated early after significant decreased in heart rate, blood pressure, systemic vascular resistance, and cardiac index were observed after the first 8 patients (planned enrollment was 60).<sup>2</sup> These changes were judged to be substantial and to represent potentially dangerous changes in 4 of these 8 patients. At baseline, all patients had been receiving nitrates, calcium channel blockers (diltiazem not allowed), angiotensin converting enzyme inhibitors, and beta-blockers. As in the other published case series, the average baseline heart rate was relatively low in this study (55 bpm). No difference according to administration rate was observed (of 4 subjects with greatest change, 2 received 0.2 mcg/kg/min, and 2 received 1 mcg/kg/min).<br><br>The results of animal studies have been mixed regarding this potential interaction. Administration of alfentanil (high-dose) or fentanyl to dogs pretreated with verapamil resulted in only minimal changes in heart rate and blood pressure.<sup>3,4</sup> When combined with both propranolol and diltiazem, sufentanil administration to chronically instrumented dogs resulted in significantly greater reductions in heart rate and vascular resistance than after administration of sufentanil alone or together with propranolol.<sup>5</sup> Even during episodes of bradycardia, adequate systemic hemodynamics were maintained in all animals.<br><br>Anilidopiperidine opioids decrease blood pressure and/or heart rate via a mechanism unique from the histamine-mediated effects of other opioids. While remifentanil reduced blood pressure and heart rate in a study of 6 patients, there were no changes in histamine concentrations.<sup>6</sup> In vitro and animal studies have shown that the anilidopiperidine opioids have a direct relaxant effect on vascular smooth muscle, including possibly both an endothelium-dependent and -independent component.<sup>7,8,9</sup> It is unclear if there are any significant differences among the anilidopiperidine opioids. One study using an isolated canine hindlimb model found no difference in vascular relaxing effects among fentanyl, alfentanil, and sufentanil.<sup>7</sup> Conversely, some have suggested that remifentanil has more potent cardiovascular effects than the other anilidopiperidine opioids,<sup>2,6</sup> and other data suggest that sufentanil may have an additional alpha-receptor-blocking ability that is unique from other anilidopiperidine opioids,<sup>8,10,11</sup> though conflicting data exist.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Starr NJ, Sethna DH,Estafanous FG, “Bradycardia and Asystole Following the Rapid Administration of Sufentanil with Vecuronium,” <i>Anesthesiology</i>, 1986, 64:521-3.</p>\n<p>2. Elliott P, O'Hare R, Bill KM, et al., “Severe Cardiovascular Depression with Remifentanil,” <i>Anesth Analg</i>, 2000, 91:58-61.</p>\n<p>3. Lehd Pedersen J, Strom J, Berthelsen P, et al., “Hemodynamic Effects of Alfentanil in Verapamil-Treated Dogs,” <i>Acta Anaesthesiol Scand</i>, 1985, 29:354-7.</p>\n<p>4. Hill DC, Chelly JE, Dlewati A, et al., “Cardiovascular Effects of and Interaction between Calcium Blocking Drugs and Anesthetics in Chronically Instrumented Dogs. Vi. Verapamil and Fentanyl-Pancuronium,” <i>Anesthesiology</i>, 1988, 68:874-9.</p>\n<p>5. Schmeling WT, Kampine JP,Warltier DC, “Negative Chronotropic Actions of Sufentanil and Vecuronium in Chronically Instrumented Dogs Pretreated with Propranolol and/or Diltiazem,” <i>Anesth Analg</i>, 1989, 69:4-14.</p>\n<p>6. Sebel PS, Hoke JF, Westmoreland C, et al., “Histamine Concentrations and Hemodynamic Responses after Remifentanil,” <i>Anesth Analg</i>, 1995, 80:990-3.</p>\n<p>7. White DA, Reitan JA, Kien ND, et al., “Decrease in Vascular Resistance in the Isolated Canine Hindlimb after Graded Doses of Alfentanil, Fentanyl, and Sufentanil,” <i>Anesth Analg</i>, 1990, 71:29-34.</p>\n<p>8. Karasawa F, Iwanov V,Moulds RF, “Sufentanil and Alfentanil Cause Vasorelaxation by Mechanisms Independent of the Endothelium,” <i>Clin Exp Pharmacol Physiol</i>, 1993, 20:705-11.</p>\n<p>9. Unlugenc H, Itegin M, Ocal I, et al., “Remifentanil Produces Vasorelaxation in Isolated Rat Thoracic Aorta Strips,” <i>Acta Anaesthesiol Scand</i>, 2003, 47:65-9.</p>\n<p>10. O'Keefe RJ, Domalik-Wawrzynski L, Guerrero JL, et al., “Local and Neurally Mediated Effects of Sufentanil on Canine Skeletal Muscle Vascular Resistance,” <i>J Pharmacol Exp Ther</i>, 1987, 242:699-706.</p>\n<p>11. Karasawa F, Iwanov V,Moulds RF, “Effects of Fentanyl on the Rat Aorta Are Mediated by Alpha-Adrenoceptors Rather Than by the Endothelium,” <i>Br J Anaesth</i>, 1993, 71:877-80.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4094":"<p><b>Title</b> Beta2-Agonists / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Beta2-Agonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use caution when using a beta2-agonist in patients who are receiving (or have only recently discontinued) a monoamine oxidase inhibitor. Monitor cardiovascular status closely, looking for signs of excess cardiovascular effects from the beta2-agonist in such situations.</p>\n<div>\n <p><b>Beta2-Agonists Interacting Members</b> Albuterol, Arformoterol, Bambuterol, Fenoterol, Formoterol, Indacaterol, Levalbuterol, Metaproterenol, Olodaterol, Pirbuterol, Ritodrine, Salmeterol, Terbutaline, Tulobuterol, Vilanterol</p>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> This potential interaction is not widely discussed in published literature or case reports. However, the product labeling for most beta2-agonists urge caution when using a beta2-agonist in a patient receiving a monoamine oxidase inhibitor (or who discontinued a monoamine oxidase inhibitor within the prior 2 weeks) due to the risk for potentiation of the beta2-agonist's cardiovascular effects.<sup>1,2,3,4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Albuterol sulfate HFA. Miami, FL: IVAX Laboratories, Inc, November 2004.</p>\n<p>2. Prescribing information. Foradil Aerolizer (formoterol fumarate). Kenilworth, NJ: Schering Corporation, June 2006.</p>\n<p>3. Prescribing information. Xopenex HFA (levalbuterol tartrate). Marlborough, MA: Sepracor Inc, March 2005.</p>\n<p>4. Prescribing information. Serevent Diskus (salmeterol xinafoate). Research Triangle Park, NC: GlaxoSmithKline, March 2006.</p>\n<p>5. Prescribing information. Brovana (arformoterol tartrate). Marlborough, MA: Sepracor Inc, October 2006.</p>\n<p>6. Prescribing information. Arcapta (indacaterol). East Hanover, NJ: Novartis Pharmaceuticals Corporation, July 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","4095":"<p><b>Title</b> Beta2-Agonists / Tricyclic Antidepressants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use caution when using a beta2-agonist in patients who are receiving (or have only recently discontinued) a tricyclic antidepressant. Monitor cardiovascular status closely, looking for signs of excess cardiovascular effects from the beta2-agonist in such situations.</p>\n<div>\n <p><b>Beta2-Agonists Interacting Members</b> Albuterol, Arformoterol, Bambuterol, Fenoterol, Formoterol, Indacaterol, Levalbuterol, Metaproterenol, Olodaterol, Pirbuterol, Ritodrine, Salmeterol, Terbutaline, Tulobuterol, Vilanterol</p>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> This potential interaction is not widely discussed in published literature or case reports. However, the product labeling for most beta2-agonists urge caution when using a beta2-agonist in a patient receiving a tricyclic antidepressant (or who discontinued a tricyclic antidepressant within the prior 2 weeks) due to the risk for potentiation of the beta2-agonist's cardiovascular effects.<sup>1,2,3,4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Albuterol sulfate HFA. Miami, FL: IVAX Laboratories, Inc, November 2004.</p>\n<p>2. Prescribing information. Foradil Aerolizer (formoterol fumarate). Kenilworth, NJ: Schering Corporation, June 2006.</p>\n<p>3. Prescribing information. Xopenex HFA (levalbuterol tartrate). Marlborough, MA: Sepracor Inc, March 2005.</p>\n<p>4. Prescribing information. Serevent Diskus (salmeterol xinafoate). Research Triangle Park, NC: GlaxoSmithKline, March 2006.</p>\n<p>5. Prescribing information. Brovana (arformoterol tartrate). Marlborough, MA: Sepracor Inc, October 2006.</p>\n<p>6. Prescribing information. Arcapta (indacaterol). East Hanover, NJ: Novartis Pharmaceuticals Corporation, July 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}